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ABSTRACT 
Vascular Endothelial Growth Factor Receptor-3 (VEGFR3/Flt4) and its ligand 
Vegfc are necessary for development of both blood and lymphatic vasculature in 
vertebrates. In zebrafish, Vegfc/Flt4 signaling is essential for formation of 
arteries, veins, and lymphatic vessels.  Interestingly, Flt4 appears to utilize 
distinct signaling pathways during the development of each of these vessels. To 
identify components of this pathway, we performed a transgenic haploid genetic 
screen in zebrafish that express EGFP under the control of a blood vessel 
specific promoter. As a result, we indentified a mutant allele of vascular 
endothelial growth factor c (vegfc), vegfcum18. vegfcum18 mutants display defects 
in vein and lymphatic vessel development but normal segmental artery (SeA) 
formation. Characterization of this allele led to the finding that the primary defect 
in vegfcum18 mutants was a general failure in vein and lymphatic vessel sprouting. 
Further genetic and biochemical analysis of this mutant revealed profound 
paracrine defects, which likely result in the observed loss of lymphatic and 
venous structures. Furthermore, double mutant analysis demonstrated that 
defects during SeA formation in vegfcum18 mutants were masked by inputs from 
the Vegfa signaling pathway. Endothelial cell autonomous expression of 
vegfcum18 induced angiogenic effects on blood vessels while endothelial cells 
lacking vegfc displayed defects in tip cell occupancy, suggesting a cell 
autonomous-autocrine role for Vegfc during developmental angiogenesis. Finally, 
we present genetic evidence that links processing of Vegfc by Furin during the 
  8 
formation of lymphatics in zebrafish. Together the data presented here suggest 
two discrete modes of signaling during blood and lymphatic vessel development, 
thus implying that regulation of Vegfc secretion and processing may play a 
pivotal role in the formation of these distinct vessel types in zebrafish.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  9 
TABLE OF CONTENTS 
TITLE PAGE..........................................................................................................1 
SIGNATURE PAGE ..............................................................................................2 
DEDICATION ........................................................................................................3 
ACKNOWLEDGEMENTS .....................................................................................4 
ABSTRACT...........................................................................................................7 
TABLE OF CONTENTS........................................................................................9 
LIST OF FIGURES AND TABLES......................................................................11 
LIST OF THIRD PARTY COPYRIGHTED MATERIAL.......................................13 
LIST OF USED ABBREVIATIONS .....................................................................14 
CONTRIBUTIONS...............................................................................................17 
CHAPTER I .........................................................................................................18 
INTRODUCTION AND LITERATURE SURVEY.................................................18 
Blood vessel development in zebrafish .................................................................. 20 
Lymphatic vessel development in zebrafish........................................................... 28 
Cellular pathways involved in blood and lymphatic vessel development in 
vertebrates. ................................................................................................................ 29 
Forward genetic screens in zebrafish ..................................................................... 46 
Goal of the project ..................................................................................................... 55 
CHAPTER II ........................................................................................................57 
A TRANSGENIC HAPLOID SCREEN IN ZEBRAFISH TO IDENTIFY Members 
of the Vegfc/Flt4 signaling pathway.................................................................57 
Introduction................................................................................................................ 58 
Materials and Methods .............................................................................................. 62 
Results........................................................................................................................ 68 
Discussion.................................................................................................................. 88 
CHAPTER III .......................................................................................................94 
Genetic, biochemical and molecular characterization of vegfcum18 reveals 
distinct modes of signaling during blood and lymphatic vessel 
development in zebrafish..................................................................................94 
Introduction................................................................................................................ 95 
Materials and Methods .............................................................................................. 98 
Results...................................................................................................................... 104 
Discussion................................................................................................................ 118 
CHAPTER IV.....................................................................................................123 
  10 
Genetic evidence for the role of Furina in the processing of Vegfc during 
lymphatic development in zebrafish..............................................................123 
Introduction.............................................................................................................. 124 
Materials and Methods ............................................................................................ 127 
Results...................................................................................................................... 131 
Discussion................................................................................................................ 141 
Final thoughts and Future Directions............................................................145 
What role does Vegfc play during blood vessel development? .............................. 152 
Limitations and future directions for the forward genetic screen presented here. .. 154 
Using vegfcum18 as a tool for future forward genetic screens. ................................. 155 
Appendices ......................................................................................................158 
Appendix I ........................................................................................................159 
Spatial and temporal overexpression of Vegfc induces pro-angiogenic 
effects on blood vessels during developmental angiogenesis in zebrafish.
...........................................................................................................................159 
Introduction.............................................................................................................. 160 
Materials and Methods ............................................................................................ 163 
Results...................................................................................................................... 168 
Discussion................................................................................................................ 183 
APPENDIX II .....................................................................................................187 
Overview of Multisite Gateway Technology.......................................................... 187 
Appendix III ......................................................................................................194 
Bibliography.....................................................................................................197 
 
 
 
 
 
 
 
 
 
  11 
LIST OF FIGURES AND TABLES 
CHAPTER I INTRODUCTION AND LITERATURE SURVEY 
FIGURE 1.I VASCULOGENESIS AND ANGIOGENESIS IN ZEBRAFISH........................................ 23 
FIGURE 2.I SECONDARY INTERSOMITIC VESSEL AND PRIMORDIAL HINDBRAIN CHANNEL 
(PHBC) FORMATION IN ZEBRAFISH.............................................................................. 27 
FIGURE 3.I LYMPHATIC VESSEL FORMATION IN ZEBRAFISH.................................................. 30 
 35 
FIGURE 4.I REQUIREMENT OF VEGFC/FLT4 SIGNALING DURING FORMATION OF DISTINCT 
VESSEL TYPES IN ZEBRAFISH....................................................................................... 36 
FIGURE 5.I BIOSYNTHESIS OF HUMAN VEGFC. ................................................................... 40 
FIGURE 6.I MODES OF GROWTH FACTOR SIGNALING........................................................... 45 
FIGURE 7.I OVERVIEW OF F3 BREEDING SCHEME FOR ENU MUTAGENESIS ......................... 50 
FIGURE 8.I OVERVIEW OF HAPLOID BREEDING SCREEN FOR ENU-BASED MUTAGENESIS ..... 53 
 69 
CHAPTER II A TRANSGENIC HAPLOID SCREEN IN ZEBRAFISH TO IDENTIFY MEMBERS OF THE 
VEGFC/FLT4 SIGNALING PATHWAY 
FIGURE 1.II A TRANSGENIC HAPLOID SCREEN IN TG(FLI1A:EGFP)Y1 ZEBRAFISH TO IDENTIFY 
MUTANTS AFFECTING VEGFC/FLT4 SIGNALING IN ZEBRAFISH........................................ 70 
FIGURE 2. II HAPLOID MUTANTS WITH DEFECTS IN VASCULAR DEVELOPMENT. ..................... 72 
TABLE 1.II LIST OF PUTANTS IDENTIFIED IN TRANSGENIC HAPLOID SCREEN.......................... 73 
TABLE 2.II PRIMORDIAL HINDBRAIN CHANNEL (PHBC) AND THORACIC DUCT (TD) FORMATION 
IN PROGENY OF UM18 HETEROZYGOUS CARRIERS. ...................................................... 73 
  
FIGURE 3.II UM18 MUTANTS DISPLAY DEFECT IN VEIN AND LYMPHATIC VESSEL DEVELOPMENT.
.................................................................................................................................. 76 
FIGURE 4.II LACK OF THORACIC DUCT FORMATION IN EMBRYOS THAT FORM A NORMAL 
PRIMORDIAL HINDBRAIN CHANNEL. .............................................................................. 77 
FIGURE 5.II UM18 MUTATION IS A TRUNCATION ALLELE OF VASCULAR ENDOTHELIAL GROWTH 
FACTOR C. ................................................................................................................. 80 
FIGURE 6.II ARTERIAL EXPRESSION OF TRANSGENIC VEGFC RESCUES LYMPHATIC 
DEVELOPMENT IN VEGFCUM18 MUTANTS. ....................................................................... 82 
  
FIGURE 7.II VEGFCUM18 MUTANTS DISPLAY PRIMARY DEFECTS IN LYMPHATIC PROGENITOR AND 
VEIN SPROUTING. ....................................................................................................... 85 
FIGURE 8.II  VEGFC/FLT4 SIGNALING IS USED REITERATIVELY DURING LYMPHATIC VESSEL 
FORMATION. ............................................................................................................... 87 
CHAPTER III GENETIC, BIOCHEMICAL AND MOLECULAR CHARACTERIZATION OF VEGFCUM18 
REVEALS DISTINCT MODES OF SIGNALING DURING BLOOD AND LYMPHATIC VESSEL 
DEVELOPMENT IN ZEBRAFISH 
FIGURE 1.III VEGFCUM18 INDUCES ZFFLT4 ACTIVATION AND IN VIVO ANGIOGENSIS............... 106 
FIGURE 2.III VEGFCUM18 LACKS THE ABILITY TO BE SECRETED AND INDUCE ANGIOGENIC 
RESPONSE IN VIVO.................................................................................................... 109 
  
FIGURE 3.III VEGFA SIGNALING MASKS DEFECTS IN VEGFCUM18 MUTANT EMBRYOS DURING 
DEVELOPMENTAL ANGIOGENESIS. ............................................................................. 113 
  
FIGURE 4.III AUTOCRINE ROLE FOR VEGFC DURING DEVELOPMENTAL ANGIOGENESIS. ...... 117 
  12 
  
CHAPTER IV GENETIC EVIDENCE FOR THE ROLE OF FURINA IN THE PROCESSING OF VEGFC 
DURING LYMPHATIC VESSEL DEVELOPMENT IN ZEBRAFISH. 
 FIGURE 1.IV CLEAVAGE OF THE VEGFC C-TERMINAL DOMAIN OF VEGFC IS REQUIRED DURING 
LYMPHATIC DEVELOPMENT........................................................................................ 133 
FIGURE 2.IV SITES OF FURIN EXPRESSION ARE ADJACENT TO DEVELOPING PARACHORDAL 
LYMPHANGIOBLASTS................................................................................................. 135 
FIGURE 3.IV FURINA IS REQUIRED FOR LYMPHATIC VESSEL FORMATION IN ZEBRAFISH....... 137 
FIGURE 4.IV FURINA DEFICIENCY NEGATIVELY AFFECTS FORMATION PARACHORDAL 
LYMPHANGIOBLASTS................................................................................................. 139 
FIGURE 5.IV NOTCH SIGNALING IN BLOOD VESSELS IS UNAFFECTED BY FURINA DEFICIENT 
EMBRYOS................................................................................................................. 140 
  
FINAL THOUGHTS AND FUTURE DIRECTIONS  
FIGURE 1. MODEL. CHARACTERIZATION OF VEGFCUM18 REVEALS CONTEXT DEPENDENT 
SIGNALING MECHANISMS DURING BLOOD AND LYMPHATIC VESSEL DEVELOPMENT IN 
ZEBRAFISH. .............................................................................................................. 149 
APPEDECIES 
FIGURE 1. APPENDIX I MULTISITE GATEWAY APPROACH TO GENERATE C-TERMINAL FUSION 
PROTEINS IN A PCS-BASED VECTOR. ......................................................................... 170 
  
FIGURE 2. APPENDIX I MULTISITE GATEWAY CLONING TO GENERATE A TISSUE-SPECIFIC TOL2 
CONSTRUCT FOR EXPRESSION OF C-TERMINAL FUSION PROTEINS.............................. 175 
  
FIGURE 3. APPENDIX I TEMPORALLY CONTROLLED PRO-ANGIOGENIC EFFECTS OF VEGFC ON 
BLOOD VESSELS DURING EMBRYONIC BLOOD VESSEL DEVELOPMENT ARE DEPENDENT ON 
FLT4. ....................................................................................................................... 179 
  
FIGURE 4. APPENDIX I PRO-ANGIOGENIC EFFECTS OF CELL AUTONOMOUS EXPRESSION OF 
VEGFC DURING BLOOD VESSEL FORMATION IN ZEBRAFISH.......................................... 182 
  
FIGURE 1. APPENDIX II.................................................................................................... 189 
FIGURE 2. APPENDIX II.................................................................................................... 193 
FIGURE 1. APPENDIX III ELEVATED MISEXPRESSION OF VEGFCUM18 INDUCES PRO-ANGIOGENIC 
EFFECTS ON BLOOD VESSELS.................................................................................... 196 
 
 
 
  13 
LIST OF THIRD PARTY COPYRIGHTED MATERIAL 
 
 
Chapter I. Figure 1: Lawson, N and Weinstein, B., Arteries and Veins: 
Making a difference with zebrafish. Nature Reviews. Genetics, 2002 (3) 674-
682. Modified. 
 
Chapter I Figure 5: Joukov, V et. al. Proteolytic processing regulates 
receptor specificity and activity of VEGF-C. EMBO J, 1997 6 (13) 3898-911 
 
Chapter I. Figure 6: Simpson and Dowsett. Aromatase and Its Inhibitors: 
Significance for Breast Cancer Therapy. Endocrine Reviews 2002 57 (1): 
317. Modified  
 
Chapter I. Figure 7: Patton E.E. and Zon L.I. The art and design of genetic 
screens: zebrafish. Nature Reviews Genetics. 2002 , (12) 956-66 
 
Chapter I. Figure 8: Covassin, L D et. al. A genetic screen for vascular 
mutants in zebrafish reveals dynamic roles for Vegf/Plcg1 signaling during 
artery development. 2009 Dev Biol. 329(2) 212-26. Modified 
 
 
 
  14 
LIST OF USED ABBREVIATIONS 
 
 
Abbreviation Term  
 
2A 
 
Viral 2A peptide sequence 
 
3’ UTR 
 
Untranslated Region  
 
ACV 
 
Anterior Cardinal Vein  
 
BP 
 
Int, IHF 
 
C-terminal 
 
Carboxy-terminal 
 
DA 
 
Dorsal Aorta 
 
DC 
 
Duct of Cuvier 
 
DLAV 
 
Dorsal Longitudinal Anastomotic Vessel 
 
dpf 
 
Days post fertilization 
 
ECM 
 
Extracellular Matrix  
 
EGF 
 
Epidermal Growth Factor 
 
ENU 
 
Ethyl-N-nitrosurea 
 
F 
 
Filial  
 
Flt4 
 
Zebrafish ortholog of Vegfr3 
 
GO terms 
 
Gene Ontology Terms 
 
hpf 
 
Hours post fertilization  
 
IHF 
 
Integration Host Factor 
 
Int 
 
Intergrase 
 
IRES 
 
Internal Ribosomal Entry Sequence 
  
  15 
Kdrl Zebrafish ortholog of Vegfr2 
 
LDA 
 
Lateral Dorsal Aorta 
 
LR 
 
Int, IHF, and excisionase 
 
LTBP 
 
Latent TFG-β Binding Proteins 
 
MO 
 
Morpholino  
 
nls 
 
Nuclear Localization Signal 
 
N-terminal  
 
Amino-terminal  
 
ORF 
 
Open Reading Frame 
 
p3E 
 
3’ Entry clone, usually containing an epitope tag  
 
p5E 
 
5’ Entry clone, usually containing a promoter element 
 
PC 
 
Propeptide Convertase 
 
PCV  
 
Posterior Cardinal Vein  
 
PHBC 
 
Primordial Hindbrain Channel 
 
PL 
 
Parachordal Lymphangioblast 
 
Plcg1 
 
Phospholipase C gamma 1 
 
PMBC 
 
Primordial Midbrain Channel 
 
pME  
 
Middle Entry clone, usually encoding a gene of interest  
 
Putant 
 
Potential mutant 
 
RTK 
 
Receptor Tyrosine Kinase 
 
SeA 
 
Segmental Artery  
 
SIV 
 
Subintestinal vessels 
 
SNP 
 
Single Nucleotide Polymorphism  
  
  16 
SS Signal Sequence 
 
SSLP  
 
Single Sequence Length Polymorphism  
 
TD 
 
Thoracic Duct 
 
Tg 
 
Transgenic 
 
TGFβ 
 
Transforming Growth Factor-Beta 
 
TGN 
 
Trans Golgi Network 
 
Vegf 
 
Vascular endothelial growth factor  
 
Vegfc 
 
Vascular endothelial growth factor c  
 
VEGF-CΔC 
 
Human equivalent to Vegfcum18 
 
Vegfd  
 
Vascular endothelial growth factor d 
 
Vegfr2 
 
Vascular endothelial growth factor receptor 2 
 
Vegfr3 
 
Vascular endothelial growth factor receptor 3 
 
VHD 
 
Vegf Homology domain 
 
ZFYM 
 
Zebrafish yolk membrane angiogenesis assay  
  
 
 
 
 
 
 
 
 
 
  17 
CONTRIBUTIONS 
 
 
 
ENU mutagenesis of Tg(fli1a:egfp)y1 males 
 
Dr. Seong-Kyu Choe and Michael Kacergis; Sagerström Lab and Lawson Lab, 
respectively.  
 
In vitro fertilization of oocytes  
Dr. Seong-Kyu Choe, Elizabeth Laver, Letitiah Etheridge and Michael Kacergis; 
Sagerström and Lawson Labs. 
 
zfVegfc and zfVegfcum18 conditioned media 
Dr. Michael Jeltsch. Alitalo Lab. Molecular/Cancer Biology Laboratory, University 
of Helsinki, fl 
 
vegfc deficient mosaic analysis 
Dr. Stefania Nicoli. Lawson Lab  
 
This rest of the work presented in this thesis was performed by Jacques A. 
Villefranc 
 
  18 
CHAPTER I  
 
 
 
 
 
 
 
 
INTRODUCTION AND LITERATURE SURVEY 
 
 
 
 
 
 
 
 
 
 
 
  19 
The enclosed body plan of chordates requires a system to communicate with 
both the exterior and internal environment to permit efficient exchange of gases, 
as well as the transport of nutrients, liquids, and metabolic wastes. In 
vertebrates, these processes are carried out by the cardiovascular system, which 
include specialized tree-like tubular structures called blood and lymphatic 
vessels1,2. Blood vessels serve as a conduit for circulation of blood cells, 
exchange of gases, as well as the delivery of metabolic products to and from 
different tissues. By contrast, the lymphatic system consists of a network of blind-
ended vessels that collect protein-rich fluid that exudes from blood vessels and 
return them back into blood circulation3. 
Blood and lymphatic vessel form through a process termed angiogenesis and 
lymphangiogenesis (see below), respectively 4-7. During adulthood, proper 
functioning of both these vessels is essential for tissue homeostasis. Indeed, 
dysfunction of the cardiovascular system leads to a large number of pathologies 
including arteriovenous malformations, arteriosclerosis, stroke and lymphedema 
8-10. Additionally, blood and lymphatic vessels are fundamental during cancer 
progression and metastasis 11,12.   
In this introduction I will describe: 1) Formation and signaling pathways 
responsible for blood and lymphatic development in zebrafish. In particular, 2) 
Vascular endothelial growth factor c (Vegfc)/ Vegf receptor 3 (Flt4) signaling. 
Although this pathway has been shown to be essential for both blood and 
lymphatic vessel development in vertebrates 8,13-18, how it orchestrates their 
  20 
formation remains unclear. In order to dissect the mechanisms involved in this 
developmental process I performed a 3) forward genetic screen in a blood vessel 
transgenic zebrafish line to identify mutants that display loss of the primordial 
hind brain channel (PHBC), a defect associated with loss of Vegfc/Flt4 signaling. 
 
Descriptive overview of vascular development in Danio rerio (zebrafish).  
Studying vascular development in vertebrates is often difficult due to internal 
embryonic development in some vertebrates, which precludes direct visualization 
of blood and lymphatic vessels. In recent years the zebrafish has emerged as an 
ideal model to study vascular development, due in large part to its external 
development, optical clarity and the existence of zebrafish transgenic lines that 
specifically label blood and lymphatic vessels with reporters encoded by 
fluorescent proteins driven by vessel specific promoters 19,20. These attributes 
make the in vivo observation of vascular development relatively straightforward.  
In this section I would like to introduce relevant aspects of blood and lymphatic 
vessel formation in the zebrafish, which will help define terms and processes that 
will be encountered in this thesis.  
 
Blood vessel development in zebrafish   
Blood vessel development is a highly conserved process in vertebrates that is 
governed by two major events: vasculogenesis and angiogenesis4,21. During 
vasculogenesis primitive mesodermal cells, called angioblasts, are specified to 
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become endothelial cells21. In the zebrafish, this process occurs between 10-20 
hours post fertilization (hpf), when angioblasts migrate from the lateral plate 
mesoderm to the lateral line and form a primitive vascular cord of endothelial 
cells22,23(Figure 1A-B). These cells then differentiate to form the dorsal aorta (DA) 
and posterior cardinal vein (PCV) following specific genetic programs 22. In 
particular, differentiation of angioblasts into arteries requires inputs from the 
Notch signaling pathway 24. More recently, studies in zebrafish found that 
Vascular endothelial growth factor (Vegf) controls the expression of Notch, which 
leads to arterial cell fate 25. By contrast, recent studies have demonstrated that 
venous differentiation is modulated by COUP-TFII, an orphan nuclear receptor 
endogenously expressed in the vein, where it represses arterial gene 
expression26,27. 
  22 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Figure 1.I Vasculogenesis and angiogenesis in zebrafish 
(A-C) 12,18, and 24 hour post fertilization (hpf) embryo, respectively. Anterior is to the left. Dorsal 
is up. (A-B) Migration of angioblasts from the lateral plate mesoderm to the lateral line. Green 
stripe represents angioblasts and eventual endothelial cells. (C-D) ISV=SegA, segmental artery. 
DA. Dorsal aorta. PCV Posterior Cardinal Vein. (C) Zebrafish undergoing SegA formation. (D) 
Sprouting SegA. Yellow cell denotes the tip cell. Orange cell denotes the stalk cell. Red cells 
denote the DA.     
  24 
At 20 hpf, following vasculogenesis and arteriovenous differentiation, endothelial 
cells designated segmental arteries (SeA), begin to sprout from the DA and 
migrate dorsally in between somite boundaries (Figure 1C). This process is a 
classic example of angiogenesis, where endothelial cells are selected to sprout 
from preexisting vessels 7,28. This sprouting requires coordination between two 
endothelial cell types, called tip and stalk cells (Figure 1 D). Tip cells acquire high 
proliferative and migratory behavior in order to lead the angiogenic sprout, while 
the stalk cell must lose these abilities in order to maintain their connection to the 
preexisting vasculature 29. Studies in both mice and zebrafish have found that tip 
and stalk cell coordination during angiogenesis is governed in large part by the 
Vegf and Notch signaling pathways 28,30-32. By 30 hpf, SeA reach the dorsal roof 
of somite boundaries where they appear to arrest an subsequently anastomose 
with adjacent SeA to form the dorsal longitudinal anastomotic vessel (DLAV), 
thus creating a primary DA derived vascular network7. 
At 36 hpf a new set of endothelial sprouts begin to emerge dorsally from the PCV 
and migrate in close proximity to the DA. During this process about half of these 
sprouts fuse with adjacent SegA in order to form secondary intersomitic vessels, 
which ultimately carry venous circulation. By contrast, studies have found that the 
remaining sprouts ultimately become lymphatic progenitors (Figure 2A, and 
below) 7,17,33,34.  
Concomitant with trunk blood vessel formation, neurovasculature in the cranial 
region begins to arise from the anterior lateral mesoderm between 10-20 hpf. 
  25 
One of the vessels formed in this region is the primordial hindbrain channel 
(PHBC), a bilateral primitive vein that returns cranial blood flow back to the heart 
via the ducts of Cuvier (DC) (Figure 2B, right panel). This vessel begins to form 
at 20 hpf, as endothelial cells from the primordial midbrain channels (PMBC) and 
anterior cardinal veins (ACV) begin to sprout in a bidirectional manner until they 
eventually fuse between 24-28 hpf 35(Figure 2B, left panel). Studies have 
demonstrated that  
  26 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Figure 2.I Secondary intersomitic vessel and Primordial Hindbrain Channel (PHBC) 
formation in zebrafish.  
(A) 36-48 hpf embryo. Anterior is to the left. Dorsal is up. SegA. Segmental artery. DA. Dorsal 
aorta. PCV Posterior Cardinal Vein. Left Panel. Blue cell represents new set of endothelial cells 
sprouting dorsally from PCV. Purple cell represents endothelial cells sprouting dorsally from that 
will become lymphatic progenitors. Right panel. Represents the formation of secondary 
intersomic vessels and lymphatic progenitors. (B) 36-48 hpf embryo. Anterior is to the left. Dorsal 
is up. PMBC. Primordial Midbrian Channel (PMBC). Anterior Cardinal Vein (ACV). Primordial 
Hindbrain Channel (PHBC). Ducts of Cuvier (DC). Left panel. Represents formation of the PHBC 
beginning at 20 hpf. Black arrows represent bidirectional sprouting of the PHBC from the PMBC 
and ACV, respectively. Right panel. Complete PHBC between 24-28 hpf. Black arrow denotes 
PHBC.    
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formation this vessel is dependent on vegfc, a member of the Vegf family of 
signaling molecules and its receptor, flt4 14,15.    
Lymphatic vessel development in zebrafish  
Similar to blood vessel development, the formation of lymphatic vessels is a 
conserved process in vertebrates. Studies in mouse, zebrafish and frog have all 
demonstrated that lymphatic endothelial cells stem from the PCV 13,16,33. In 
zebrafish, this process occurs between 1.5-2 days post fertilization (dpf) where 
endothelial cells, presumably lymphatic progenitors, begin to sprout dorsally from 
the PCV to horizonal myoseptum at which point they arrest and form parachordal 
lymphangioblasts (PL) (Figure 3A, 1.-2.). At 3 dpf, a subset of PLs migrate 
ventrally along SegA to the DA and PCV (Figure 3A, 3). Finally, between 4-5 dpf 
PLs extend laterally to form the future thoracic duct (TD), the first functional 
lymphatic structure homologous to that in mouse and humans 17,36 (Figure 3A, 4).  
Prior to sprouting, lymphatic progenitors are specified in the PCV 1,6(ref) by a 
genetic program that includes the transactivation of Prox1 by Sox18 37,38. To 
date, these two transcription factors are the only two markers of lymphatic vessel 
specification, however the mechanism involved in this process remains unclear39. 
Following specification, lymphatic endothelial cells sprout away from the 
PCV(above). Studies in vertebrates have demonstrated this process is 
dependent on Vegfc and its receptor Vegfr3 (Vegfr3 also Flt4) (see below)16,33.  
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Cellular pathways involved in blood and lymphatic vessel development in 
vertebrates.  
VegfA signaling. The Vascular endothelial growth factor (Vegf) family of 
signaling molecules plays a prominent role on the formation of both blood and 
lymphatic vessels in a largely non-redundant manner. One member of this 
pathway, VegfA, is the most important factor controlling blood vessel 
development in vertebrates(ref)1,29. VegfA is a growth factor that binds and 
induces the activation of its receptor Vegf receptor 2 (Vegfr2/ Kdrl in zebrafish), 
which in turn recruits various effector signaling molecules (discussed below) that 
result in the proliferation, migration and differentiation of endothelial cells 40. 
Consistent with its role in these processes, vertebrates lacking vegfa display 
severe defects in blood vessel development. In particular, mice lacking at-least 
one copy of vegfa display severe defects in blood vessel differentiation and 
morphogenesis 41. In zebrafish, genetic downregulation of vegfa negatively 
affects both differentiation and developmental angiogenesis 42. Similar to loss of 
Vegfa, vertebrates lacking vegfr2 display defects in endothelial cell differentiation 
and developmental angiogenesis 14,43-45.  
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Figure 3.I Lymphatic vessel formation in zebrafish 
(A) Schematic representing lymphatic vessel formation in zebrafish between 1.5- 5 dpf. Anterior 
is to the left. Dorsal is up. Ventral is down. SegA. Segmental artery. DA. Dorsal aorta. PCV 
Posterior Cardinal Vein. PL. Parachordal lymphatic progenitor. TD. Thoracic Duct. Horizontal 
myoseptum is denoted in grey. 1. Represents the dorsal sprouting of lymphatic progenitors to the 
horizontal myoseptum to form PLs at 1.5 dpf. 2. Represents arresting PLs at the horizontal 
myoseptum and their lateral migration at 2.5 dpf. 3. Represents ventral migration of PLs toward 
the DA and PCV at 3-4 dpf. 4. Represents the elongation of TD in between the DA and PCV at 5 
dpf.     
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The diverse functions of VegfA during blood vessel development require tight 
control of its biological effects on endothelial cell function. One way in which 
VegfA regulates its effects on endothelial cells is through the expression of 
alternatively spliced variants of vegfa. These conserved isoforms of vegfa 
modulate ligand availability and thus control aspects of blood vessel 
development1,46. In particular, the expression of these isoforms differs in their 
capacity to bind heparin and thereby association with the extracellular matrix 
(ECM) . As a consequence, these distinct isoforms of VegfA vary in their mode of 
signaling. Soluble VegfA isoforms induce blood vessel enlargement where as 
ECM bound VegfA isoforms coordinate branching and migration of endothelial 
cells 9. Paracrine VegfA induces blood vessel branching while autocrine VegfA 
induces blood vessel survival 9,47.  
In addition to the distinct uses of ligand isoforms, VegfA signaling also 
coordinates its effects on blood vessels by differential usage of phosphorylated 
tyrosine residues within activated Vegfr2. In particular, the Y1175 residue of 
human Vegfr2 is required for its function, as mice containing a homologous 
mutation in this residue (Y1173F) display severe vascular and hematopoietic 
defects similar to vegfr2 null mice 48,49. This specific residue was shown to be 
required for its interaction with Phosholipase C gamma 1 (Plcg1) and the p85 
subunit of PI3K 50,51. Indeed, studies have demonstrated that the Y1175 is 
required for Plcg1-Erk1/2 and PI3K mediated proliferation of endothelial cells 
50,51. More recently, studies have found that PI3K-Akt signaling modulates Plcg1-
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Erk1/2 signaling during various aspects Vegfa induced Vegfr2 signaling 52,53. 
Additionally, Vegfr2 signaling is also regulated by its subcellular localization, 
adding another level of modulation to VegfA induced signaling 54.  
While the aforementioned studies describe the activation of distinct intracellular 
signaling pathways in the modulation of Vegfr2 signaling, recent studies have 
also implicated the differential use of Vegfrs as a way to modulate Vegfr2 
signaling during aspects of blood vessel development. In particular, studies have 
shown that Vegfr2 is able to heterodimerize with Vegfr3 and display distinct 
phosphorylation patterns as those induced by Vegfr2 and Vegfr3 homodimers 55. 
More recently, studies have found that Vegfr2/Vegfr3 heterodimers are essential 
for angiogenic sprouting 56. Taken together, these studies suggest that 
differential outputs of Vegfr2 signaling can be modulated by the activation of 
distinct intracellular signaling pathways, Vegfr2 localization or differential Vegfr 
usage. 
Further insight into the functional interactions between members of the Vegf 
signaling pathway during blood vessel development has come from zebrafish 
studies performed in our lab 14. We demonstrated that SegA formation is 
governed by vegfa/kdrl/plcg1 signaling along with inputs from vegfc/flt4 signaling 
(below). In particular, we showed that genetic down regulation of vegfa, chemical 
pan-inhibition of Vegfr signaling or a mutation in plcg1 all resulted in the lack of 
SegA sprouting(ref). However, we found that a kinase dead allele of kdrl (otholog 
of Vegfr2) displayed less serve effects on the formation of SegA when compared 
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to pan-inhibition of Vegfrs, or separate deficiencies in vegfa or plcg1 suggesting 
the involvement of another Vegfr(s) in the formation of SeA. Indeed, our studies 
demonstrated that genetic reduction of flt4 or its ligand vegfc resulted in partial 
sprouting of SegA and zebrafish embryos deficient for both flt4 and kdrl displayed 
a complete loss of SegA formation. These data suggest that cooperation 
between members of the Vegf signaling pathway is required during 
developmental angigenesis (Figure 4A). Interestingly, we found that defects 
resulting form deficiencies in either vegfa or plcg1, did not affect vein 
morphogenesis. However, we found that genetic reduction of either flt4 or vegfc 
severely affected formation of head veins in particular the PHBC. More recently, 
others have demonstrated a requirement for vegfc and flt4 during secondary 
intersomitic and lymphatic vessel formation 15,33,36(Figure 4B-C). Importantly, 
formation of these vessels were also independent of vegfa signaling17,57(personal 
observation). As whole, these studies demonstrate that SeA formation is 
dependent on a pathway that largely involves vegf/kdr/plcg1 with inputs from the 
vegfc/flt4 signaling pathway. By contrast, formation of veins and the lymphatic 
vasculature appears to be independent of vegfa/plcg1 and largely governed by 
the vegfc/flt4 pathway implying that Flt4 signals through distinct downstream 
signaling molecules during vein and lymphatic vessel formation (Figure 4A-C).  
 
Vegfc signaling Vegfc is a secreted growth factor and a member of the Vegf 
family of signaling molecules 40,58. Vegfc functions by binding and inducing the 
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phosphorylation of its endothelial specific receptor Flt4, which in turn activates 
distinct intracellular kinases namely; Erk1/2, Akt, and JNK59-61. The activation of 
these downstream effectors is mediated by specific adaptor proteins that bind 
particular phosphorylated tyrosines within activated Flt4. Interestingly, the distinct 
use of these adaptor proteins at specific phosphorylation sites lead to separate 
biological outputs in endothelial cells61. In particular, Flt4 mediated cell survival is 
a consequence of direct binding of the adaptor protein CRKI/II to the 
phosphorylated Y1063 residue within Flt4, which in turn induces a signaling 
cascade that ultimately activates JNK. By contrast, Flt4 mediated cell 
proliferation and migration is the result of the direct recruitment of GRB2 to the 
phosphorylated Y1230 and Y1231 residues within activated Flt4, this leads to the 
activation of both Akt and Erk1/2. Although the differential activation of these 
signaling pathways lead to specific and separate biological outcomes in cells, the 
in vivo significance of this distinctive activation remains unclear. 
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Figure 4.I Requirement of Vegfc/Flt4 signaling during formation of distinct vessel types in 
zebrafish. 
(A-C) SegA. Segmental artery. DA. Dorsal aorta. PCV Posterior Cardinal Vein. TD. Thoracic 
Duct. PHBC. Primordial Hindbrain Channel. (A) Artery development requires vegf/kdr/plcg1 with 
inputs from the vegfc/flt4 signaling pathway. (B) Vein development is largely governed by 
vegfc/flt4 and independent of vegfa/kdrl/plcg1. (C) Lymphatic development is governed by the 
vegfc/flt4 signaling pathway. This process is also independent of vegfa/kdrl/plcg1 signaling.  
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During zebrafish development, flt4 is concomitantly expressed in the axial vein 
and developing segmental arteries 14,28. Consistent with its expression, flt4 has 
been shown to be involved in the formation of SegA and secondary intersomitic 
vessels 14,15. Accordingly, recent studies have shown its requirement during 
developmental and pathological angiogenesis in mice62. Flt4 signaling is also 
essential for lymphatic vessel development in vertebrates8,15,63,64. Indeed, 
humans with congenital missense mutations in Flt4 develop severe lymphedema.  
In most cases, these mutations eliminate the ability of Flt4 to undergo activation 
in response to Vegfc 8. Similar to its receptor, Vegfc is involved in the formation 
of blood and lymphatic vessels in vertebrates 14,16,17,33. In zebrafish, vegfc 
expression is restricted to the axial artery and developing SegA. Accordingly, 
downregulation of vegfc cause defects in SeA and vein morphogenesis 
(described above) 14. In addition, mice and zebrafish lacking vegfc display 
defects in lymphatic progenitor sprouting, causing a complete loss of the 
lymphatic system15,16,33.  
Biosynthesis and structure of Vegfc. Unlike VegfA, Vegfc is synthesized a 
proprotein that undergoes a series of cleavages in order to be active. A similar 
synthesis of proproteins is also a hallmark of other growth factors such epidermal 
growth factor (EGF), transforming growth factor beta (TGFβ) and interleukin 1α 
and 1β 60,65. An elegant biochemical study using human VEGF-C found that 
cleavage events define distinct domains within Vegfc, which include a Vegf 
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homology domain (VHD) required for receptor activation, an N-terminal domain 
and C-terminal silk homology domain of unknown function. 
Upon biosynthesis Vegfc is folded into an anti-parallel dimer, which is linked by 
disulfide and non-covalent bonds (Figure 5A, 1.). Following homodimerization, 
Vegfc is cleaved at a conserved Furin cleavage motif that separates the VHD 
from the C-terminal domain (Figure 5A, 2.). The resulting secreted Vegfc is in the 
form of a tetramer, which undergoes further processing at the N-teriminus to 
remove the N-terminal domain to produce mature Vegfc, which is held together 
by non-covalent bonds (Figure 5A, 3.). The mature form of Vegfc is subsequently 
able to bind and activate both Vegfr2 and its major endothelial cell specific 
receptor Flt4 58,60,66. Interestingly, all forms of Vegfc are able bind and activate 
Flt4 at varying levels, but it is only the mature form that is able to bind and 
activate Vegfr2 60.  
Previous studies in cultured cells have suggested that the existence of the N-
terminal and C-terminal domains flanking the VHD of Vegfc may regulate its 
activity during the various aspects of vascular development. This was borne out 
of the observation, that removal of the N-terminal domain and C-terminal 
homology domain of Vegfc induced activation of Vegfr2 and observable effects 
on blood vessel morphology, suggesting that these accessory domains may 
regulate its angiogenic and lymphangiogenic activity60. However, exactly how this 
proposed regulation occurs is unknown. More recently, studies have found that 
replacing the heparin-binding domain of VegfA165, with the C-terminal domain of 
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VEGFC increased VegfA165 angiogenic activity implying a role to the C-terminal 
domain in angiogenesis67. Inspection of C-terminal domain of Vegfc reveals 
strikingly similarity to the secretory silk protein (BR3P), which is characterized by 
series of repeated cysteine-rich motifs 59,60,66,68. In addition to these motifs, the C-
terminal domain of Vegfc also contains short motifs homologous to Epidermal 
growth factor(EGF)-like domains contained in other secreted proteins.  These 
domains have been shown to facilitate protein secretion as well as association 
with the extracellular matrix (ECM) 69-71. Interestingly, the structure of secreted 
Vegfc is similar to that of TGFβ; the C-terminal domain being similar to that of 
latent TGFβ-binding proteins, which are required for the association of TGFβ with 
the ECM and making it available to be active72,73. Taken together, these studies 
imply that the accessory domains of Vegfc may play a role in the regulation of 
Vegfc signaling. As a result, these domains may play a role in modulating 
aspects Vegfc activity during blood and lymphatic vessel development. However, 
to this date the exact biological function of these accessory domains remains 
unknown. 
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Figure 5.I Biosynthesis of Human Vegfc. 
(A) Schematic model of the proteolytic processing of VEGF-C. The regions of VEGF-C 
polypeptide are marked as follows: signal sequence, black box; VEGF homology domain, grey 
box; N-terminal and C-terminal propeptides, dotted and open boxes, respectively. Cysteine 
residues and putative sites of N-linked glycosylation are shown as (Y); the cysteine residues in 
the C-terminal propeptide are not marked for clarity. Numbers indicate molecular mass (kDa) of 
the corresponding polypeptide in reducing conditions. Disulfide bonds are marked as -S-S-; non-
covalent bonds as dotted lanes. The hypothetical binding of the C-terminal domain to the 
extracellular matrix (ECM). (1.) Denotes the dimerization of VEGF-C and. (2.) Represents 
cleavage of the C-terminal domain and the secreted VEGF-C tetramer. (3) Represents 
processing of the N-terminal domain to form mature VEGF-C. Importantly, this schematic 
represents processing of Human VEGF-C. 
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The role Vegfc processing during vascular development. Studies have found that 
processing at the Furin cleavage motif which separates the VHD from the C-
terminal domain in Vegfc is required for its effects on blood vessel formation in 
cultured cells and fin regeneration in the adult zebrafish (Figure 5A, 1.) 74,75. In 
particular, mutating this cleavage motif in Vegfc takes away its ability to induce 
blood vessel formation in cultured cells74. This study suggests that cleavage of 
Vegfc appears to have a functional role during blood vessel formation although 
its functional role during lymphatic vessel development remains unclear. This 
same study pointed to the requirement of the propeptide convertase (PC) Furin 
as a possible mediator of Vegfc processing at the C-terminal domain. In 
particular, the authors demonstrated that Furin directly processed Vegfc at the C-
terminal domain of Vegfc in order to produce its mature form 74.  
Furin function is required for the activation of various signaling molecules 
required for proper embryonic development76. Thus it is not surprising that mice 
lacking furin are embryonic lethal. As consequence, investigating its role during 
vascular development in mice would require the use of a tissue specific or 
conditional knock-out mice, which to date have not been reported. The zebrafish 
genome encodes to two furin genes (furinA and furinB), which have been shown 
to play partially redundant roles in craniofacial development 77. In this study, the 
observation that a single mutation in furinA was not as severe as a deficiency for 
both furinA and furinB allowed for a more refined analysis of function during 
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embryonic development. This genetic particularity of furin in zebrafish may help 
shed light in to a possible role for furin during vascular development. To date 
studies accessing the role of either furin genes during vascular development in 
zebrafish have not been reported. 
Modes of cell communication. Cells communicate using a variety of signaling 
molecules that regulate various aspects of cell biology including differentiation, 
migration, proliferation and survival. A subset signaling molecules called growth 
factors are peptides that interact with specific receptors on target cells. Binding of 
a ligand to its cognate receptor leads to receptor activation and subsequent 
initiation of signaling cascades that mainly lead to transcription of specific target 
genes, which in turn a regulate aspects of cell physiology.  
The effects of growth factors on target cells depend on a variety of elements 
including; signaling contexts set by other growth factors, the differentiated state 
of the target cell, and the way in which the growth factor signals. Growth factors 
typically signal locally in either a paracrine or autocrine manner. In the case of 
the former, secreted growth factors from the signaling cell act as local mediators 
affecting target cells with cognate receptors that are in the immediate vicinity 
(Figure 6A). Most growth factors act in paracrine manner and they include: EGF, 
Insulin growth factor (IGF), Platelet-derived growth factor (PDGF), and members 
of the Vegf family growth factors among others. In particular, paracrine VegfA is 
required for chemotaxis and differentiation of angioblasts as well as endothelial 
cell proliferation1,25,78. Paracrine Vegfc is required for budding of lymphatic 
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endothelial cells from the cardinal vein to form the lymphatic system. Exogenous 
Vegfc and has also been shown to potently induce lymphangiogenesis 1,2,10,16. 
In contrast to paracrine signaling, where the signaling cell and target are often 
different cell types, autocrine signaling is distinguished by the ability of cells to 
secrete growth factors that can signal back onto themselves (Figure 6B). 
Examples of this mode of signaling include: reinforcement of a developmental 
decision such as differentiation of a specific cell type, providing cells with 
information about a local environment, amplification and duration of an 
intracellular response, or persistent migratory behavior79,80. High levels of the 
cognate receptor often characterize cells displaying autocrine modes of 
signaling, while secretion of the autocrine ligand is tightly regulated. Examples of 
such factors include: Interleukin-2 (IL-2), TGF-β, EGF, as well as members of the 
Vegf family of growth factors47,81-83. In contrast to its paracrine role, autocrine 
VegfA promotes postnatal endothelial cell survival 47, while forced endothelial 
derived Vegfc has pro-angiogenic and lymphangiogenic effects on blood and 
lymphatic vessels84. 
More recently, studies have described a type of internal autocrine loop. This so-
called intracrine mode of signaling requires an autocrine ligand and intracellular 
biologically active receptors in order to transduce signals (Figure 6C). The 
mechanisms governing intracrine signaling are largely unknown, although studies 
have found that intracrine signaling can occur at the level of the nuclear envelop, 
chromatin as well other subcellular compartments85. Studies have speculated 
  44 
that intracrine mediated signaling result in self-sustaining signaling loops that 
behave as long lasting signals during aspects of cell physiology85,86.  
Together these context dependent modes of cellular communication result in the 
modulation of distinct aspects of cell biology. 
Multiple roles for Vegfc/ Flt4 signaling in vascular development. It is clear 
that Vegfc/Flt4 is required for the formation of distinct vessel types that vary in 
location, architecture and function. However, the exact molecular mechanism(s) 
of how the formation of these vessel types is achieved remains unclear. A survey 
of the current literature suggests at least one possible mechanism may be the 
manipulation of varying downstream effectors in order to elicit discrete biological 
functions, which in turn may be regulated by homo-and heterodimeric Flt4 
complexes. One other possibility may lie in the posttranslational processing and 
usage of accessory domains by Vegfc, which may in turn control its ability to 
signal during various aspects of vascular development.  Together, these possible 
modes Vegfc/Flt4 modulation may contribute to the diverse biological effects of 
Flt4 signaling during vascular development. Thus, identifying players involved in 
Vegfc/Flt4 signaling could shed light on to how exactly this signaling pathway 
coordinates its diverse effects.  
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Figure 6.I Modes of growth factor signaling 
(A-C) White circles represent a growth factor; sun-like graphics represent a cognate receptor. (A) 
Graphic depicting paracrine signaling. Growth factors secreted from the signal cell stimulate 
neighboring target cells expressing cognate receptors. (B) Graphic depicting autocrine signaling. 
A growth factor from the signaling cell signals back on its own receptor. (C) Graphic depicting 
intracrine signaling. Autocrine ligand and biologically active receptor induce an internal autocrine 
loop.      
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Forward genetic screens in zebrafish 
Forward genetic screens have proved to be an efficient method to isolate genes 
involved in a biological process based on a desired phenotypic output. This 
forward genetic approach has been used in tractable genetic organisms such as 
Caenorhabditis elegans and Drosophila melanogaster to dissect complex 
pathways involved in various developmental processes 87,88. In general, this 
method of screening affords an unbiased survey of the genes required for a 
developmental process. Making use of this approach in vertebrates requires the 
availability of an organism with rapid stereotypical embryonic development, 
optical clarity, and increased progeny size. In recent years the zebrafish has 
become an ideal system for the genetic analysis of vertebrate development due 
to the aforementioned characteristics. Initial mutagenesis studies in zebrafish 
relied on gamma irradiation in order to induce genetic lesions leading to 
embryonic mutant phenotypes. Although lesions affecting only a few base pairs 
were possible, the majority of induced mutations resulted in large deletions, 
making the resulting pleiotropic phenotypes more difficult to study 89,90. As a 
result, the majority of mutagenic screens in zebrafish have been performed using 
N-Ethyl-N-nitrosourea (ENU)45,91,92. ENU is alkylating agent that has been shown 
to largely induce point mutations in pre-meiotic germ cells of the zebrafish. These 
point mutations can induce partial loss of function or null alleles90.  
In 1996 the Journal Development published a complete issue describing two 
large-scale mutagenesis screens in zebrafish; one performed in the Boston,MA 
  47 
93and another in Tubigen, Germany 92, which identified mutants with obvious 
defects in early development  that could be visualized under a simple dissection 
microscope. This screen for morphological defects in development helped 
identify mutants affecting a variety of developmental processes including; body 
axes determination, brain, blood and cardiovascular development, as well as 
mutations affecting adult phenotypes such as pigmentation patterns and fin 
development 91,92,94,95. Although this approach was clearly able to identity 
mutants affecting nearly all aspects of development, more detailed studies of 
developmental processes and organ function lead to the initiation of screens 
focused on specific developmental processes. As result, researchers have 
employed more sensitive assays in order to identify mutants affecting a particular 
developmental process. These include, the use of histological sectioning, whole 
mount in situ hybridization and antibody staining as a way to identify mutants 
affecting a given aspect of development 96,97. More recently, researchers have 
taken advantage of the genetic tractability of zebrafish in order to generate 
transgenic lines where cis-elements drive expression of a reporter a specific cell 
type, allowing serial observation of given developmental process and reducing 
the amount of downstream technical manipulations. Subsequently, researchers 
have gone back to the initial mutants identified by morphological defects and 
have used transgenic lines to perform secondary screens 20. In some cases, 
others have used transgenic lines as a primary tool to screen for mutants 
affecting a given developmental process 45,98,99. In addition to these methods of 
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screening, researchers have also devised screens in order to assess organ 
function and have identified mutants affecting lipid metabolism, cancer 
susceptibly and host response to infectious disease98,100,101. In most of these 
examples, general embryo morphology was overtly normal and would other wise 
be obviated in previous morphology based screening approach. 
F3 breeding scheme. Most genetic screens in zebrafish (ex. Boston and 
Tubigen screens) are based on a three-generation crossing scheme. In this 
scheme, wild type parental males are treated with a given mutagen and crossed 
to wild type untreated females to produce an F1 family, where half of the progeny 
will harbor mutated chromosomes. The F1 families of fish (founder fish) are out-
crossed to wild type fish to generate an F2 generation, half of which will contain 
mutated chromosome of interest. In turn, the F2 family of fish is randomly in-
crossed to obtain recessive mutant offspring (Figure 7). F2 fish carry a myriad of 
mutations in their genome of which only a portion will become homozygous in a 
single in-cross. Therefore, many F2 crosses are required in order to recover as 
many mutants as is practical. As a result, this breeding scheme requires large 
amounts of space and personnel, which is cost prohibitive for a small research 
group. 
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Figure 7.I Overview of F3 breeding scheme for ENU mutagenesis 
In F3 screens, a mutagen, such as ethylnitrosourea (ENU), is used to generate hundreds of point 
mutations in the male pre-meiotic germ cells (spermatogonia). ENU-treated males are crossed to 
wild-type females to produce the F1 heterozygous progeny. F1 fish are then crossed to siblings to 
create F2 families, half of which are genotypically heterozygous for a specific mutation (m), 
whereas the other half are wild type. F2 siblings are crossed, and the resulting F3 progeny are 
25% wild type (+/+), 50% heterozygous (+/m) and 25% homozygous (m/m) for a recessive 
mutation. Together, the Boston and Tübingen screens, starting from about 300 ENU founder 
males, involved raising more than 5,000 F2 families, analysing more than 6,000 mutagenized 
genomes and selecting more than 2,000 new developmental mutants for characterization. 
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Haploid breeding scheme. Recently, we along with others have taken 
advantage of the ability to generate haploids in zebrafish in order to perform 
mutagenesis screens 45,57. In this breeding scheme, parental mutagenized males 
are out-crossed to wild type non-mutagenized females to generate an F1 family 
of females of which half harbor mutations in their chromosomes (Figure 8A). 
Haploid embryos are generated by in vitro fertilization of eggs generated from an 
F1 female and UV-irradiated sperm from a wild type zebrafish male. Since the 
DNA contained in the sperm has been irradiated it will not contribute to the 
offspring. Once haploids mutants are identified (Figure 8A), the F1 female is out-
crossed to a wild type male zebrafish to produce an F2 family. This allows the 
introduction of polymorphic markers into the resulting progeny, which can then be 
used for genetic mapping of the causative mutation (Figure 8B).  F2 siblings are 
then randomly in-crossed to obtain dipliod recessive mutant offspring (Figure 
8B). The main advantage of this breeding scheme is that it reduces the amount 
of generations required in a screen by one. This is due to the fact that 
mutagenized DNA in a F1 female may represent only one allele at a given locus, 
therefore the establishment of haploid embryos allows the direct assessment of a 
recessive mutations. 
One central drawback of haploid embryos is that they are inviable and die by four 
days post fertilization. Additionally, haploid embryos are mildly abnormal, 
exhibiting small cell size, abnormal brain development and short stature, which 
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often cause a crinkled trunk. Despite these defects, haploid embryos develop 
various structures in a normal manner, which allows for phenotypic screening of 
various developmental processes 90,102. In particular, we have previously used 
this breeding scheme in a transgenic blood vessel background, in effort to 
indentify mutants affecting vascular development. We noted that although 
haploids often displayed morphological defects, blood vessel development was 
robust in wild type haploids thus making possible the identification of vascular 
mutants 45.  
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Figure 8.I Overview of Haploid breeding screen for ENU-based mutagenesis 
(A) In haploid screens, a mutagen, such as ethylnitrosourea (ENU), is used to generate point 
mutations in the male pre-meiotic germ cells. ENU-treated males are crossed to wild-type 
females to produce the F1 heterozygous progeny. F1 females, which are genotypically 
heterozygous for a specific mutation (+/m),  are squeezed for oocytes and fertilized with UV-
treated sperm in order to generate haploid embryos. (B) A haploid clutch of embryos will contain 
50% mutant and 50% wildtype. (C) The heterozygous mutant female (+/m) is subsequently out 
crossed to a wild type male in order to generate an F2/ Map cross generation. F2 siblings are 
randomly crossed to obtain dipliod recessive mutant offspring. 
 
 
 
 
  54 
Isolation of causative mutation. Although the ENU method of mutagenesis has 
proven to be an efficient way to recover mutants affecting a given developmental 
process, the main drawback lies in the identification of the genetic lesion causing 
the observed phenotype. Inherent characteristics of the zebrafish itself along with 
enormous genomics efforts in the zebrafish community have helped alleviate the 
painstaking task of cloning mutations. First, zebrafish produce a very large clutch 
size, which allows the analysis of large number of meioses with which to map the 
mutated locus. Additionally, studies have found that the zebrafish and human 
chromosomes are surprisingly syntenic. Thus, once a few genes close to the 
mutation are identified, the syntenic region on the human chromosome can be 
surveyed to identify genes that display functional characteristics or expression 
patterns that may be linked to the observed mutant phenotype in zebrafish 103. 
In recent years, work done in the zebrafish community has greatly facilitated the 
cloning of mutations recovered in forward mutagenic screens by enabling a 
series of readily available genomic resources. These include; a reliable physical 
and genetic linkage maps 104, along with the development of a large panel of 
known single sequence length polymorphisms (SSLPs) and the annotation of 
single nucleotide polymorphisms (SNPs) between strains. Together, these 
resources can be used as genetic markers for linkage analysis 90,102. For 
example, once embryos are identified with a recessive phenotype, the large 
annotated panels of SSLPs can be used for initial bulk segregant mapping on 
wild type and mutant embryos to establish the genetic interval in which the 
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mutation lies.  Fine mapping of the locus can further be achieved using SSLPs 
and known SNPs. Once a candidate gene is identified, it possible to take 
advantage of gene ontology (GO terms) as well as expression pattern and 
microarray data to further narrow down the list of candidate genes, which can be 
subsequently sequenced to identify the genetic lesion 102. 
In some cases increased genomic complexity or misannotation of a given locus 
precludes the aforementioned approach from being enough to identify a given 
genetic lesion. As result, researchers have recently taken advantage of the wider 
availability of deep sequencing as way to facilitate the identification candidate 
genes. In one recent study, researchers employed deep sequencing methods to 
identify the causative mutation of the magellan allele. However, given the large 
size of the zebrafish genome, this first required the fine mapping of homozygous 
mutant versus heterozygous mutant embryos using SSLPs and SNPs 105. As 
sequencing techniques continue move forward it conceivable that in the future 
zebrafish researchers will be able to directly sequence mutant progeny to identify 
causative mutations.      
 
Goal of the project 
Initial observations in our laboratory as well as those by others demonstrated that 
Vegfc/Flt4 signaling is involved in the formation of both blood and lymphatic 
vessels in vertebrates 13-15,33,62. Studies have suggested that differential receptor 
usage and/or manipulation varying downstream effectors may be required to 
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elicit discrete biological functions 55,56,61,106. Additionally, reports suggests that 
posttranslational processing and usage of accessory domains by Vegfc may 
control its ability to signal during various aspects of vascular development 
60,67,74,75. As a result, I decided to investigate how Vegfc/Flt4 signaling 
coordinates the formation of distinct vessel types during embryonic development 
in zebrafish. To do this I conducted a forward genetic screen in transgenic 
zebrafish embryos where blood vessel expressed Egfp under the control of an 
endothelial promoter, and screened for mutants that failed to form a PHBC; a 
defect associated with loss of Vegfc/Flt4 signaling.  
Questions addressed in this thesis: 
i. How does Vegfc/Flt4 signaling orchestrate the formation of distinct 
vessel types in zebrafish?  
ii. Are there context dependent signaling mechanisms that regulate 
formation of distinct vessel types?  
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CHAPTER II 
 
 
 
 
 
 
 
A TRANSGENIC HAPLOID SCREEN IN ZEBRAFISH TO IDENTIFY 
MEMBERS OF THE VEGFC/FLT4 SIGNALING PATHWAY.  
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Introduction 
Danio rerio (Zebrafish) has become an ideal model system for genetic analysis 
of vertebrate development. This is due in large part to its ex vivo fertilization, 
optical clarity and genetic amenability. Forward genetic screens in other 
tractable genetic organisms such as Caenorhabditis elegans and Drosophila 
melanogaster have been used to uncover novel genes and dissect complex 
pathways involved in various developmental processes87,88. In general, forward 
genetic screens afford an unbiased survey of the genes required for a given 
developmental process. The majority of mutagenic screens in zebrafish have 
been performed using N-Ethyl-N-nitrosurea (ENU)92,93. Although ENU has 
proven to be an efficient mutagen, the central drawback lies in the subsequent 
identification of the causative mutation for a given observed phenotype.  
Previously, a forward genetic screen to identify cardiovascular mutants relied 
on observed circulatory defects in mutant zebrafish embryos 95. This screen 
identified mutants affecting cardiac contractility, such as the silent heart mutant, 
and mutants affecting circulatory function and vascular stability, such as 
gridlock and bubble head, respectively 107-109. Although this method of 
screening yielded mutants with vascular defects, the presence of a normal 
circulatory loop is not always indicative of proper vascular morphology14. More 
recently, the use of transgenic lines, which specifically label zebrafish 
vasculature, has allowed the isolation of mutants affecting aspects of vascular 
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development in the presence of normal circulatory function. Examples of these 
mutants include full of fluid and expando, both of which affect lymphatic vessel 
formation, yet display normal circulation 15,34. However, the three-generation 
crossing scheme (so-called F3 screen) used to identify these mutants is labor 
intensive and cost prohibitive for a small research group. (F3 screens are 
reviewed in Chapter I).  
Recently, we and others have taken advantage of the ability to generate 
haploid zebrafish embryos and the availability of a blood vessel specific 
transgenic line in order to perform haploid mutagenesis screens for mutants 
affecting blood vessel development 45,57 (Haploid mutagenesis screens are 
reviewed in Chapter I). As a result, we identified mutants affecting various 
aspects of blood vessel development including endothelial cell specification, 
artery differentiation and developmental angiogenesis 45. One drawback of the 
haploid approach is the inability to screen for phenotypes past 3 days post 
fertilization (dpf). Therefore, identifying mutants that affect aspects of vascular 
development following this time point, such as secondary vascular sprouting 
and lymphatic vessel formation, is difficult.  
Studies in vertebrates have demonstrated that lymphatic endothelial cells 
originate from vascular endothelial progenitors in the vein13,16,17,33. Therefore, it 
is not surprising that these two cell types share common signaling pathways 
that govern their development.  Among these are components of the Vascular 
endothelial growth factor (Vegf) family of signaling molecules.  In particular, 
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previous studies have described the requirement of Vegfc signaling during both 
blood and lymphatic vessel formation in vertebrates14,15,62. Unlike other 
members of the Vegf family, Vegfc is expressed as a secreted proprotein that 
undergoes a series of proteolytic cleavage events that are required for its 
activation.  The sites of these cleavage events define distinct domains within 
Vegfc, including a central Vegf homology domain, which is essential for 
receptor binding and a C-terminal silk homology domain of unknown function60. 
Vegfc functions by binding to and inducing phosphorylation of its cognate 
receptor tyrosine kinase, referred to as Vegfr-3, or Flt4 58. Flt4 in turn activates 
a number of different signaling effectors, including MAP kinases, JNK, and Akt. 
Interestingly, activation of each of these downstream targets can elicit discrete 
biological outputs in endothelial cells 61.   Consistent with the diverse roles of 
Vegfc/Flt4 signaling in cultured endothelial cells, we along with others have 
found that Vegfc/Flt4 signaling is required for cranial vein and segmental artery 
morphogenesis, as well as lymphatic vessel development in zebrafish 14,33. 
Interestingly, defects in vein and lymphatic patterning appear to be 
independent of segmental artery defects 17,57. Therefore, it is likely that 
Vegfc/Flt4 signaling acts in distinct signaling contexts throughout the formation 
of these distinct vessel types.  
In this chapter, we employ a transgenic haploid screen to identify genes that 
are required for Vegfc/Flt4 signaling in distinct vascular contexts. We screen for 
haploid mutants that fail to form a primordial hindbrain channel (PHBC), a 
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defect known to be associated with loss of Vegfc/Flt4 signaling 14, and identify 
a mutant referred to as um18. This mutant displays defects in PHBC formation 
with a concomitant loss of lymphatic vessel patterning, although SeA formation 
is overtly normal. Positional cloning revealed that um18 encodes a truncation 
allele of vegfc that eliminates its C-terminal domain. Further characterization of 
this mutant suggested that the observed lymphatic defects were due to earlier 
defects in the sprouting of lymphatic progenitors. Finally, we show that arterial 
expression of vegfc is sufficient to rescue lymphatic vessel patterning in 
vegfcum18 mutants. These findings show that it is possible to use a haploid 
transgenic screen as way to screen for and identify mutants involved in 
Vegfc/Flt4 signaling. Additionally, they suggest a paracrine role for Vegfc from 
the DA in the formation of the lymphatic system in zebrafish.  
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Materials and Methods 
Zebrafish Handling and Maintenance 
Zebrafish were housed and maintained in accordance to standard protocols 
described elsewhere.  
 
Transgenic and Mutant Lines 
The F1 Tg(fli1a:egfp)y1 m588.5  female was derived from a cross between ENU 
mutagenized Tg(fli1a:egfp)y1 male and a wild type Tg(fli1a:egfp)y1 female. The 
Tg(fli1a:egfp)y1 zebrafish line expresses Egfp in endothelial cells and is 
described elsewhere. The F1 Tg(fli1a:egfp)y1 m588.5   was crossed to wild type TL 
(Tupfel Long fin)  fish in order to obtain um18+/- carriers. um is the institutional 
line designation of the University of Massachusetts Medical School (ZFIN.org). 
To better visualize the TD we generated the 
Tg(fliep:dsRedEX)um13;Tg(flk1:crgfp)zn1 line. The Tg(fliep:dsRedEx)um13 line 
which labels both blood and lymphatic vessels was out crossed to the 
Tg(flk1:crgfp)zn1 line, which specifically labels blood vessels. 
 
Mutagenesis and Screening  
N-ethyl-N-nitrosourea (ENU) mutagenesis was performed as described 
previously 45,93. The haploid screen was performed as follows. We treated 
homozygous Tg(fli1a:egfp)y1 male adult zebrafish with 3mM ENU for 1hr once 
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a week for a total of four weeks. After two weeks of recovery, Tg(fli1a:egfp)y1 
ENU treated males were crossed to wild type females in order to clear 
unwanted mutagenized gametes which have been shown to harbor gross 
chromosomal aberrations 110. Mutagenized Tg(fli1a:egfp)y1 males were 
subsequently crossed to untreated homozygous Tg(fli1a:egfp)y1 females to 
generate an F1 generation. At six months of age, F1 females were used to 
generate haploid embryos by in vitro fertilization. Briefly, squeezed eggs from 
F1 females were fertilized with UV irradiated sperm from wild type males. Each 
F1 female that successfully gave viable embryos was maintained in an 
individual tank. Tg(fli1a:egfp)y1 haploid embryos were subsequently screened 
at 30 hpf and at 50 hpf for defects in PHBC formation and SeA formation, as 
well as overall morphology. This was performed using a dissection scope 
equipped with epifluorescence. The screening took place once a week for a 
total of six months. F1 Tg(fli1a:egfp)y1 females that gave clutches in which 50% 
displayed a vascular phenotype were subsequently out-crossed to wild type 
male TL zebrafish to generate a map cross. Females generating haploid 
embryos that displayed general morphological defects were not used. 
 
Positional Cloning of um18 
To map the um18 locus, the F1 putant (potential mutant) female was out 
crossed to a wild type TL male in order to generate an F2 generation map-
cross. The resulting progeny from individual F2 in-crosses were assayed for 
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the formation of the PHBC at 26 hpf and circulation at 30 hpf. Finally, siblings 
were assayed for the formation of the TD at 5 dpf and again at 7 dpf. Embryos 
that failed to form both PHBC and TD were designated mutants and were 
subsequently arrayed in a 96 well plate, referred to as the ‘mutant panel’. DNA 
was isolated, amplified, and assayed for polymorphisms as described 
elsewhere 57,111. We performed candidate linkage mapping analysis for vegfc 
(ensembl ID ENSDARG00000069640) and flt4 (ensembl gene ID 
ENSDARG00000015717). The um18 mutation was mapped using simple 
sequence length polymorphisms (SSLPs). Before a specific SSLP marker was 
used to map the mutation, we first confirmed that it was polymorphic in F2 
individuals that produced mutant embryos. The following primers were used to 
amplify specific SSLP markers: Z25069, 5’ AGTTACTTGCGATCCGACCA 3’ 
and 5’ TCACTGGTAAACACCCCTACA 3’. Z11618, 5’ 
TGAGTGGGTGTAGAGGGACA 3ʼ and 5ʼ GATAAGGGGCCTCTTGGTTC 3ʼ. 
Z26040, 5ʼ CCAGAGAACTCCACTTGTGC 3’ and 5’ 
CCCAACTCTGGTCACAATACAA 3’. Z24128, 5’ 
CTCATCACCGCTGCAATAAA 3’ and 5’ ATCTTGTGGGAAACGAGTGG 3’. In 
addition, a single nucleotide polymorphism (SNP) was identified in the 3’ UTR 
of vegfc was subsequently used for finer genetic mapping and genotyping; 
mutants linked to this SNP created an XcmI endonuclease restriction site. The 
vegfc 3ʼUTR locus was amplified using the 5’ CCAACCAACAGTGCAGATG 3’ 
and 5’ GGTTCGAAATGAATGAGTTGC 3ʼ primer pairs, and subsequently 
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digested with XcmI.  Finally, phenotypically mutant and wild type embryos were 
separately digested in DNA lysis buffer. We then separately amplified all seven 
exons of vegfc, including about 100 bp of the surrounding introns and 
subsequently sequenced the CDS and all intron/exon boundaries of vegfc, in 
both phenotypically wild type and mutant embryos.  
 
Phenotypic and Imaging analysis  
Imaging of general morphology and circulation was performed using 
transmitted light on a Leica MZ FLIII using a Zeiss AxioCam MRc digital 
camera. Images of blood vessels and thoracic duct (TD) in Tg(fli1a:egfp)y1 
embryos were obtained using a Leica DMIRE2 confocal microscope (Objective: 
HC PL APO 20x/ 0.70CS). To better visualize parachordal lymphangioblasts 
(PLs) and TD formation, microangiography was performed at 2, 3, 4, and 5 dpf 
using a 1% solution of rhodamine dextran in nuclease free water as described 
elsewhere 112.  Quantification of intersomitic arterial and venous connections 
was based on directional flow in 3 dpf embryos using light transmitted from a 
Leica MZ125 microscope. Segmental arteries and veins were counted laterally 
from the fifth somite through the end of the embryo, anterior to posterior. 
 
vegfc rescue experiments 
To generate expression clones that allowed for tissue specific expression of 
vegfc or vegfcum18, we generated Gateway Entry clones that encoded vegfc 
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and vegfcum18 using the following primers. pMEvegfc: forward 5’ 
GGGGACAAGTTTGTACAAAAAAGCAGGCTGGGCCACCATGCACTTATTTG
GATTTTCTG 3’ and reverse 5’ 
GGGGACCACTTTGTACAAGAAAGCTGGGTTTTAGTCCAGTCTTCCCCAGT
A 3’ primers. To amplify generate pMEvegfcum18 we used the forward 5’ 
GGGGACAAGTTTGTACAAAAAAGCAGGCTGGGCCACCATGCACTTATTTG
GATTTTCTG 3’ and reverse, 5’ 
GGGGACCACTTTGTACAAGAAAGCTGGGTCTTGTTTTGACAAACAGCTGC
AGG 3’ primers. In both cases we eliminated the stop codon from the primer 
and designed them so it would be in frame with a 3’ epitope tag.  To create a 
transgenic vector that allowed endothelial-specific expression of vegfc, 
vegfcum18, or control egfp, we generated pTol2fliebs:vegfc-2Amcherry,  
pTol2fliebs:vegfcum18-2Amcherry and pTol2fliebs:egfp-2Amcherry. To visualize 
expression, a viral 2A sequence was fused in frame with the middle entry ORF. 
The 2A sequence allows expression of multiple proteins from one transgene. 
We mixed pDestTol2pA, p5Efliebs, pMEvegfc w/o stp or pMEvegfcum18 w/o stp 
or pMEegfp3 with p3E2Amcherry at equal molar ratios and subjected them to a 
multisite LR reaction. Positive clones were identified through restriction enzyme 
digest analysis. To assay rescue of the TD formation in vegfcum18 mutants by 
either vegfc or vegfcum18 we injected the embryos from an in-cross of 
Tg(fli1a:egfp)y1;vegfcum18 heterozygous carriers with 25pg either of 
pTol2fliebs:vegfc-2Amcherry , pTol2fliebs:vegfcum18-2Amcherry or 
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pTol2fliebs:egfp-2Amcherry. In all cases, embryos were concomitantly injected 
with 25pg of tol2 transposase mRNA to facilitate genome integration. Injected 
embryos were allowed to develop until 5 dpf and subsequently selected for 
embryos expressing mCherry in endothelial cells. mCherry expressing embryos 
were then scored for presence of the TD and ultimately genotyped. 
MAZ-51 (VEGFR-3 inhibitor) Treatment 
Tg(flk1:crgfp)zn1 ;Tg(fliep:dsRedEX)um13 were separately treated at 48 hpf, 72 
hpf and 96 hpf with 10uM MAZ-51 in egg water and compared to 0.01% DMSO 
control cultured embryos. Embryos were treated and raised in 6-well tissue 
culture plates. The 10uM MAZ-51 solution was replaced daily. 48 hpf, 72 hpf 
and vehicle treated embryos were assayed for TD formation at 96 hpf. 96 hpf 
treated embryos where assayed for TD formation at 120 hpf. 
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Results 
 
A transgenic haploid screen in zebrafish identifies a mutant that mimics 
loss of Vegfc/Flt4 signaling.  
To cause mutations in the zebrafish pre-meiotic germline we treated 
homozygous adult male Tg(fli1a:egfp)y1 zebrafish with ENU (Figure 1A). 
Mutagenized males were subsequently out-crossed to wild type females 
Tg(fli1a:egfp)y1 to generate F1 families of females (Figure 1A) . We generated 
haploid embryos from F1 females (see methods) and subsequently screened 
for PHBC formation at 30 hpf, a defect associated with loss of Vegfc/Flt4 
signaling (Figure 1B-C). Similar to previous haploid screens we noted that 
haploid embryos were morphologically short and stocky which contributed to 
kinks in the notochord and floor plate (Figure 1D). Additionally, we noted that 
morphogenesis of the brain often appeared to be abnormal, however eyes and 
otic vesicles formed normally in haploid embryos (Figure 1D). Despite these 
abnormalities cranial and trunk blood vessel morphology was usually normal in 
wild type Tg(fli1a:egfp)y1 haploid embryos (Figure 1E). In total we screened 
approximately 400 mutagenized genomes and found four females where 
approximately 50% of their haploid offspring failed to form a PHBC by 30 hpf 
(Figure 2A-D and Table 1). In addition to this PHBC mutant phenotype, we 
were able to identify two mutants that displayed ectopic formation of segmental 
arteries (Figure 2E-H and Table 1). A similar class of trunk vessel mutant has  
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Figure 1.II A Transgenic haploid screen in Tg(fli1a:egfp)y1 zebrafish to identify mutants 
affecting Vegfc/Flt4 signaling in zebrafish.  
A. (1) P0 Tg(fli1a:egfp)y1 males were treated with N-Ethyl-N-nitrosurea (ENU) to induce pre-
meiotic germline. (2) Mutagenized males were subsequently out-crossed to wild type untreated 
Tg(fli1a:egfp)y1 females to establish F1 families. (3) Eggs from individual F1 females were in vitro 
fertilized with UV-irradiated sperm from wild type males. B-C. (4) Haploid embryos were allowed 
to develop and screened for the formation of a primordial hindbrain channel (PHBC) and 
segmental artery formation (SegA) at 28 hpf. B. White arrows indicate the presence of the PHBC. 
C. Brackets with an asterisk indicate the absence of a PHBC. Approximately 400 genomes were 
screened. D-E. Wild type haploid Tg(fli1a:egfp)y1 zebrafish embryo. D. Black arrows indicate 
normal eyes and otic vesicle. Black arrow also indicates a kink in the notochord. E. Illumination to 
visualize green fluorescence in haploid Tg(fli1a:egfp)y1 zebrafish embryo. White arrows indicate 
normal PBHC and SegA formation in the head and trunk, respectively.  
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Figure 2. II Haploid mutants with defects in vascular development.  
(A-F) Anterior is to the left. Dorsal is up. (A-D) Haploid progeny from F1 female (m588.5). A,C. 
Transmitted light illumination B,D. Illumination to visualize green fluorescence. (A-B). Wild type 
Tg(fli1a:egfp)y1 haploid embryo. White arrows indicate the presence of the PHBC. (n=7/12 
embryos). (C-D). Mutant Tg(fli1a:egfp)y1 haploid embryo. D. Bracket with asterisk indicates 
absence of PHBC (n=5/12 embryos). (E-H) Haploid progeny from F1 female (m532.15). E,G. 
Transmitted light illumination F,H. Illumination to visualize green fluorescence. (E-F). m532.15 
Wild type Tg(fli1a:egfp)y1 haploid embryo. F. White arrows indicate normal SeA formation. 
(n=13/28 embryos). (G-H). m532.15 mutant Tg(fli1a:egfp)y1 haploid embryo. H. White arrow 
indicate ectopic SeA formation.   
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Table 1.II List of putants identified in transgenic haploid screen.  
ND- Not determined. Q- Glutamine (Gln). Primodial Hindbrain Channel (PHBC).  
Table 2.II Primordial hindbrain channel (PHBC) and thoracic duct (TD) formation in 
progeny of um18 heterozygous carriers.  
Embryos were scored at 30 hpf. for the presence of the primordial hindbrain channel (PHBC) and 
subsequently scored at 5 dpf. for the presence of a thoracic duct (TD). N= total amount of 
embryos scored.    
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been identified previously and appears to be linked to the plexinD1 gene 45,113. 
Once we identified PHBC “putants” (potential mutants); each F1 female, 
presumed heterozygous carries of the mutated allele, was individually crossed 
to wild type male TL zebrafish. This served two important purposes, the first 
being confirmation of the vascular defect observed in the haploid embryos in 
diploid progeny. Second, it allowed the introduction of polymorphic markers 
that were used for linkage analysis (see below). Of the four putant F1 females, 
we were only able to establish one viable F2 family, where the subsequent F3 
progeny displayed identical loss of the PHBC, similar to mutant haploid 
embryos (Table 1). Together, these results suggest that we are able to identify 
a mutant phenotype that phenocopies loss of Vegfc/Flt4 signaling in zebrafish 
using a haploid transgenic screening method. In addition, these results further 
confirm the use of the haploid transgenic screen as a way to rapidly identify 
vascular mutants in zebrafish.   
 
A truncation allele of vegfc perturbs vein and lymphatic development. 
In-crossing individual heterozygous Tg(fli1a:egfp)y1  F2 family members 
(derived from putant F1 females) yielded F3 progeny where about 20% of 
embryos failed to form a PHBC at 30hpf; these mutants were otherwise 
morphologically indistinguishable from wild type embryos with a fully formed 
PHBC (Figure 3A-D Table 2). The lower than expected ratio of PHBC mutant 
progeny suggested this defect was partially penetrant. In fact, we noted that 
PBHC formation recovered by 40 hpf in affected embryos (personal  
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Figure 3.II um18 mutants display defect in vein and lymphatic vessel development.  
(A-H) Anterior is to the left and dorsal is up. DA, Dorsal Aorta. PCV, Pisterior Cardinal Vein. 
PHBC. Primordial Hindbrain Channel. TD. Thoracic Duct. (A-B) Transmitted light illumination. A. 
Wild type um18 diploid Tg(fli1a:egfp)y1. B. Mutant um18 diploid Tg(fli1a:egfp)y1 embryo. (C-D) 
Confocal micrographs of head blood vessels at 30 hpf. C.  PHBC of um18 wild type diploid 
Tg(fli1a:egfp)y1. White arrows denote PHBC. D. PHBC of a mutant um18 diploid Tg(fli1a:egfp)y1 
embryo. Arrows indicate absence of PHBC. (E-F) Confocal micrographs of trunk blood vessels at 
30 hpf. E. Segmental arteries of wild type um18 diploid Tg(fli1a:egfp)y1. Arrows indicate normal 
segmental arteries. F. Segmental arteries of mutant um18 diploid Tg(fli1a:egfp)y1 embryo. Arrows 
indicate normal segmental arteries. (G-H) Confocal micrographs of trunk blood vessels at 5 dpf. 
G. TD in wild type um18 diploid Tg(fli1a:egfp)y1 embryos. Arrows indicate formation of the TD. 
Brackets denote its location with respect to the DA and PCV. H. TD in mutant um18 diploid 
Tg(fli1a:egfp)y1. Arrows and bracket with asterisk indicate absence of the TD.  
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Figure 4.II Lack of thoracic duct formation in embryos that form a normal primordial 
hindbrain channel.  
(A-B) Confocal micrographs of trunk blood vessels at 5 dpf. in progeny from a um18 carrier in-
cross. Embryos were subjected to Microangiography (Red). A. Embryo from um18 carrier in-cross 
with normal formation of PHBC (+) and TD (+). White arrows indicate presence of the TD. B. 
Embryo from um18 carrier in-cross with normal formation of PHBC (+) and absence of TD (-). 
White arrows indicate absence of the TD. 
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observation). To further investigate the extent of defects in this mutant, we 
examined other aspects of blood development and formation lymphatic 
vessels. Examination of SeA formation, which takes place between 22-30 hpf 
in wild type embryos (Figure3E), revealed that SeA were overtly normal in 
embryos that failed to form a PHBC  (Figure 3F). We next investigated whether 
formation of the lymphatic system was affected in mutant embryos. In wild type 
Tg(fli1a:egfp)y1 zebrafish, the first identifiable lymphatic vessel is the thoracic 
duct (TD), a thin blind-ended vessel that normally forms by 5 dpf and lies 
between the dorsal aorta (DA) and posterior caudal vein (PCV; Figure 3G). By 
contrast, we observed that the TD was absent at 5 dpf in mutants that failed to 
form a PHBC. Additionally, we also noted that a high proportion of embryos 
failed to form a TD (70%) within that same clutch, suggesting that this mutation 
caused haploinsuffiency during TD formation (Figure 4A-C and Table 2). 
However, we detected carriers at expected frequencies in adults suggesting 
that they are capable of recovering from this early defect (personal 
observation). We subsequently designated this mutant allele, um18.   
To map the um18 mutant allele we performed candidate gene mapping 
analysis which involves four steps: I) Identification of mutant carriers and 
establishment of the mutant phenotype (above). 2) Identification of polymorphic 
markers in the vicinity of the candidate genes; followed by 3) analysis of 
linkage between a polymorphic marker and the observed mutant phenotype. 
Linkage is based on the analysis of recombination events (meioses) between 
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an inherited marker and mutant allele causing the observed phenotype. If the 
phenotype was not linked to a polymorphic marker then you would expect to 
observe independent assortment of the marker and the phenotype. However, if 
the phenotype was linked to a polymorphic marker then you would expect to 
observe co-segregation of the marker with the mutated locus due to less 
recombination events, which suggest the phenotype is “linked” to a given 
marker. Once a linkage interval is established, one can proceed with the 
sequencing of candidates to identify the causative genetic lesion.   
Since the phenotypic defects observed in um18 mutants were similar to 
Vegfc/Flt4 loss of function 14,15, we treated them as potential genes harboring 
the mutation (candidate gene) and tested whether um18 was linked to either 
loci. We identified single sequence length polymorphisms (SSLPs), also known 
as CA markers, which were in the vicinity of flt4 and vegfc. We subsequently 
assessed linkage to the given locus by analyzing the number of recombination 
events in a panel of phenotypically mutant embryos. We observed that um18 
mutants displayed random assortment of polymorphic CA makers that were in 
close proximity to the flt4 locus (personal observation). We next investigated 
whether um18 mutants were linked to polymorphic CA markers adjacent to the 
vegfc locus. Indeed, we found that um18 lies within 0.2cM (1cM= 0.01 
recombination frequency) of CA marker z11618 of chromosome 1 (Figure 5A). 
Finer mapping of the locus was accomplished by identifying a single nucleotide 
polymorphism (SNP) in the vegfc 3’UTR. 
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Figure 5.II um18 mutation is a truncation allele of Vascular endothelial growth factor c.  
A. Schematic representing region linked to um18 in chromosome 1. Polymorphic markers used in 
this study are indicated above the map. Ratios represent the number of recombination events in 
mutant embryos over total meioses analyzed.    
B. Grey outline box indicating the  CAA (Gln) → TAA (X) transition in the fourth exon of the vegfc 
coding sequence. C. Graphic describing Vegfc protein domains. SS-Signal Sequence(Orange). 
N-Terminal domain(Blue). VHD-VEGF Homology Domain(Red). C-Terminal Domain(Green). 
Black arrow represents a Furin cleavage motif.  
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We observed zero recombination events in 428 analyzed meioses indicating 
tight linkage of um18 to the vegfc gene (Figure 5A). Subsequent sequencing of 
the vegfc coding sequence in um18 mutants revealed a CAA (Gln) to TAA 
(Ochre) transition (Figure 5B). The resulting truncating allele of vegfc 
(vegfcum18) eliminates the C-terminal domain of Vegfc, which is separated from 
the Vegf homology domain (VHD) by a Furin cleavage motif (Figure 5C). 
To confirm that the loss of thoracic duct in vegfcum18 mutants was indeed due to 
loss of vegfc, we performed rescue experiments. Since vegfc is normally 
expressed in arterial endothelial cells, we drove expression of either wild type 
vegfc or vegfcum18 in arterial endothelial cells of vegfcum18 mutant embryos 
using an Ets-binding element from the fli1a gene (Also used in Appendix I). To 
visualize ligand-expressing cells, both vegfc and vegfcum18 were fused in frame 
to mcherry separated by a viral 2A peptide sequence, which allows the 
production of multiple proteins from a single transgene. In control vegfcum18 
mutant embryos expressing fliebs:egfp-2Amcherry in arterial endothelial cells, 
we noted full penetrance of vegfcum18 lymphatic defects (Figure 6A-C and J), 
while transient mosaic expression of fliebs:vegfc-2Amcherry rescued TD 
formation in greater than 60 percent of mutant embryos (Figure 6D-F and J). 
This rescue was mosaic and proximal to arterial cells displaying red 
fluorescence, sites of presumed vegfc transgenic expression (Figure 6E-F, 
yellow arrowheads). By contrast, arterial cells expressing fliebs:vegfcum18- 
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Figure 6.II Arterial expression of transgenic vegfc rescues lymphatic development in 
vegfcum18 mutants.  
(A-I) Confocal micrographs of trunk blood vessels at 5 dpf. Anterior is to the left dorsal is up. DA, 
Dorsal aorta. PCV. Posterior Cardinal Vein. TD. Thoracic Duct. (A-C) Tg(fli1a:egfp)y1vegfcum18 
mutant injected with 25pg of Tol2 transposase and  pTol2egfp-2Amcherry. Yellow arrowheads 
indicate colocalization of Egfp and mCherry. Bracket with asterisk indicate absence of TD. (D-F) 
Tg(fli1a:egfp)y1vegfcum18 mutant injected with 25pg of Tol2 transposase and  pTol2vegfc-
2Amcherry. Yellow arrowheads indicate colocalization of Egfp and mCherry. White arrows 
indicate mosaic rescue of the TD. (G-I) Tg(fli1a:egfp)y1vegfcum18 mutant injected with 25pg of Tol2 
transposase and  pTol2vegfcum18-2Amcherry. Yellow arrowheads indicate colocalization of Egfp 
and mCherry. Bracket with asterisk indicate absence of TD. (J) Quantification of rescue. 
Expressed as the percent of indicated genotype of an injected clutch of um18 heterozygous 
carriers.   
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2Amcherry failed to rescue TD formation in vegfcum18 mutant embryos (Figure 
6G-J). Taken together, these data demonstrate a requirement for the C-
terminal domain of Vegfc during vein and lymphatic vessel development. 
Furthermore, they suggest that arteries guide lymphatic patterning, in part, by 
providing a source of vegfc. 
vegfcum18 mutants display general failure in vein and lymphatic progenitor 
sprouting.  
To investigate why vegfcum18 mutants fail to form lymphatics we analyzed 
various aspects of vascular development that are required in order to form 
lymphatics in zebrafish. Recently, a descriptive analysis of lymphatic 
development in zebrafish found that similar to mice; lymphatic vasculature in 
zebrafish is derived from endothelial cells that sprout from the PCV. Following 
initial sprouting, these venous cells either form secondary intersomitic veins or 
(1.) migrate to the horizontal myoseptum where they become parachordal 
lymphangioblasts (PLs) by 1.5 to 2 dpf. (2.) PLs then migrate dorsally or 
ventrally, where they (3.) eventually become part of the TD between 3-5 dpf 
(Figure 7A). To determine what step in this process was affected in vegfcum18 
mutants, we scored for the formation of PLs and secondary intersomitic veins 
in embryos from an in-cross of heterozygous carriers. While PLs were evident 
in the horizontal myoseptum of wild type siblings (Figure 7B white arrows, E), 
they were completely absent in homozygous mutants as well as vegfcum18 
heterozygotes (Figure 7C-E, brackets). We next investigated secondary  
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Figure 7.II Vegfcum18 mutants display primary defects in lymphatic progenitor and vein 
sprouting.  
(A) Diagram describing lymphatic vessel formation in zebrafish. 1. Dorsal sprouting of 
parachordal lymphangioblsts (PLs) from the posterior cadinal vein (PCV) 1.5-2dpf. 2-3. Ventral 
migration of PLs to form part of the TD. (B-D) Confocal micrographs of trunk blood vessels at 2 
dpf. Anterior is to the left dorsal is up. DA, Dorsal aorta. PCV. Posterior Cardinal Vein. 
Parachoradal lymphangioblast (PL). Embryos were subjected to microangiography. B. 
Tg(fli1a:egfp)y1vegfcum18 homozygous wild type embryo. White arrows indicate presence of PLs. 
C. Tg(fli1a:egfp)y1vegfcum18 homozygous mutant embryo. White brackets with asterisk indicate 
absence of PLs. D. Tg(fli1a:egfp)y1vegfcum18 heterozygous mutant embryo. White brackets with 
asterisk indicate absence of PLs. E. Quantification of PL formation given the indicated genotype. 
Embryos where scored for the presence or absence of PLs at 2dpf. and subsequently genotyped. 
Values are shown as percent embryos of indicated genotype displaying either presence or 
absence of PLs. (F-G) Confocal micrographs of trunk blood vessels at 3 dpf. Anterior is to the left 
dorsal is up. DA, Dorsal aorta. PCV. Posterior Cardinal Vein. SeA. Segmental artery. SeV. 
Segmental vein. White arrowheads denote SeA. White arrows denote SeV. Embryos were 
submitted to microangiography. F. Wild type vegfcum18 embryo.  G. Homozygous vegfcum18 mutant 
embryo. H. Quantification of percent artery and vein connections in phenotypically wild type and 
vegfcum18 mutant embryos. Embryos were scored for the formation of PHBC at 30 hpf. Those 
displaying a PHBC were denoted wild type, those with absence of PHBC were denoted um18 
mutants. At 3dpf. embryos of both phenotypic classes where scored for the connection of 
intersegmental vessel to either DA or PCV was based blood flow, starting from the  anterior fifth 
somite onward. Intersegmental vessels returning blood flow into the DA were denoted as an 
arterial connection. Intersegmental vessels returning blood flow into the PCV were denoted as a 
venous connection. The values shown are based on the average of three independent 
experiments.  
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intersomitic vein formation and found that in comparison to wild type siblings, 
homozygous vegfcum18 mutants had significantly less secondary intersomitic 
vein connections (Figure 7F-H), although vegfcum18 heterozygotes appeared 
normal in this regard (personal observation). These data suggest that the 
primary defect in vegfcum18 mutants is a failure in venous and lymphatic 
progenitor sprouting.  
Our data suggest an early defect in sprouting is the primary defect in vegfcum18 
mutants. To determine whether Vegfc/Flt4 signaling was required for 
subsequent events in lymphatic pattering, we blocked Flt4 activation at 
separate time points before and after PL sprouting using a kinase inhibitor of 
Flt4 (MAZ-51). To better visualize the TD in treated embryos we used the 
Tg(flk1:crgfp)zn1;Tg(fliep:dsRedEX)um13 double transgenic line, which labels the 
TD red. Tg(flk1:crgfp)zn1;Tg(fliep:dsRedEX)um13 embryos were separately  
treated with and subsequently maintained in MAZ-51 at 1,2, 3, and 4 dpf. 
Treated embryos were assessed for TD formation at 5 dpf. We found that 
inhibition of Flt4 signaling at 1, 2, 3 and 4 dpf significantly impaired the ability of 
embryos to form a complete TD when compared to vehicle treated siblings 
(Figure 8A-B, TD labeled Red). Taken together, these data demonstrate a 
requirement for the C-terminal domain of Vegfc during sprouting of lymphatic 
progenitors and segmental vein morphogenesis. Furthermore, these data 
suggest the reiterative use of Vegfc/Flt4 signaling throughout lymphatic vessel 
patterning. 
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Figure 8.II  Vegfc/Flt4 signaling is used reiteratively during lymphatic vessel formation.  
(A). Confocal micrographs of trunk blood vessels in Tg(flk1:crgfp)zn1 ;Tg(fliep:dsRedEX)um13 at 5 
dpf. Red vessels are denoted as a TD by expression of the fliep:dsRedEX transgene. Yellow 
vessels are denoted blood vessels by colocalization of the flk1:crgfp and fliep:dsRedEX 
transgenes. Anterior is to the left dorsal is up. DA, Dorsal aorta. PCV. Posterior Cardinal Vein. 
Thoracic Duct (TD). Embryos were treated in 10uM MAZ-51 at 24 hpf, 48 hpf, 72 hpf.  and 96 hpf. 
Control embryos were treated in 0.01% DMSO and subsequently assayed for the formation of the 
TD at 120 hpf. (B) Quantification of TD in embryos displaying a Continuous TD, Partial TD or 
Absent TD at 120 hpf. Embryos for each treatment were scored for the above-mentioned 
phenotypes and compared to the total amount of embryos scored per treatment to calculate the 
percent of embryos displaying the observed phenotype. Values shown are based on the average 
of three independent experiments.  
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Discussion 
 
Vegfc/Flt4 signaling is required for various aspects of vascular development in 
zebrafish. We hypothesized that screening for early defects in vein 
morphogenesis in mutant haploid embryos would lead to the identification of 
genes that are required for Vegfc/Flt4 signaling. Indeed, our findings 
demonstrate the ability to efficiently carry out a transgenic haploid screen in 
zebrafish to identify mutants with vein and lymphatic defects. Here, we 
identified and positionally cloned a truncation allele of vegfc that displays vein 
and lymphatic vessel patterning defects but overtly normal segmental artery 
formation.   
Previously, work by others has relied of the use of F3 ENU mutagenesis 
screens performed in the Tg(fli1a:egfp)y1 background to isolate mutants that 
effect lymphatic vessel patterning 15,34. Although this standard F3 crossing 
scheme has yielded mutants with lymphatic defects, the amount of time, space, 
and labor involved is prohibitive for a small lab group. Here we show that 
screening for early defects in vein development in mutant transgenic haploid 
embryos expressing Egfp in endothelial cells can be used as a way to isolate 
mutants with defects in Vegfc/Flt4 signaling. Importantly, this method of 
screening reduced the number of generations in our screen by one, thus 
reducing the amount of time it takes to recover embryos with a given recessive 
trait. Similar to previous haploid screens45 we observed that the putative 
  89 
haploid phenotype was recapitulated in diploid embryos, which further 
demonstrates that this method of screening can be used to identify mutants 
affecting vascular development.  
We previously used this same haploid strategy in a blood vessel transgenic 
background to isolate mutants with defects in SeA formation. This screen 
yielded 17 mutant loci of approximately 1200 mutagenized genomes. The 
authors were able to establish 14 F2 families of the 17 mutant loci of which only 
10 recapitulated the haploid mutant phenotype. These 17 mutants 
encompassed four distinct classes of segmental artery phenotypes 45. By 
contrast, our screen focused on the specific absence of the PHBC and we 
observed 4 mutant loci of approximately 400 mutagenized genomes; of which 
we were only able to establish 1 F2 family. This F2 family yielded F3 progeny 
that recapitulated the observed mutant haploid phenotype. As a result, one of 
the main differences we observed between this and the aforementioned 
haploid screen was in the recovery of F2 families (82%, previous vs. 25%, 
present). Given that both screens focused on particular aspects of vascular 
development; one on SeA formation 14 and the other PHBC formation (present 
study) we can speculate that if we were able to recover a higher proportion of 
F2 families then we would increase the rate of identifying PHBC mutants.  
Although we were able to successfully identify a lymphatic mutant using this 
indirect screening approach, this method of screening would possibly fail to 
obtain genes that are involved in lymphatic vessel development but not PHBC 
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formation. Some of these examples include: the calcium and collagen binding 
EGF-like domain 1 gene (cceb1), synectin, sox18 and prox1, all of which 
display lymphatic defects but normal PHBC formation (personal 
observation)34,53. Additionally, this method of screening could potentially fail to 
identify genes involved in aspects of vascular development that are required 
past the formation of the PHBC, therefore excluding genes involved in 
lymphatic vessel function and maintenance for example. However, during the 
characterization of the vegfcum18 mutant we noted that the Flt4 signaling 
pathway was used reiteratively throughout the formation of the TD (Figure 8A-
B). This implies that indirectly screening for early defects in vein 
morphogenesis, which requires Vegfc/Flt4 signaling, may be useful to identify 
additional mutant alleles that affect aspects of lymphatic vessel development in 
zebrafish. 
The profound defects of the vegfcum18 mutation on lymphatic vessel 
development suggest that the C-terminal domain of Vegfc is necessary for 
proper vein and lymphatic vessel formation but dispensable for segmental 
artery formation. Our finding that that vegfcum18 mutants display general defects 
in venous and lymphatic progenitor cell sprouting were strikingly similar to 
those observed in Vegfc knockout mice and Vegfc morphant zebrafish 
embryos, where lymphatic progenitor cells fail to sprout from the PCV 16,17,33. 
Why are lymphatic defects so severe in vegfcum18 mutants? Further insight may 
come from biochemical and molecular characterization of Vegfcum18, which 
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include investigation into its secretion and ability to activate Flt4. Structurally 
the C-terminal domain of Vegfc is similar to the secretory silk protein, BR3P. In 
addition, it also contains short motifs homologous to EGF-like domains, which 
have been known to associate with the extracellular matrix (ECM) 59,60. 
However, to this date no function has been ascribed to this domain.  
We observed a haploinsufficient lymphatic vessel phenotype in vegfcum18 
mutants. This phenotype was reminiscent of Vegfc heterozygous knockout 
mice, which display developmental and functional lymphatic vessel defects. 
Therefore, our data suggests that vegfcum18 may act as a null allele during 
lymphatic vessel development. Interestingly, we were able to recover visibly 
healthy heterozygous vegfcum18 carriers at the expected frequency suggesting 
recovery of the lymphatic defects. Therefore, it is possible that the TD is 
delayed in vegfcum18 heterozygotes and recovers later in development. Yet 
another possibility may be the existence of an additional factor, which may act 
redundantly to pattern the TD. Vegfd is member of the Vegf family that has 
been shown to activate Flt4. In mice, recombinant Vegfd was able to rescue 
migration in vegfc deficient lymphatic cells 16. However, similar to mice, 
endogenous vegfd is not expressed near areas of TD formation in zebrafish 
(personal observation).      
In zebrafish, vegfc is normally expressed in the dorsal aorta. Recently a study 
in this model system has described the requirement of arterial endothelial cells 
in the formation of lymphatics 36. Consistent with these studies, expression of 
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vegfc in arterial cells rescued lymphatic vessel formation in vegfcum18 mutants 
(Figure 5D-F and J). This expression was adjacent to where the TD ultimately 
forms. Additionally, similar expression of vegfcum18 failed to rescue lymphatics 
in affected embryos homozygous mutant embryos. However, we noted a partial 
rescue of lymphatics in vegfcum18 heterozygotes, implying that increased levels 
of vegfcum18 in the presence of a wild type copy of vegfc is enough to pattern 
lymphatics. Taken together, these data imply that vegfcum18 mutants may have 
paracrine defects, which ultimately perturb budding of lymphatic progenitors. 
These data also support a paracrine mode of signaling by Vegfc from blood 
vessels in the formation of lymphatics during development. However, further 
characterization of Vegfcum18 should help uncover the molecular basis for 
defects in vegfcum18 mutants.  
Finally, we have previously demonstrated that vegfc is required for proper 
segmental artery morphogenesis in zebrafish. Interestingly, segmental arteries 
develop normally in vegfcum18 mutants. Why is segmental artery formation 
normal in vegfcum18 mutants? Since vegfc is expressed in SegA, it is possible 
that vegfcum18 may still be active in this context of vascular development, 
independent of the Vegfc C-terminal domain. Further biochemical and genetic 
analysis of vegfcum18 presented in the proceeding chapter will shed light into the 
role of Vegfc during developmental angiogenesis.  
In summary, we successfully employ a transgenic haploid screen to identify 
mutants that affect distinct aspects of vascular development through Vegfc/Flt4 
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signaling. The mutant allele identified in this study helped revealed a previously 
unknown requirement for the C-terminal domain of Vegfc during vein and 
lymphatic vessel sprouting. The non-cell autonomous rescue of lymphatics by 
wild type vegfc demonstrates a paracrine signaling mechanism of Vegfc by the 
dorsal aorta to pattern the lymphatics during embryonic development.  
Interestingly, the C-terminal domain appears to be dispensable during 
developmental angiogenesis. Together, these data highlight the diverse role of 
Vegfc/Flt4 signaling during vascular development and imply a context 
dependent role for this signaling pathway during formation of distinct vessel 
types in zebrafish.  
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CHAPTER III 
 
 
 
 
 
 
 
GENETIC, BIOCHEMICAL AND MOLECULAR CHARACTERIZATION OF 
VEGFCUM18 REVEALS DISTINCT MODES OF SIGNALING DURING BLOOD 
AND LYMPHATIC VESSEL DEVELOPMENT IN ZEBRAFISH. 
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Introduction 
In the preceding chapter we identified and cloned a mutant allele of vegfc 
(vegfcum18), which results in the premature truncation of zebrafish Vegfc and 
eliminates its C-terminal domain. Affected embryos lack lymphatic vessel 
formation due to earlier defects in parachoradal lymphangiobalst (PLs) and 
venous sprouting. We found that transient transgenic expression of vegfc in the 
DA rescued lymphatic vessel formation as indicated by presence of the thoracic 
duct (TD) in mutant embryos. Interestingly, we observed that segmental arteries 
(SegA) developed normally in vegfcum18 mutants when compared to their wild 
type siblings. Our results suggest the C-terminal domain of Vegfc is required for 
certain aspects of vascular development (i.e. vein and lymphatic vessels) yet 
dispensable for others (i.e. SeA formation), thus emphasizing the diverse role of 
the Vegfc/Flt4 signaling pathway during vascular development.  
Vegfc is a secreted growth factor that undergoes proteolytic processing events 
that regulate its activity. As mentioned in the preceding chapter, sites of 
processing reveal domains within Vegfc including a central Vegf homology 
domain (VHD), which is separated from the C-terminal domain by a conserved 
Furin motif. The VHD has been shown to be necessary and sufficient for receptor 
activation, while the function of the C-terminal domain is largely unknown60,74. 
The um18 mutation creates a truncated version of Vegfc with an intact VHD but 
absent C-terminal domain. Structurally, the C-terminal domain of Vegfc is similar 
to the secretory silk protein, BR3P, and contains short motifs that are 
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homologous to EGF-like domains of other secreted proteins 58,59,66,114. These 
short motifs are involved in protein secretion and interactions with the 
extracellular matrix (ECM) 73,114.  
Genetic evaluation of vegfcum18 mutants suggest that the observed phenotype 
during vein and lymphatic vessel formation may be due to a functional failure of 
Vegfc/Flt4 signaling. This phenotype is consistent with previous vegfc/flt4 loss of 
function studies in vertebrates, which have demonstrated that proper functioning 
of this signaling pathway is necessary for vein and lymphatic vessel 
formation8,15,16,33. Interestingly, vegfcum18 mutants do not phenocopy vegfc/flt4 
loss of function during developmental angiogenesis14,62 implying that Vegfc/Flt4 
signaling may still be functional in vegfcum18 mutants in this context. Further 
insight into to the mechanisms that regulate the formation of these distinct vessel 
types during development may come from evaluating how the vegfcum18 mutation 
affects the molecular function of Vegfc.  
In this chapter we present evidence that suggests two modes of signaling by 
Vegfc during blood and lymphatic vessel development in zebrafish. We find that 
inefficient secretion is the primary molecular defect of Vegfcum18, thus implying 
that the observed lymphatic defects in vegfcum18 is due to inadequate paracrine 
activity by Vegfc. By contrast, during SeA formation, we observe functional 
redundancy from the Vegfa signaling pathway that likely compensates for the 
secretion defects in vegfcum18 mutants. Additionally, we find that Vegfc appears to 
act in an autocrine manner during blood vessel development. We observed that 
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Vegfcum18 induced mild effects on blood vessels when expressed in an 
endothelial autonomous manner. Moreover, we find that cell autonomous 
downregulation of vegfc in endothelial cells reduces their ability to occupy the tip 
cell position during developmental angiogenesis, suggesting a cell autonomous/ 
autocrine role for Vegfc during developmental angiogenesis. As a whole, we 
believe our results suggest a possible mechanism that involves discrete modes 
of cell signaling by the Vegfc/Flt4 pathway in the formation of blood and 
lymphatic vasculature in zebrafish. 
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Materials and Methods 
Zebrafish, transgenic and mutant lines 
Zebrafish were housed and maintained in accordance to standard protocols 
described elsewhere. The um18 is stop codon mutation in the fourth exon of 
vegfc and was isolated from a haploid mutagenesis screen. um18 mutant carriers 
were crossed in the Tg(fli1a:egfp)y1 background. Wild type Tg(fli1a:egfp)y1 
zebrafish embryos were used for ZFYM assay and mammalian cell xenograft 
studies.  
Phenotypic analysis and microscopy of zebrafish embryos. 
Imaging general morphology of zebrafish using transmitted light was performed 
on a Leica MZ FLIII using a Zeiss AxioCam MRc digital camera. Images of blood 
vessels, subintestinal vessels (SIVs) and xenografted NIH3T3 cells expressing 
either ligand in Tg(fli1a:egfp)y1 embryos were obtained using a Leica DMIRE2 
confocal microscope (Objective: HC PL APO 20x/ 0.70CS). To measure 
segmental artery length, embryos were fixed and subjected to antibody staining 
using an α-EGFP antibody (Molecular Probes) 14. Images of segmental arteries 
were captured using confocal microscopy and length was quantified using Imaris 
software (Bitplane).  
Conditioned zfVegfc and zfVegfcum18 media. 
The pMT-Ex-zfVEGF-C-wt vector for the expression of full-length wild type 
zebrafish VEGF-C in Drosophila S2 cells (Invitrogen) was constructed by cloning 
the BamHI/NotI-cleaved PCR product forward primer: 5' 
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GAGGATCCATTCGAGTCAAGTCACGACTAC-3', reverse primer: 5'-
GGGCCCTCTAGACTCGAGCG-3', template: full-length zebrafish VEGF-C cDNA 
(Ref1) into a pMTBiP-V5His-C vector (Invitrogen), that had been modified to a) 
include the hygromycin resistance gene from pCoHygro (Invitrogen) and b) have 
a frameshift mutation between the coding sequence for the BiP signal peptide 
and the multiple cloning site such that the 5'-GAT-3' from the BglII site codes for 
an aspartic acid residue. The construction of pMT-Ex-zfVEGF-C-um18 was done 
in the same way except that the reverse primer was 5'-
CTGCGGCCGCTTATTTTGACAAACAGCTGCAGGAAG-3'. S2 cells were 
transfected with the constructs and stable cell pools were created according to 
standard protocols. To produce protein, cells were induced with 1 mM CuSO4 
and conditioned cell supernatant was harvested 3.5 days post induction. These 
media were produced by Michael Jelstch in a collaboration with the Alitalo 
Lab (Univ. of Helsinki) 
 
Zebrafish yolk membrane angiogenesis assay (ZFYM) and Mammalian 
cell/zebrafish xenografts.   
We separately injected 4nL of normalized zebrafish Vegfc (zfVegfc), zfVegfcum18 
and negative control conditioned media into the perivitellene space of 
anesthetized 48 hpf Tg(Fli1a:egfp)y1 embryos as described elsewhere115. 
Injected embryos were assayed for the total amount of ectopic vessels sprouting 
from SIVs at 3.5 dpf. Images of embryos were obtained using a Leica DMIRE2 
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confocal microscope (Objective: HC PL APO 20x/ 0.70CS) and analyzed using 
the Imaris imaging software package (Bitplane).  
For the xenograft studies, we anesthetized 48 hpf embryos injected with ~1500 
cells/nL stable NIH 3T3 cells expressing either zfvegfc-2Acherry or zfvegfcum18-
2Acherry diluted in matrigel (Sigma). Xenografted embryos were allowed to 
develop 2 days post engraftment and subsequently evaluated for 
neovacularization of grafted cells. Imaris imaging software (Bitplane) was used to 
quantify the relative amount of ligand expressing cells (red voxels) and vessels 
(green voxels)116.  
VEGF-C secretion analysis in cultured cells  
NIH3T3 cells cultured in DMEM supplemented with 10% newborn fetal calf 
serum were transiently transfected with either pSport6CMVVEGF-C (Open 
Biosystems) or pCSVEGF-CΔC. To generate the VEGF-CΔC expression vector 
we generated a VEGF-CΔC Gateway entry clone as described elsewhere. We 
used the pSport6CMVVEGF-C plasmid as a template and amplified VEGF-CΔC 
using the following primers: 5’ 
GGGGACAAGTTTGTACAAAAAAGCAGGCTGGGCCACCATGCACTTGCTGG
GCTTCTTCT 3’ and 5’ 
GGGGACCACTTTGTACAAGAAAGCTGGGTCTTATTTAGACATGCATCGGCA
GG 3’. pME VEGF-CΔC was LR cloned into the pCSDest plasmid to create the 
pCSVEGF-CΔC. Cells were collected at 30 hour post transfection and 72 hours 
post transfection and subsequently lysed in RIPA lysis buffer (RIPA- 150mM 
  101 
NaCl, 50mM Tris ph 8.0, 1% NP-40, 0.1%SDS, Complete Mini (Roche)). Media 
was collected and concentrated using centrifugal filter units (Ultragel -10K, 
Millipore). Lysates and media were subjected to SDS-PAGE immunoblot analysis 
and probed with a polyclonal human anti-VEGF-C antibody (provided by the 
Alitalo). Membranes were stripped and re-probed with a monoclonal α-Tubulin 
(Green Lab) antibody as a loading control.  
Flt4 activation assay    
NIH3T3 cultured in DMEM supplemented with 10% newborn fetal calf serum 
were transiently transfected with pCSzfflt4-HA. At 24 hrs post transfection, cells 
were starved for 24 hrs and separately stimulated with normalized zfVegfc, 
zfVegfcum18, and negative control conditioned media. Cells were lysed in RIPA 
lysis buffer and submitted to immunoprecipitation analysis using a polyclonal 
antibody raised to the zebrafish homologue of VEGFR3 (zfFlt4). 
Immuoprecipitated samples were subsequently submitted to SDS-PAGE 
immunoblot analysis and probed with a monoclonal antibody raised to 
phosphoTyrosine (4G10 clone, Millipore). Membranes were stripped and re-
probed with a monoclonal α-HA (BABCO) to normalize against total zfFlt4. To 
generate pCSzfflt4-HA, we created pMEflt4 w/o stp using the forward 5’- 
GCCACCATGAAGAGAGATTTTACGTTTTTCTG-3’ and reverse: 5’- 
CGTAAACGGCCTGGTCTGAG-3’. pMEflt4 w/o stp and p3E-HA were cloned into 
pCSDest2 using LR clonase plus II.  
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Genotyping  
To genotype Tg(fli1a:egfp)y1vegfcum18;kdry17 double mutants, DNA was extracted 
as described elsewhere. The kdry17 allele was genotyped using the dCAP oligos 
(ref.) followed by DdeI restriction enzyme digest. To genotype the vegfcum18 
allele, DNA was extracted as described elsewhere and subjected to a 
customized TaqMan SNP genotyping assay (Applied Biosystems).  
Zebrafish DNA injections 
To analyze the autonomous effect of vegfc and vegfcum18 on blood vessels we 
injected one-cell stage Tg(fli1a:egfp)y1 embryos with 25pg of either 
pTol2flieb:vegfc-2Amcherry, pTol2flieb:vegfcum18-2Amcherry or pTol2fliebsegfp-
2Acherry together with 25pg of tol2 transposase mRNA. We subsequently 
counted the amount of ectopic vessel of mCherry expressing segmental arteries 
over the span of six hemisegments.  
Mosaic Analysis 
For mosaic analysis of vegfc deficient cells in wild type vasculature, we injected 
either vegfc MO or control MO into Tg(fli1a:egfp)y1 embryos at 1-2 cell stage and 
allowed to develop. At the high stage, cells from the marginal zone were 
separately extracted from vegfc deficient and control MO injected Tg(fli1a:egfp)y1 
embryos and transplanted into Tg(kdrl:rasmcherry)s916 host embryos at the same 
stage. Embryos were allowed to develop until 30 hpf. We subsequently noted the 
position of the transplanted vegfc MO or control MO endothelial cells (green) in 
the wild type Tg(kdrl:rasmcherry)s916 host. We noted contribution to the tip cell, 
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stalk, dorsal aorta or posterior cardinal vein in both control and vegfc MO 
transplanted cells.   
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Results 
 
The C-Terminal domain of Vegfc is required for its secretion 
To better understand how the um18 mutation affects the molecular function of 
Vegfc, we first tested the ability of wild type and mutant Vegfc to activate Flt4. In 
mammalian cells expressing the zebrafish homolog of Flt4, we observed that 
Vegfc-conditioned media potently induced autophosphorylation of Flt4 compared 
to both the negative conditioned media and PBS treated controls (Figure 1A 
lanes 1,2 and 4). Likewise, we observed that Vegfcum18-conditioned media 
induced Flt4 activation to levels similar to wild type Vegfc (Figure 1A, compare 
lane 2 and 3).  As a parallel in vivo assay, we compared the activity of wild type 
Vegfc and Vegfcum18 using the zebrafish yolk angiogenesis assay (ZFYM)115. 
Following injection of Vegfc-conditioned media into the perivitelline space of 
zebrafish embryos at 48 hpf, we observed significant induction of ectopic sub 
intestinal vessels (SIVs) when compared to uninjected embryos or those injected 
with mock conditioned media (Figure 1B-E). Additionally, we found that 
Vegfcum18-conditioned media induced ectopic SIV formation similar to levels 
induced by Vegfc (Figure 1D-F). Together, these observations indicate that loss 
of the C-terminal domain of Vegfc caused by the um18 mutation does not affect 
its ability to activate Flt4 or to directly induce an angiogenic response in vivo.   
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Figure 1.III Vegfcum18 induces zfFlt4 activation and in vivo angiogensis. 
(A) Phosphorylation of zebrafish Flt4 (zfFlt4) by wild type zebrafish Vegfc (zfVegfc) and zebrafish 
Vegfcum18 (zfVegfcum18). Mouse fibroblasts (NIH 3T3) transiently expressing zfFlt4 and starved for 
24 hrs were treated separately with conditioned Negative control, zfVegfc, and zfVegfcum18 
conditioned media. PBS treated cells were used as control for autophosphorylation. Subsequent 
immuneprecipitation of lysates with an antibody directed toward zebrafish Flt4 followed by 
western blot analysis with an anti- phosphotyrosine (pTyr) antibody. Membranes were stripped 
and probed with zfFlt4 antibody to assess total levels of zfFlt4 in immunoprecipitated lysates. (B-
C, E-F) In vivo zebrafish yolk membrane angiogenesis assay (ZFYM). Confocal micrographs of 
SIV, Sub intestinal vessels at 3.5 dpf, 1.5 days post injection. Anterior is to the left, dorsal is up. 
(B) uninjected Tg(fli1a:egfp)y1 embryo. White arrowheads indicate the Sub-Intestinal Vessels 
(SIVs). (D) Tg(fli1a:egfp)y1 embryo injected with Negative control conditioned media. (E) 
Tg(fli1a:egfp)y1 embryo injected with zfVegfc conditioned media. (F) Tg(fli1a:egfp)y1 embryo 
injected with zfVegfcum18 conditioned media. (E-F) White arrows indicate ectopic SIVs. (G.) 
Quantification of ectopic SIVs. Values are shown based on the average of three independent 
experiments  (*, **p< 0.05) (N.S.- not significant).   
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These observations are consistent with previous studies on human Vegfc in 
which the Vegf-homology domain alone is sufficient to activate Flt4 60.  
Vegfc is a growth factor that is thought to act in a paracrine manner to induce 
lymphangiogenesis1,2,16. Therefore, we examined whether the C-terminal domain 
of Vegfc was required for its secretion. Since an appropriate antibody against 
zebrafish Vegfc was not available, we analyzed lysates and media of mammalian 
cells transiently expressing human VEGF-C (VEGF-C) or the human equivalent 
of Vegfcum18 (VEGF-CΔC). As expected, we were able to detect the presence of 
both the unprocessed and processed forms of VEGF-C in lysates and media 
fractions of transfected cells (Figure 2A, lanes 1 and 3). By contrast, we noted an 
increased accumulation of VEGF-CΔC in cell lysates compared to wild type 
VEGF-C (Figure 2A, lanes 1 and 2) and we were unable to detect any VEGF-
CΔC in the media from expressing cells at 30 hours post transfection (Figure 2A, 
lane 4, and 2B), although by 72 hours post transfection, media from mammalian 
cells expressing VEGFC-CΔC displayed levels of secretion similar to those 
observed in media of mammalian cells expressing VEGFC. (Figure 2C, compare 
lane 3 and 4). Evaluation of lysates of both VEGFC or VEGFC-ΔC expressing 
cells at this time point revealed that VEGFC-ΔC continued to accumulate in cell 
lysates (Figure 2C, lane 2). By contrast VEGFC was efficiently secreted, as it 
was barely detectable in the cytoplasmic fraction but at high levels in the media 
(Figure 2C lanes 1 and 3), implying that VEGFC-ΔC is inefficiently secreted.   
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Figure 2.III Vegfcum18 lacks the ability to be secreted and induce angiogenic response in 
vivo.  
(A-B) Biochemical evidence that the C-terminal domain of Vegfc is required for its secretion. Cell 
lysates and Media from NIH3T3 cells transiently expressing human vegfc (VEGF-C) and human 
equivalent of vegfcum18 (VEGF-CΔC) separately, were used to monitor both VEGF-C and VEGF-
CΔC secretion. Cytoplasmic and Media fractions were collected 30 hrs post transfection and 
subsequently analyzed by immunoblot with VEGF-C antisera. Western blot analysis of total cell 
lysate was performed with an anti- α Actin antibody. (H) Quantitative analysis of VEGF-C and 
VEGF-CΔC secretion. The histogram is a quantification of western blot analysis (A) where the 
amount of VEGF-C and VEGF-CΔC secretion was expressed as a ratio of Media arbitrary units 
(A.U.) over the Total (Media and Cell Lysate fractions) A.U. Values are shown based on the 
average of three independent experiments (*p<0.05). (C) Cell lysates and Media from NIH3T3 
cells transiently expressing human vegfc (VEGF-C) and human equivalent of vegfcum18 (VEGF-
CΔC) separately. Cytoplasmic and Media fractions were collected 72h hrs post transfection and 
subsequently analyzed by immunoblot with VEGF-C antisera. (D-F) in vivo zebrafish xenograft 
assay. Confocal image of a 4.5dpf Tg(fli1:egfp)y1 where NIH3T3 cells expressing either Vegfc-
P2Amcherry or Vegfcum18-P2Amcherry were xenografted  in to the perivitellene space of the 
embryos at 2.5dpf and subsequently investigated invasiveness of the xenograft  by blood vessels 
at 4.5dpf. Anterior is to the left, dorsal is up.  (D) Tg(fli1:egfp)y1 with xenografted NIH3T3 cells 
expressing Vegfc-P2Amcherry. (E) Tg(fli1:egfp)y1 with xenografted NIH3T3 cells expressing 
Vegfcum18-P2Amcherry. (F) Quantification of zebraffish xenograft assay. Where invasiveness of 
the xenograft was measured as a ratio of green voxels (blood vessel) over red voxels 
(mammalian cells) expressing. Values are shown based on the average of three independent 
experiments (*p<0.05).    
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These results suggest that a defect in Vegfc secretion is likely responsible for the 
lymphatic defects in vegfcum18 mutants.  
To further confirm the consequence of this secretion defect in vivo, we assessed 
the ability of xenografted cells expressing either zebrafish vegfc or vegfcum18 to 
induce blood vascular growth in zebrafish embryos. As above (Chapter II), both 
vegfc and vegfcum18 were fused to 2Amcherry to visualize ligand-expressing cells. 
At 2 days post graft we noted that mock-transfected cells were unable to induce 
appreciable levels of vascularization, while those expressing Vegfc-2Amcherry 
were highly vascularized (data not shown and Figure 2D). By contrast, grafted 
cells expressing Vegfcum18-2Amcherry induced significantly lower levels of 
neovascularization (Figure 2E-F). Taken together, these data suggest that the C-
terminal domain of Vegfc is required for its efficient secretion and ability to act in 
a paracrine manner to induce neovascularization and lymphatic vessel formation.  
A role for Vegfc signaling during developmental angiogenesis. 
We have previously shown that genetic downregulation vegfc impairs SeA 
sprouting in zebrafish embryos, showing 14. However, we did not observe 
significant defects in SeA length of vegfcum18 mutants when compared to wild 
type siblings (see below). Since vegfc is expressed in the endothelial cells of the 
SeA themselves, it is plausible that Vegfc might act in an autocrine manner, in 
which case the secretion defect caused by um18 would have mild or no effects 
on blood vessel sprouting. Given that SegA formation involves signals from other 
signaling pathways, it is further plausible that compensatory signals from other 
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signaling pathways such as Vegfa could mask these effects, i.e. defect 
associated with vegfcum18 . Previously, we along with others have shown that the 
Vegfa signaling pathway is essential for angiogenesis 14,44,57,78. To determine 
whether Vegfa signaling compensates for defects in vegfcum18, we generated 
adult zebrafish bearing the Tg(fli1a:egfp)y1 transgene that were doubly 
heterozygous for vegfcum18 and kdrly17, a kinase dead mutation in the zebrafish 
ortholog of vegf receptor-2, kdrl, and assessed SeA length in their progeny.  In 
vegfcum18 homozygous mutant embryos from Tg(fli1a:egfp)y1 double mutant 
carriers, we did not observe any significant reduction in SeA length at 30 hpf 
compared to embryos that were homozygous wild type at both loci (Fig. 3A, B, 
E).  By contrast, we observed variable, but significantly reduced, SeA length in 
kdry17 mutant embryos that were wild type for the vegfc locus, similar to our 
previous work (Fig. 3C, E)45. However, in kdrly17;vegfcum18 double mutant 
embryos (vegfc-/-;kdr-/-), we noted much more severe and significant decreases in 
SeA length as compared to either wild type or kdrly17 mutants alone (Fig. 3A-E). 
These observations suggest that normal sprouting can proceed in vegfcum18 
mutants as a result of compensatory signaling through the Vegfa pathway. 
Moreover, these data also imply that Vegfc signaling has marginal effects on 
blood vessel development, in comparison to its prominent role during lymphatic 
vessel development.  
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Figure 3.III Vegfa signaling masks defects in vegfcum18 mutant embryos during 
developmental angiogenesis.  
(A-F) Confocal micrographs of trunk blood vessels at 30 hpf. Anterior is to the left, dorsal is up. 
DA, Dorsal Aorta. PCV, Posterior Cardinal Vein. (D) Wild type Tg(Fli1:egfp)y1 embryo. (D) 
Tg(Fli1:egfp)y1;vegfcum18 mutant embryo. (E) Tg(Fli1:egfp)y1;kdry17 mutant embryo. White arrows 
denote defects in SegA sproouting (F) Tg(Fli1:egfp)y1;kdry17vegfcum18 double mutant embryo. 
White arrowheads denote severe defects in SeA sprouting. (G) Quantification of SegA length. 
SegA length was measured across seven SegA for each embryo at 30hpf. Embryos were and 
subsequently genotyped. Values are shown based on the average of two independent 
experiments. (*, **,***p>0.05) (N.S.-Not Significant). 
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An endothelial autonomous role for Vegfc during developmental 
angiogenesis.  
In situ expression analysis revealed that vegfc is expressed in the endothelial 
cells of the SeA themselves 14, similar to flt4 expression. This endothelial cell 
autonomous expression of vegfc and its receptor suggest an autocrine mode of 
signaling during developmental angiogenesis. In fact, we find that Vegfc acts in 
parallel with the Vegfa signaling during angiogenesis (above). To investigate the 
cell autonomous role for Vegfc during blood vessel development, we first 
determined the autonomous effect of Vegfc and Vegfcum18 on endothelial cells by 
using the fli1ebs element to drive their expression in wild type vasculature.  We 
observed that transient expression of fli1ebs:vegfc-2Amcherry in developing 
segmental arteries could induce ectopic vessel formation within the horizontal 
myoseptum, as compared to transient expression of egfp-2Amcherry, which had 
no effect (Figure 4A-B and D). Likewise, we observed ectopic vessel formation in 
segmental vessels expressing fliebs:vegfcum18-2Amcherry (Figure 4C).  However, 
vegfcum18 elicited this effect in a significantly lower proportion of vessels 
compared to wild type vegfc (Figure 4D).  Thus, vegfcum18 is still capable of 
inducing a modest, albeit reduced, angiogenic effect on endothelial cells in which 
it is expressed, despite the loss of the C-terminus that is required for proper 
secretion.  This is in stark contrast to its complete inability to induce 
lymphangiogenesis or rescue the vegfcum18 phenotype compared to wild type 
Vegfc (see Chapter III, Figure 6). Our results demonstrate that endothelial-
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expressed Vegfc can induce angiogenic cell behaviors, even when its secretion 
is compromised, suggesting that it acts in an autocrine and/or autonomous 
manner.  
Our results demonstrate that endothelial-expressed Vegfc can induce angiogenic 
cell behaviors, even when its secretion is compromised, suggesting that it acts in 
an autocrine and/or autonomous manner. Therefore, to determine if endogenous 
Vegfc was required in a cell autonomous manner, we performed mosaic analysis. 
For this purpose, we transplanted cells from donor Tg(fli1:egfp)y1 embryos 
injected with Vegfc or control morpholino into Tg(kdrl:rasmcherry)s916 host 
embryos.  We subsequently assayed the ability of GFP-positive donor cells to 
occupy either the vein, artery, stalk or tip cell position at 30 hpf.  We found that 
control donor endothelial cells were able to occupy all trunk blood vessel 
positions (Figure 4E and G) with relatively equal frequency. By contrast, vegfc-
deficient cells displayed much less frequent contribution to both the distal tip cell 
position and posterior cardinal vein than control morphant cells (Figure 4F and 
G).  Together with our endothelial over-expression manipulations, these 
observations suggest that vegfc is required in an endothelial cell autonomous 
manner for sprouting cell behaviors and efficient angiogenesis. 
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Figure 4.III Autocrine role for Vegfc during developmental angiogenesis.  
(A-B) Confocal micrographs of trunk blood vessels at 30 hpf. Anterior is to the left, dorsal is up. 
DA, Dorsal Aorta. PCV, Posterior Cardinal Vein. (A) Tg(fli1a:egfp)y1 embryos injected with 25 pg 
transposase mRNA and 25 pg  pTol2fliebs:egfp-2Acherry. White arrows indicate co-localization of 
transgene expression in SegA. (B) Tg(fli1a:egfp)y1 embryos injected with 25 pg transposase 
mRNA and 25 pg  pTol2fliebs:vegfc-2Acherry. White arrows indicate co-localization of the 
transgene in SegA that display ectopic branching. (C) Tg(fli1a:egfp)y1 embryos injected with 25 pg 
transposase mRNA and 25 pg  pTol2fliebs:vegfcum18-2Acherry. White arrows indicate co-
localization of the transgene in SegA that display ectopic branching. (D) Quantification of ectopic 
branching of SegA in for fliebs:egfp-2Acherry (n=12) and fliebs:vegfc-2Acherry (n=18) injected 
embryos expressing the transgene in SeA. Values are shown as proportion of embryos 
expressing the given transgene within SegA and displaying ectopic branching over the total 
amount of embryos expressing the given transgene within SeA.  NOTE. Parts of this figure 
appear in Appendix I. (E-F) Confocal micrographs of trunk blood vessels at 30 hpf 
Tg(kdrl:rasmcherry)s916 host embryos. Anterior is to the left, dorsal is up. DA, Dorsal Aorta. PCV, 
Posterior Cardinal Vein. (E) Tg(kdrl:rasmcherry)s916 host embryo transplanted with vegfc deficient 
cells. White arrow denotes a stalk cell. (F) Tg(kdrl:rasmcherry)s916 host embryo transplanted with 
Ctrl MO deficient cells. White arrow indicates tip cell position. (G) Quantification of endothelial cell 
occupancy in a wild type host at 30 hpf. 
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Discussion 
In this study we show that inefficient secretion of Vegfc is the primary molecular 
defect in vegfcum18 mutants. This lack in paracrine activity is likely responsible for 
the observed defects in lymphatic vessel formation in this mutant. By contrast, 
we find that despite Vegfc secretion defects, SeA formation proceeds normally in 
vegfcum18 mutants due to compensation by Vegfa signaling. Additionally, we 
present endothelial cell autonomous loss- and gain-of-function observations, 
which suggest a cell autonomous autocrine mode of signaling by Vegfc during 
developmental angiogenesis. As a result these findings reveal distinct endothelial 
cell autonomous and non-autonomous requirements for Vegfc during blood and 
lymphatic vessel development in zebrafish.  
Our Flt4 activation and in vivo angiogenesis studies imply that vegfcum18 mutants 
retain the ability to activate Flt4. Together, these observations coincide with 
those of others showing that the VHD domain of Vegfc is essential and sufficient 
for activation of both Flt4 and Vegfr-2 60. Furthermore, they imply that activation 
of Flt4 by Vegfcum18 is on its own unable to pattern lymphatic vessels and that the 
C-terminal domain of Vegfc was likely crucial for some aspect of its function that 
was independent of Flt4 activation. Indeed, further molecular characterization of 
Vegfcum18 revealed that that the C-terminal domain of Vegfc was required for its 
efficient secretion. This was borne out of our findings that Vegfcum18 was 
inefficiently secreted into the media of mammalian cells expressing its human 
equivalent (VEGF-CΔC), and that Vegfcum18 was unable to induce 
  119 
neovascularization from xenografted cells expressing Vegfcum18. Therefore, 
together with our findings that vegfcum18 mutants display defects in lymphatic 
vessel formation, which can be rescued by transient transgenic expression of 
wild type vegfc in the DA (Chapter III); we can speculate that the C-terminal silk 
homology domain of Vegfc plays a significant role in its ability to act as a 
paracrine factor to guide lymphatics during development. These data also 
coincide with previous findings in vegfc knockout mice, which implied that Vegfc 
was required in a paracrine manner to induce lymphatic endothelial cell budding 
of the PCV16.  
Until now the structural domain(s) in Vegfc required for its paracrine activity were 
unknown. Our findings imply a novel secretory function for the C-terminal domain 
of Vegfc. Examination of the C-terminal domain of Vegfc reveals conserved 
tandemly repeated cysteine-rich motifs resembling the silk secretory protein, 
BR3P59. Additionally, this domain contains short EGF-like motifs found in other 
secreted proteins. These motifs are reminiscent of those contained in latent TGF-
β binding proteins (LTBPs). Similar to Vegfc, TGF-β is a proprotein that requires 
post-translational processing in order to be active.  Although, TGF-β has a signal 
sequence and is translocated to the endoplasmic reticulum after synthesis, it is 
inefficiently secreted on its own 72,117. Interestingly, LTBPs have been suggested 
to augment the secretion of TGF-β 118. In particular, deletion of the cysteine 
repeats and or EGF-like domains decreased secretion of TGF-β119. Therefore, it 
is possible that the C-terminal domain of Vegfc acts in a similar fashion to 
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LTBPs, enhancing Vegfc secretion. In fact, others have found that replacing the 
heparin binding domain of Vegf165, a potent angiogenic isoform of VegfA, with the 
C-terminal domain of Vegfc increased its angiogenic potential when compared to 
Vegf165 by itself, which has been shown to be the most angiogenic isoform of 
Vegf 67. Based on our findings, we can speculate that this is due to an increase in 
Vegf secretion, conferred by the C-terminal domain of Vegfc. Taken together, our 
data imply that during lymphatic vessel development Vegfc is secreted by the 
dorsal aorta and signals in a paracrine mode to induce venous and lymphatic 
progenitor sprouting as well as guidance of lymphatic vessels. Moreover our data 
imply that the C-terminal domain of Vegfc enhances Vegfc paracrine activity by 
increasing its secretion. 
Is there a role for Vegfc during developmental angiogenesis? Although the 
majority of studies involving Vegfc signaling have focused on its role during 
lymphatic development, several lines of evidence support its function during 
blood vessel development. First, vegfc expression is evident in intersomitic 
vessels of zebrafish and mice 14,62, suggesting a cell autonomous and/or 
autocrine mode of signaling during their formation. Second, we have previously 
shown that genetic knockdown of vegfc results in the formation of partial SegA 
sprouts in zebrafish 14. However, vascular defects have not been reported in 
vegfc knockout mouse embryos and analyses in zebrafish have been the limited 
to the aforementioned knockdown technique. Third, studies in zebrafish have 
suggested that Vegfc and Vegfa signaling genetically interact during blood vessel 
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formation14,15. Lastly, both missexpresion and forced endothelial cell specific 
expression of Vegfc in mice and zebrafish elicits pro-angiogenic effects 84 
(Chapter II). Surprisingly, we did not observe developmental angiogenesis 
defects in vegfcum18 mutants, although forced endothelial cell-autonomous 
expression of Vegfcum18 was mildly angiogenic. Our biochemical data suggest 
that although Vegfcum18 is mainly trapped in the cell, it may be secreted at a lower 
rate. Since vegfc is expressed in the endothelial cells of the SeA and cell 
autonomous downregulation of its expression led to observable angiogenic 
defects (Figure 4F,G), we hypothesized that Vegfc might act in an autocrine 
manner, in which case the secretion defect caused by vegfcum18 would have mild 
or no effects on blood vessel sprouting. Indeed, our results demonstratethat the 
Vegfa signaling pathway masked defects caused by Vegfcum18, implying that 
vegfcum18 acts as a hypomorph during blood vessel development and is only 
made severe when Vegfa signaling is disrupted. As result, our findings suggest 
that Vegfa signaling provides compensatory signals in the absence of efficient 
Vegfc signaling during developmental angiogenesis. These genetic findings shed 
light on the interplay between Vegfc and Vegfa signaling during developmental 
angiogenesis. In particular, Vegfr2 and Flt4 have been shown to form 
heterodimers and promote angiogenic sprouting upon exogenous Vegfc or Vegfa 
stimuli, although Vegfc does so more readily56. Thus, Vegfc induced heterodimer 
signaling may be required for some yet unknown aspect(s) of developmental 
angiogenesis.  
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In conclusion, our characterization of the vegfcum18 allele helped uncover two 
features of Vegfc signaling required for separate processes of vascular 
development. The C-terminal domain of Vegfc, which is missing in vegfcum18, 
appears to be required for its paracrine activity during lymphatic vessel 
development. By contrast, our data suggest that during blood vessel 
development, Vegfc signals in an autocrine manner to drive aspects of 
developmental angiogenesis. In this context, compensatory signals from Vegfa 
signaling appear to counteract inefficacies in Vegfc secretion. Interestingly, 
Vegfcum18 is able to induce weak angiogenic effects when expressed in an 
endothelial cell autonomous manner although endothelial cells deficient for vegfc 
have defects in leading angiogenic sprouting, suggesting a cell autonomous 
autocrine role for Vegfc during developmental angiogenesis. These findings 
suggest two modes of signaling by Vegfc/Flt4 signaling in order to regulate 
discrete aspects of vascular development. In this case a structural domain within 
Vegfc itself regulates its ability to act in either a paracrine or autocrine fashion 
leading to its distinct effects on blood and lymphatic vessel development in 
zebrafish.  
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CHAPTER IV 
 
 
 
 
 
 
 
GENETIC EVIDENCE FOR THE ROLE OF FURINA IN THE PROCESSING OF 
VEGFC DURING LYMPHATIC DEVELOPMENT IN ZEBRAFISH 
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Introduction 
Vascular endothelial growth factor c (Vegfc) is a member of the Vegf family of 
growth factors. Unlike other members of the Vegf family, vegfc is translated into a 
preproprotein, which undergoes complex proteolytic maturation (reviewed in 
Chapter 1) that ultimately contributes to its ability bind Vegfr3 and Vegfr259,60. 
Vegfc is made up of an N-terminal signal sequence (SS) followed by N-terminal 
propeptide domain, a Vegf homology domain (VHD) and a C-terminal cysteine-
rich silk homology domain60(ref.), which we showed in the previous chapter is 
required for secretion. Examination of the Vegfc amino acid sequence reveals a 
series of proteolytic cleavage sites that separate its various domains59,74. 
Following cleavage of the SS, the Vegfc propeptide is secreted as a homodimer 
that contains the C-terminal silk homology domain, which is eventually cleaved in 
order for it to activate Vegfrs. Others have shown the existence of a conserved 
dibasic motif (-HSIIRR↓-) separating the VHD from the C-terminal domain of 
Vegfc. These cleavage motifs are recognized and cleaved by Propetide 
convertases (PCs), a family of endoproteases 74. Cleavage at this site in Vegfc 
has been shown to be required for aspects of vascular development both 
humans and fin regeneration in zebrafish74,75. 
Furin is a transmembrane PC that cycles between the cell surface and the trans 
golgi network (TGN), its function being the processing of proproteins. Protein 
precursors such as growth factors, receptors and glycoproteins have all been 
shown to be substrates for Furin 120-122(ref.). Furin knockout mice are embryonic 
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lethal, likely due to a failure in processing of factors important for embryogenesis, 
thus precluding the ability to study its function during embryonic development76. 
The zebrafish genome encodes two duplicates of the furin gene (furinA and 
furinB). These duplicate furin genes have been shown to play a major role during 
zebrafish craniofacial development 77. Interestingly, a null mutation in furinA 
displayed less severe skeletal defects than the deficiency in both furin genes; 
thus allowing a more refined analysis of their function during aspects of 
development.  
In the preceding chapters we described the isolation and characterization of a 
truncation allele of vegfc, vegfcum18, which completely lacks the Vegfc C-terminal 
domain.  Our studies suggest that this structural domain regulates the ability of 
Vegfc to signal in either a paracrine or autocrine manner, thus outlining 
contextual signaling mechanisms by Vegfc during lymphatic and blood vessel 
development, respectively (Chapters II and III). Inspection of the Vegfc amino 
acid sequence revealed that the truncation in Vegfcum18 occurred prior to the 
conserved Furin dibasic cleavage motif (-HSIIRR↓-), which separates the VHD 
from the C-terminal silk homology domain. Cleavage at this site has been shown 
to be required for aspects of blood vessel development in cultured and tumor 
cells74. However, the in vivo biological role of processing at the C-terminal 
domain of Vegfc during lymphatic patterning remains undetermined. Therefore, 
investigating whether processing at this Furin cleavage motif is required for 
lymphatic development may give further insight into the signaling mechanisms 
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used by Vegfc during lymphatic development. Additionally, structure-function 
studies have demonstrated that partially processed forms of Vegfc are able to 
activate Vegfr3 to varying degrees; while in its mature form, Vegfc is able to 
activate both Vegfr3 and Vegfr260. For this reason, examining the PC(s) involved 
in processing the C-terminal domain of Vegfc may uncover processing-
dependent and/or independent roles for Vegfc during vascular development.  
In this chapter, we find that processing of Vegfc at the C-terminal domain is 
required in order to pattern lymphatics in zebrafish. Furthermore, we present 
genetic evidence that demonstrate a requirement of furinA during lymphatic 
vessel development but not blood vessel development. Together our findings 
imply that FurinA cleaves Vegfc in order to activate its function during lymphatic 
vessel pattering in zebrafish. 
 
 
 
 
 
 
 
 
 
 
  127 
Materials and Methods 
Zebrafish, transgenic and mutant lines 
Zebrafish were housed and maintained in accordance to standard protocols 
described elsewhere. Wild type EK (Ekkwill Farm derived) and Golden (golb1) 
embryos were used for whole mount in situ hybridization analysis. Tg(fl1ia:egfp)y1 
embryos where used for  injections and phenotypic analysis 19(ref). 
Tg(fli1ep:dsredEx);Tg(nfkb1:egfp) embryos where used to identify PLs in relation 
to structures of the lateral line  and neuromasts. Tg(fli1a:egfp)y1;vegfcum18 mutant 
line was used to carry out rescue experiments. The 
TgTP1:d2egfpum42;Tg:Fli1ep:dsRedExum13 transgenic line was used to analyze 
Notch activity in furinA deficient embryos. 
Construction of non-cleavable vegfc (vegfcSS) 
 To generate a non-cleavable form of vegfc (vegfcSS) we specifically mutated the 
conserved furin cleavage consensus from 209HIIRR213 to 209HIISS213 using 
overlapping PCR and pMEvegfc w/o STP as a template(ref.). Mutating these 
amino acid residues have been shown to abrogate C-terminal cleavage of 
Vegfc74,75(ref.). The resulting PCR product was flanked by attB1 and attB2 sites 
and subsequently BP cloned to pDONR211 to generate pMEvegfcSS w/o STP. 
This plasmid was used to generate pTol2fliebs:vegfcSS-2Amcherry as well as 
pCSvegfcSS-HA.  
VegfcSS secretion analysis in cultured mammalian cells. 
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293Ts cells cultured in DMEM supplemented with 10% calf serum were 
transiently transfected with either pCSzfvegfc-HA or pCSzfvegfcss-HA. At 72 hour 
post transfection, cells were collected and lysed in RIPA lysis buffer (RIPA- 
150mM NaCl, 50mM Tris ph 8.0, 1% NP-40, 0.1%SDS, Complete Mini (Roche)). 
Media was collected and concentrated using centrifugal filter units (Ultragel -10K, 
Millipore). Lysates and media were subjected to SDS-PAGE immunoblot analysis 
and probed with a monoclonal antibody recognizing the HA epitope (BABCO).  
vegfcSS rescue experiments  
The pTolfliebs:vegfcSS-2Amcherry was generated as described earlier (Chapter 
II, Methods). To assay rescue of the TD formation in vegfcum18 mutants by 
vegfcSS we injected the embryos from an in-cross of Tg(fli1a:egfp)y1;vegfcum18 
heterozygous carriers with 25pg either of pTol2fliebs:vegfc-2Amcherry , 
pTol2fliebs:vegfcSS-2Amcherry or pTol2fliebs:egfp-2Amcherry. In all cases, 
embryos were concomitantly injected with 25pg of tol2 transposase mRNA to 
facilitate genome integration. Injected embryos were allowed to develop until 5 
dpf and subsequently selected for embryos expressing mCherry in endothelial 
cells. mCherry expressing embryos were then scored for presence of the TD and 
ultimately genotyped as described elsewhere. (Chapter III, Methods) 
Riboprobes 
Full length furinA was amplified using the following primers: forward 5’ 
GGGGACAAGTTTGTACAAAAAAGCAGGCTCCGCCACCATGGATCTCAGGCT
TGCCTC’3 and reverse 5’ 
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GGGGACCACTTTGTACAAGAAAGCTGGGTGGGGTTAAAGAGCACTTTGTGT
TTTG’3, which were flanked by attB1 and attB2 site, respectively. pfurinA was 
used as a template (Kimmel Lab). The resulting PCR product was used to 
generate pMEfurinA as described earlier. pMEfurinA  was used to generate 
pCSfurinA as described elsewhere (Chapter II, Gateway cloning). pCSfurinA was 
linearized using NotI and purified as described elsewhere. T7 pol II (Roche) was 
used to generate antisense furinA probe (ref.). Standard whole-mount in situ 
hybridization was performed as described elsewhere 123.  
Morpholino injections and Phenotyping 
Embryos resulting from a Tg(fli1a:egfp)y1 in-cross were separately injected with 
16ng standard control MO (Gene tools) and or 16ng furinA SA9 MO 77(ref.). 
Injected embryos were subsequently assayed for general morphology and SeA 
length at 30 hpf as described elsewhere (Chapter IV). PLs formation was 
assessed in Tg(fli1a:egpf)y1 embryos at 2 dpf and formation of secondary 
intersomitic veins was assessed by assaying physiological venous or arterial flow 
through intersegmental vessels at 72 hpf (Chapter IV). Finally TD formation was 
assessed at 5 dpf. These phenotypic analyses were performed using a second 
antisense MO that was designed to target the splice acceptor sequence of the 
third exon of the furinA transcript. furinASA3 MO. 
Imaging of general morphology and circulation was performed using transmitted 
light on a Leica MZ FLIII using a Zeiss AxioCam MRc digital camera. Images of 
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blood vessels, PLs and TD in Tg(fli1a:egfp)y1 embryos were obtained using a 
Leica DMIRE2 confocal microscope (Objective: HC PL APO 20x/ 0.70CS). 
Furin Inhibitor treatments 
Wildtype Tg(fli1a:egfp)y1 embryos were treated in 8uM Furin I inhibitor (Cal 
Biochem) or 0.01% DMSO vehicle egg water solution at 30 hpf and allowed to 
develop and subsequently assessed TD formation as described above. 
FurinA loss of function and Notch activation.  
To assess Notch activity in furinA deficient embryos we separately injected 
(TgTP1:d2egfpum42;Tg:Fli1ep:dsRedExum13) embryos with 16ng of either 
furinASA9 MO or standard control MO. Embryos were qualitatively assayed for 
differences in Notch activation in blood vessels as judged by  a yellow 
fluorescence at  30 hpf. 
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Results 
Cleavage at the C-terminal domain of Vegfc is required for lymphatic 
development in zebrafish.  
Inspection of zebrafish Vegfc functional domains revealed a conserved Furin 
processing motif that separates the VHD from the C-terminal domain (Figure 1A). 
Interestingly, the vegfcum18 truncation allele eliminates this conserved Furin 
processing motif in Vegfc. As shown previously (Chapter III), embryos harboring 
this mutation fail to form lymphatics. Therefore, we determined the importance of 
this motif by assessing the ability of a cleavage-resistant form of Vegfc to rescue 
lymphatic defects in vegfcum18 mutants.   For this purpose, we constructed a 
version of Vegfc containing amino acid substitutions in the furin cleavage motif 
(HSIIRR>HSIISS, referred hereafter as zfVegfcSS Figure 1B). Immunoblot 
analysis of cell lysates expressing hemagglutinin epitope tagged zfVegfcSS 
confirmed its inability to be cleaved (Figure 1B, compare lanes 1 and 2). 
Interestingly, we found significant amounts of uncleaved zfVegfcSS-HA in the 
medium suggesting that furin-mediated cleavage is not required for Vegfc 
secretion (Figure 1B, lane 4).    
To determine the functional effects of blocking furin-mediated cleavage, we drove 
expression of either wild type or cleavage-resistant vegfc (referred to as vegfcss) 
fused to 2A-cherry specifically in arterial endothelial cells of vegfcum18 mutant 
embryos.  In control vegfcum18 embryos expressing egfp-2A-cherry in arterial 
endothelial cells, we noted full penetrance of lymphatic defects displayed by 
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Figure 1.IV Cleavage of the Vegfc C-terminal domain of Vegfc is required during lymphatic 
development.  
(A) Graphic describing Vegfc protein domains. SS-Signal Sequence(Orange). N-Terminal 
domain(Blue). VHD-VEGF Homology Domain (Red). C-Terminal Domain(Green). Black 
arrowhead represents Furin cleavage motif. Black box outlines the conserved (HSIIRR) Furin 
cleavage motif. (B) Graphic describing HSIIRR> HSIISS mutation. Biochemical evidence that a 
mutation in the Furin clevage domain of zebrafish Vegfc (zfVegfcSS) inhibits processing. Cell 
lysates and Media from HEK293T cells transiently expressing zfVegfc-HA and zfVegfcSS-HA 
separately, were used to monitor both zfVegfc and zfVegfcSS biosynthesis and secretion. 
Cytoplasmic and Media fractions were collected 72 hrs post transfection and subsequently 
analyzed by immunoblot with HA epitope antisera. (C-L) Rescue experiment showing partial 
rescue of thoracic duct formation in vegfcum18 mutants by arterial expression of vegfcSS-
2Amcherry. (C-K). Confocal micrographs of trunk blood vessels at 5 dpf. Anterior is to the left 
dorsal is up. DA, Dorsal aorta. PCV. Posterior Cardinal Vein. TD. Thoracic Duct. (C-E) 
Tg(fli1a:egfp)y1vegfcum18 mutant injected with 25pg of Tol2 transposase and  pTol2egfp-
2Amcherry. Yellow arrowheads indicate coloaclization of Egfp and mCherry. Bracket with asterisk 
indicate absence of TD. (F-H) Tg(fli1a:egfp)y1vegfcum18 mutant injected with 25pg of Tol2 
transposase and  pTol2vegfc-2Amcherry. Yellow arrowheads indicate coloaclization of Egfp and 
mCherry. White arrows indicate mosaic rescue of the TD. (I-K) Tg(fli1a:egfp)y1vegfcum18 mutant 
injected with 25pg of Tol2 transposase and  pTol2vegfcum18-2Amcherry. Yellow arrowheads 
indicate coloaclization of Egfp and mCherry. Bracket with asterisk indicate absence of TD. (L) 
Quantification of rescue. Expressed as the percent of indicated genotype of an injected clutch of 
um18 heterozygous carriers.  NOTE: Portions of this figure appear in Chapter III 
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vegfcum18 mutants, while expression of fliebs:vegfc-P2Amcherry rescued TD 
formation in greater than 60 percent of mutant embryos (Figure 1C-H,L Note: this 
data also seen in Chapter II). By contrast, arterial cells expressing of 
fliebs:vegfcSS-P2Amcherry was able to partially rescue TD formation in vegfcum18 
(Figure 1I-L), although the degree of rescue in this case was significantly lower 
compared to that of fliebs:vegfc-2A-mcherry (Figure 3L). Taken together, these 
data suggest that furin-mediated cleavage of Vegfc may be required for proper 
lymphatic patterning in zebrafish. 
Loss of furinA function in zebrafish suggests a role during lymphatic 
vessel formation.  
Given the decreased ability of a furin-resistant form of Vegfc to rescue lymphatic 
defects in vegfcum18 mutants, we investigated whether Furin itself was required 
for lymphatic development.   While the zebrafish genome encodes two duplicates 
of the furin gene (furina and furinb) the expression pattern of furina suggested a 
possible role in lymphatic patterning.   By whole mount in situ hybridization 
analysis, we observed furinA expression in neuromasts and cells dispersed along 
the lateral line at 2 dpf (Figure 2A).  These structures, which can be visualized 
along with the developing vascular and lymphatic vessels in 
Tg(fli1ep:dsredEx;Nfkb1:egfp) double transgenic embryos, are located 
immediately adjacent to the PL as it is forming (Figure 2B-C).  To investigate if 
furinA was required for lymphatic vessel development, we injected 
Tg(fli1a:egfp)y1 embryos with a previously published antisense morpholino  
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Figure 2.IV Sites of Furin expression are adjacent to developing parachordal 
lymphangioblasts.  
(A-C) micrographs 2 dpf zebrafish embryos. Anterior is to the left dorsal is up. DA, Dorsal aorta. 
PCV. Posterior Cardinal Vein. TD. Thoracic Duct. NM-Nuero Masts. LL. Lateral Line. PL. 
Parachordal Lymphangioblasts. (A) Whole mount in situ hybridization for furinA. Black 
arrowheads indicate expression in the LL and NM. (B-C) Confocal micrographs of trunk blood 
vessels at 2 dpf. in Tg(fli1ep:dsredEx;Nfkb1:egfp) double transgenic. (B) Yellow arrowheads 
highlight similar trangene expression to that of furinA in the LL. Brackets indicate transgene 
expression in the  (C) White arrows depict PL formation adjacent to the LL and NM. 
NM. 
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targeting the furinA transcript. furinA-deficient embryos displayed relatively 
normal morphology when compared to control morphant siblings at 30 hpf, 
although slight curvature of the tail was noted (Figure 3A-B).  Formation of the 
primary circulatory network was not affected by loss of furinA (Figure 3C-D).  
However, at 5 dpf furinA-deficient embryos displayed notable defects in TD 
formation when compared to control morphant siblings (Figure 3E-G). To 
investigate whether loss of TD in furinA morphants was due to earlier defects in 
PL formation, we scored the formation of these structures in Tg(fli1a:egfp)y1 Ctrl 
MO and furinA MO injected embryos. We observed fewer PLs in furinA defiecient 
embryos when compared to control morphant siblings (Figure 4A-C), while 
secondary intersomitc vessels appeared normal (Figure 4D). Additionally, we 
found that a second non-overlapping morpholino targeting the furinA transcript 
showed similar effects on lymphatic patterning (personal observation).  
Our results suggest that furinA is required for proper sprouting of PLs and 
subsequent pattering of lymphatics in zebrafish. To determine whether defects 
observed in lymphatic patterning were specific to Furin activity during this 
process we pharmacologically inhibited its function using Furin inhibitor I, a 
catalytic inhibitor of Furin(ref.). Tg(fli1:egfp)y1 embryos were treated with Furin 
inhibitor I at 30 hpf, a time prior to PL sprouting and subsequently assayed for 
the TD formation at 5 dpf. Tg(fli1:egfp)y1 embryos treated with Furin inhibitor I 
displayed a significant loss of TD formation at 5 dpf when compared to vehicle  
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Figure 3.IV furinA is required for lymphatic vessel formation in zebrafish.   
(A-B) Bright field illumination of 30 hpf Tg(fli1a:egfp)y1 zebrafish embryos. Anterior is to the left 
dorsal is up. (A) Tg(fli1a:egfp)y1 embryo injected with Ctrl MO. (B) Tg(fli1a:egfp)y1 embryo injected 
with furinA MO. (C-D) Confocal micrographs 30 hpf. zebrafish embryos. DA, Dorsal aorta. PCV. 
Posterior Cardinal Vein. (C) Tg(fli1a:egfp)y1 embryo inject with Ctrl MO. (D) Tg(fli1a:egfp)y1 
embryo injected with furinA MO. (E-F) Confocal micrographs 5 dpf. zebrafish embryos. DA, 
Dorsal aorta. PCV. Posterior Cardinal Vein. TD. Thoracic duct. (E) Tg(fli1a:egfp)y1 embryo inject 
with Ctrl MO. (F). Tg(fli1a:egfp)y1 embryo injected with furinA MO. Bracket with asterisk denotes 
albescence of  TD. (G) Quantification of TD in embryos. Embryos were assayed for coverage of 
TD between six hemisegments of the trunk. Values shown are based on the average of three 
independent experiments. 
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treated controls (Figure 4E). These data further suggest a requirement for FurinA 
function during the lymphatic patterning process.  
In addition to our proposed role for Furin in Vegfc activation, Furin function is also 
required for Notch activation124(ref). Recently, studies have shown the 
requirement Notch signaling during lymphatic vessel development125. To address 
any indirect effects on lymphatic development by loss of Notch signaling, we 
used a double transgenic line (TgTp1:d2egfpum42;Tg:fli1ep:dsRedExum13) that 
allowed visualization of dynamic Notch activity (TgTp1:d2egfp) as well as blood 
vessel formation (Tg:fli1ep:dsRedEx) in furinA deficient embryos. Evaluation of 
blood vessel formation at 30 hpf in furinA deficient embryos reveals levels of 
Notch activation that where qualitatively indistinguishable from control morphant 
embryos (Figure 5A-B). Taken together, these data suggest that FurinA itself 
may be responsible for the C-terminal cleavage of Vegfc during lymphatic vessel 
development in zebrafish.  
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Figure 4.IV furinA deficiency negatively affects formation parachordal lymphangioblasts.  
(A-B) Confocal micrographs of trunk blood vessels at 2 dpf. Anterior is to the left dorsal is up. DA, 
Dorsal aorta. PCV. Posterior Cardinal Vein. Parachoradal lymphangioblast (PL). Embryos were 
subjected to microangiography. (A) Tg(fli1a:egfp)y1 embryo inject with Ctrl MO. Brackets indicate 
PL formation (F). Tg(fli1a:egfp)y1 embryo injected with furinA MO. Brackets with asterisks denote 
absence of PLs. (C) Quantification of PLs in embryos. Embryos were assayed for coverage of 
PLs between six hemisegments of the trunk. (D) Quantification of percent artery and vein 
connections in Ctrl MO and furinA MO injected embryos. (E) Quantification of TD in embryos 
embryos treated with 8uM Furin inhibitor I at 2 dpf . Embryos were assayed for coverage of TD 
between six hemisegments of the trunk at 5 dpf. Values shown are based on the average of three 
independent experiments. 
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Figure 5.IV Notch signaling in blood vessels is unaffected by furinA deficient embryos.  
(A-B) Confocal micrographs of trunk blood vessels at 30 hpf in 
TgTp1:d2egfpum42;Tg:fli1ep:dsRedExum13 zebrafish embryos. Anterior is to the left dorsal is up. 
DA, Dorsal aorta. PCV. Posterior Cardinal Vein. (A) Ctrl MO injected embryo. White arrows 
denote Notch activation in blood vessels (yellow). (B) furinA MO injected embryos. White arrows 
indicate Notch activation in blood vessels.   
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Discussion 
In this chapter we present genetic evidence linking Furin function to the C-
terminal domain processing of Vegfc during lymphatic development in zebrafish. 
These conclusions are borne out of our findings, which demonstrated that a non-
cleavable form of Vegfc (vegfcSS) only partially rescued lymphatic pattering in 
vegfcum18 mutant embryos. Our biochemical studies suggest that cleavage at the 
C-terminal domain of Vegfc is not a pre-requisite for its secretion and that 
perhaps some other aspect of its function was affected. One possibility may be 
an inability to activate Flt4. Indeed, biochemical analyses of Vegfc function have 
found that a non-cleavable mutant of Vegfc, similar to the one presented in this 
study, is able to bind and activate Flt4 albeit to lower levels than that of mature 
wild type Vegfc60. This decreased activation may explain why vegfcSS was able to 
partially rescue lymphatics in vegfcum18 mutant embryos. Together, these data 
suggest that complete processing of Vegfc is required to fully induce Flt4 activity 
during lymphatic vessel formation in zebrafish.  
Our finding that Furin mediated C-terminal processing of Vegfc was required for 
optimal lymphatic patterning led us to investigate a role of Furin itself during 
vascular development. Our results suggest that furinA is required during 
lymphatic development perhaps by coordinating the sprouting of lymphatic 
progenitors. These findings were further supported by our pharmacological 
studies, which demonstrated that inhibition of Furin function during this process 
ultimately effected the formation of the TD. These observations were reminiscent 
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of vegfc and flt4 deficiency15,17,33, suggesting a link between FurinA activity and 
that of Vegfc signaling during lymphatic patterning. Studies in zebrafish have 
found that sprouting and subsequent migration of lymphatics is quite complex 
36,125,126. During this process, cells need to sprout off the PCV arrest the 
horizontal myoseptum and subsequent migrate ventrally to be come part of the 
TD; exactly what aspect of this process is affected by furinA deficiency will likely 
require further cell biological investigation. 
Previous studies in cultured cells have found that Vegfc is a substrate for Furin74. 
However, the exact mechanism of how Furin exerts its effects on Vegfc in vivo, 
remain unclear. Previous studies have found that PLs normally migrate along 
arteries during lymphatic development36. Additionally, we have shown that vegfc 
is expressed in arterial endothelial cells14 from where it is produced in order to 
pattern lymphatics. Our in situ expression analysis demonstrated that furinA is 
expressed in cells of the lateral line, which are in close proximity to developing 
PLs. Thus it is plausible that Furin may process arterial derived Vegfc in a non-
cell autonomous manner during lymphatic development. Two lines of evidence 
suggest that this may be the case. First, cell biological studies have found that 
Furin is transmembrane protein that cycles between the TGN the cell membrane, 
suggesting it can act at the cell membrane 120,122. Second, during the course of 
our biochemical analysis we observed that cell lysates from mammalian cells 
expressing Vegfc contained little to no evidence of processed Vegfc (Figure 1B 
lane 1), suggesting processing of Vegfc occurred out side the producing cell and 
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further implicating the C-terminal domain of Vegfc during its secretion. While this 
mechanism of action may hold true, further in vivo molecular analysis of the 
expressed processed forms of Vegfc during vascular development should shed 
further light on this process. 
Interestingly, we found that loss of furinA had no effect on the formation of 
segmental arteries or that of secondary intersomitic vessels, which are affected 
by deficiencies in Vegfc/Flt4 signaling 15,34. This difference in phenotype suggests 
the intriguing possibility that differential processing may regulate the diverse 
aspects of Vegfc signaling. Thus, while complete processing of Vegfc may be 
required for its function during lymphatic development, similar processing could 
be dispensable for its function during segmental artery and intersomitic vessel 
development. As a result, Furin mediated processing may induce context 
dependent effects of Vegfc during the formation of these vessel types. However, 
the fact that we do not see any effects on segmental artery or intersomitic vessel 
formation may also suggest the existence of another propeptide convertase that 
cleaves Vegfc during the formation of these two vessel types. Indeed, studies 
have found that Vegfc can be a substrate for related propeptide convertases 
such as PC5 and PC774.  
Our studies imply that Vegfc is the major substrate for FurinA during lymphatic 
vessel development in zebrafish. As a result, we find that loss of furinA does not 
affect processing of Notch, implying that the observed lymphatic defects are 
probably due to its effects on Vegfc signaling. In addition to Notch, studies have 
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found that Sema3E is substrate of Furin127-129. Recently, studies in zebrafish 
have described a role for Sema3E signaling during developmental 
angiogenesis127. We find that the primary angiogenic network forms normally in 
furinA deficient embryos, suggesting that Sema3E is not a substrate for FurinA 
during this process and would not affect lymphatic patterning.  
In conclusion, the data presented here suggest a functional link between Furin 
and C-terminal cleavage of Vegfc during lymphatic vessel development. 
Moreover, they suggest the intriguing possibility that differential processing of 
Vegfc may regulate its diverse effects during vascular development. However, 
the question of where this processing occurs and the exact cell biological effect 
of furinA deficiency on PLs during lymphatic vessel development will require 
further investigation.  
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Previous studies have demonstrated that Vegfc/Flt4 signaling is essential for 
both blood and lymphatic vessel development in vertebrates 14-16,62. However, the 
molecular mechanism(s) of how it orchestrates their formation remains unclear. 
In this study we used a transgenic haploid screen to identify genes affecting 
Vegfc/Flt4 signaling. We identified and cloned a truncation allele of vegfc 
(vegfcum18), which completely lacks the Vegfc C-terminal silk homology domain. 
These mutants display defects in vein and lymphatic vessel formation but normal 
developmental angiogenesis (Chapter II). Characterization of this allele led to the 
finding that the primary defect in vegfcum18 mutants was a general failure in vein 
and lymphatic vessel sprouting, which was rescued by transgenic expression of 
wild type full length vegfc in the dorsal aorta (DA) (Chapter II). Further genetic 
and biochemical analysis of vegfcum18 revealed profound paracrine signaling 
defects, which likely result in the observed loss of lymphatic and venous 
structures in these mutants.  Together, our findings imply that paracrine Vegfc 
derived from arteries acts as a chemo-attractant for lymphatic endothelial cells 
during lymphatic vessel formation (Figure 1A and Chapter III). Furthermore, they 
suggest that the C-terminal domain is absolutely required for efficient paracrine 
activity of Vegfc in this context vascular development (Figure 1B and Chapter III).  
Interestingly inefficient secretion of Vegfc in vegfcum18 mutants did not negatively 
affect SegA formation. Genetic and molecular analysis showed that normal SeA 
formation in these mutants was possibly due to functional redundancy by the 
Vegfa signaling pathway and weak autocrine and/or intracrine signaling by 
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Vegfcum18 in the context of SeA formation. Additionally, we observed that vegfc 
was required in an endothelial cell autonomous manner for tip cell occupancy, 
together implying a cell autonomous autocrine role for Vegfc during 
developmental angiogenesis (Figure 1 C-D and Chapter III). Finally, we present 
genetic evidence that links processing of the C-terminal domain of Vegfc by 
FurinA during lymphatic development (Figure 1A and Chapter IV). However, 
furinA appears to be dispensable during blood vessel development (Chapter IV). 
Taken as whole, the data presented in this thesis demonstrate two discrete 
modes of signaling by Vegfc/Flt4 during blood and lymphatic vessel development 
in zebrafish. They imply that context dependent regulation of Vegfc secretion and 
processing play a pivotal role in the how these vessels are formed in zebrafish.  
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Figure 1. Model. Characterization of vegfcum18 reveals context dependent signaling 
mechanisms during blood and lymphatic vessel development in zebrafish.  
(A-C) Anterior is to the left dorsal is up. DA, Dorsal Aorta. PCV, Posterior Cardinal Vein. TD, 
Thoracic Duct. SeA, Segmental Artery. SeV, Segmental Vein. Bracket and asterisk denote 
absence of TD and SeV. (A-B) Graphic describing the role of Vegfc during lymphatic vessel 
development in zebrafish. (A) During normal lymphatic vessel development, paracrine signaling 
by Vegfc from the DA and SegA guide lymphatic endothelial cells to ultimately form the TD. 
FurinA expression at the lateral line is required for processing Vegfc, for a yet unknown aspect of 
parachordal lymphangioblast (PL) formation. (B) Absence of the C-terminal domain in vegfcum18 
mutants impairs Vegfc paracrine activity, which leads to a failure of SeV and PLs sprouting and 
ultimate loss of the TD. (C-D) Graphic describing the role of Vegfc during developmental 
angiogenesis in zebrafish. (C) During normal SeA formation, cell autonomous autocrine signaling 
by Vegfc promotes angiogenesis at the leading tip cell. Additionally, formation of SeA requires 
inputs from the VegfA signaling pathway, where vegfa is supplied by adjacent somites in a 
paracrine manner. (D) Absence of the C-terminal domain in vegfcum18 mutants has no effects on 
SeA formation. This is likely due to redundant signaling from VegfA signaling pathway coupled to 
functional autocrine and/or intracrine signaling by Vegfcum18 within SeA themselves. 
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What does vegfcum18 tell us about Vegfc function during lymphatic development? 
In this study we show that the C-terminal domain of Vegfc is required for its 
paracrine effects by coordinating PL and secondary intersomitic vessel formation. 
One question that arises is whether the C-terminal domain of Vegfc is a general 
factor that increases secretion. Further insight to this question may come from 
rescue experiments to investigate whether expression of the C-terminal domain 
on its own can recue Vegfcum18 defects. This can be performed both in vivo and 
in vitro, by assessing whether the Vegfc C-terminal domain can rescue the TD in 
vegfcum18 mutant embryos and secretion in mammalian cells expressing VEGF-
CΔC.   
During the course of our study we noted that heterozygous vegfcum18 embryos 
displayed defects in lymphatic development. Interestingly, formation secondary 
intersegmental vessels were unaffected in these embryos, implying that higher 
levels of Vegfc/Flt4 signaling are required during lymphatic vessel development. 
These findings coincide with a recent study, which demonstrated that a 
hypomorphic allele of flt4 in mouse displayed severe defects in lymphatic vessel 
formation although blood vessel development was unaffected, strikingly similar to 
vegfcum18 63. Moreover, a kinase dead allele of flt4 in zebrafish also displays 
profound defects in lymphatic vessel formation, while developmental 
angiogenesis is unaffected 15. Together these findings suggest that distinct levels 
of Vegfc/Flt4 signaling may be required for separate formation of vessel types. 
Further insight into this hypothesis may come from studies that evaluate the 
  151 
formation of distinct vessel types by varying levels of Vegfc/Flt4 signaling using 
MOs targeting their expression. This study could be complemented by the 
assessing the formation of distinct vessels in separate alleles of either of these 
genes.   
Finally, several lines of evidence from our studies suggest that there may be a 
context dependant role for Vegfc during lymphatic development. First, we find 
that Vegfc/Flt4 signaling is required throughout lymphatic development, 
suggesting this pathway maybe used in the migration of PLs to form the TD. 
Second, we find that cleavage of the Vegfc C-terminal domain is required for 
lymphatic development but not its secretion. Third, we present expression and 
functional data that links FurinA to Vegfc processing in perhaps a non-cell 
autonomous manner at the horizontal myoseptum. Interestingly, vegfcum18 
mutants fail to form intersegmental vessels while furinA deficient embryos seem 
to be normal in this respect implying that perhaps Furin activity is independent of 
venous sprouting. These data imply that FurinA may be involved in some other 
aspect of lymphatic development, perhaps guidance, by enacting a context 
dependent cleavage of Vegfc. To investigate whether this is the case, we first 
have to pinpoint the exact cellular defect in PLs of furinA deficient embryos, 
which can be done using current tools available. These include time-lapse 
microscopy and the use transgenic and mutant lines, which should allow a better 
assessment of PL formation in furinA deficient embryos. In addition to this, 
generation of antibodies that recognize distinct forms of Vegfc could also be used 
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to elucidate this proposed context dependent function of Vegfc. Such antibodies 
would allow direct whole-mount visualization of the distinct processed forms of 
Vegfc. However, such antibodies are currently unavailable.  
While the aforementioned scenario may be plausible, the existence of other 
signaling pathways may also be involved in the guidance of lymphatics. During 
our study we observed that chemical inhibition of Flt4 during lymphatic 
development had incomplete penetrant effects on TD formation, implying 
functional redundancy by other signaling pathways. In fact, molecules involved in 
neuronal pathfinding have also been implicated in vascular development. In 
particular, a recent study demonstrated that the canonical neuronal guidance 
factor, unc5b, was necessary for the formation of PLs in zebrafish 130. Therefore, 
it is plausible that inputs from the Vegfc/Flt4 signaling pathway along with those 
involved in neuronal pathfinding are required for proper guidance of lymphatic 
progenitors during lymphatic vessel formation.   
What role does Vegfc play during blood vessel development? 
Previous studies in our lab demonstrated that embryos deficient for vegfc 
displayed partial formation of SegA 14. In our study, we find that blood vessel 
defects in vegfcum18 embryos are masked by inputs from the Vegfa signaling 
pathway further implying a role for Vegfc during SegA formation. Interestingly, 
studies have found that Vegfc largely induces the formation of Vegfr2/Vegfr3 
heterodimers 56 and that the formation of these heterodimers is required for 
sprouting and migration of blood vessel endothelial cells. Furthermore, blocking 
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heterodimer formation decreased in vivo vascular network formation in NOD-
SCID mice xenograted with Vegfc matrigel plugs containing human blood vessels 
56,106. Taken together these data suggest that Vegfc induced formation of 
Vegfr2/Vegfr3 hetrodimers may be required for sprouting and migration during 
active angiogenesis. Further insight in to the exact cellular role for Vegfc during 
blood vessel development may come from time-lapse imaging of migration and 
proliferation events in the SegA of vegfc deficient zebrafish embryos in a blood 
vessel transgenic background. 
We demonstrated that deficiencies in Vegfa and Vegfc signaling severely 
affected sprouting of SegA. Thus one question that arises is: how do endothelial 
cells coordinate sprouting? During sprouting angiogenesis a subset endothelial 
cells, tip cells, need to be selected for sprouting. Selected cells undergo 
phenotypic changes that allow them to acquire invasive motile behavior. Vegfa 
signaling has been shown to involved in the selection and guidance of tip cells, in 
addition to its role in proliferation during angiogenesis 31,78. Given the diverse 
functions of Vegfa signaling during the sprouting process, how is it that tip cells 
maintain their polarity and continual directional migration? Until now the cell 
autonomous function of Vegfc during blood vessel development was unknown. 
Our mosaic analyses suggest that Vegfc plays a role in defining tip cell behavior. 
This is consistent with the observation that vegfc is concomitantly expressed with 
Vegfr3 and Vegfr2, at the leading tip cells of angiogenic sprouts 62. Moreover, 
Vegfc induced Flt4/Vegfr2 heterodimers preferably localized to the tip cell 
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position 56. Together, these observations suggest that Vegfc is required to in an 
endothelial cell autonomous manner for a yet unknown aspect of tip cell 
physiology. However, based on our findings and those by others we can 
speculate that Vegfc may act in a cell autonomous manner to induce 
Vegfr3/Vegfr2 heterodimers to elicit a signal that results in the invasive and 
directional migratory phenotype exhibited by tip cells during angiogenesis.  
Limitations and future directions for the forward genetic screen presented here. 
Our study demonstrates that screening for early defects in PHBC formation in 
mutant transgenic haploids can be used as an indirect way to find genes involved 
in vein and lymphatic vessel formation. Although we were able to recover a 
mutant using this strategy, a variety of points may have limited our study. The 
first of them being the amount of genomes scored. During this screen we scored 
a total of 410 haploid genomes, which is about one-third of the amount of 
genomes screened in our previous haploid screen45 and roughly a tenth of the 
original genomes scored in the zebrafish F3 screens performed in Tubingen and 
Boston92,93. Thus, increasing the size of the scored genomes may have led to the 
recovery of more mutants in this screen. In addition to this limitation, we also 
encountered a problem in the generation of F2 families (Table 1, Chapter III). Of 
the four putant F1 females with observed PHBC defects in their haploid progeny, 
we were only able to recover two that could be out crossed to produce an F2 
generation. Unfortunately, we were only able to produce one F2 generation. This 
low recovery of F2 families may be attributable to technical difficulties involving 
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the injury to the F1 female as a result of multiple in vitro fertilization attempts, 
which could have lead to problems in fecundity (personal observation).  
Screening for early defects in vein formation as an indirect way to identify 
lymphatic mutants could fail to identify mutations affecting specific aspects of 
lymphatic vessel formation that are independent of vein morphogenesis. One 
example would be genes required for specification of lymphatic endothelia cells. 
Studies have demonstrated that specification of lymphatic endothelial cells is 
independent of Vegfc/Flt4 signaling and occurs prior to their sprouting, which 
does requires Vegfc/Flt4 signaling 16,33. Thus, we would potentially fail to identify 
mutant alleles of factors such as sox18 and prox1, both of which are essential for 
lymphatic specification37,38. Importantly, deficiency in these genes has no effect 
on vein morphogenesis (personal observation). Very little is known about the 
genes required for lymphatic vessel specification, therefore further insight may 
come from screens designed to target aspects of sox18 and/or prox1 function.  
Using vegfcum18 as a tool for future forward genetic screens.  
vegfcum18 allele displays phenotypic advantages that could be used as way to 
screen for genes involved in distinct aspects of blood vessel development. First, 
we noted that heterozygous vegfcum18 embryos displayed loss of PL sprouting 
and subsequent TD, however sprouting of secondary intersomitic vessels and 
PHBC were unaffected, highlighting the distinct requirement for Vegfc signaling 
during these processes. These discrete phenotypic outputs could be taken 
advantage of in order to carry out an enhancer screen 131. For example, one 
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could cross the F1 progeny, derived from mutagenized males, into the sensitized 
vegfcum18 heterozygous background and subsequently screen F3 progeny for 
separate defects in secondary intersomitic vessels or PHBC. One could also 
screen for mutants that affected both, although this last phenotypic method of 
screening could lead to the identification of another vegfc allele. Nevertheless, 
performing an enhancer screen in the vegfcum18 sensitized background could lead 
to the identification of novel alleles that modulate the formation of distinct blood 
vessels. 
During the course of this study we also noted that we were sometimes able to 
recover adult homozygous vegfcum18 mutants. These mutants displayed defects 
associated with the inability to drain fluid, similar to patients with lymphedema10. 
Assuming you were able to breed these fish, one could envision performing a 
suppressor haploid screen to identify mutants that suppressed the PHBC 
phenotype. For example, one could cross the F1 progeny (derived from 
mutagenized homozygous vegfcum18 males) to homozygous vegfcum18 females to 
generate an F2 family of homozygous vegfcum18 fish carrying germline mutations. 
Haploid embryos would be generated from F2 females and subsequently 
screened for PHBC formation. Embryos carrying a suppressor mutation would 
result in 50% of the progeny rescuing PHBC formation and 50% displaying 
complete penetrance of the vegfcum18 mutation. This screening approach could 
result in the identification of genes with possible disease relevance.  
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Finally, one could also envision a third type of screen using adult homozygous 
vegfcum18 mutants that involves pharmacological compounds. As mentioned 
earlier, adult homozygous vegfcum18 mutants that make it to adulthood display 
overt lymphatic defects. Given the availability of affordable pharmacological 
libraries it would be feasible to screen a library of compounds for agents that 
ameliorated lymphatic defects in adult homozygous vegfcum18 mutants. As a 
result, this could lead to the identification of drugs that could potential be used to 
treat patients with congenital lymphedema.  
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APPENDIX I 
 
 
 
 
 
 
SPATIAL AND TEMPORAL OVEREXPRESSION OF VEGFC INDUCES PRO-
ANGIOGENIC EFFECTS ON BLOOD VESSELS DURING DEVELOPMENTAL 
ANGIOGENESIS IN ZEBRAFISH. 
 
 
 
 
 
 
 
 
 
 
Portions of this work appear in: Villefranc J.A., Amigo J and Lawson N.D  
 Dev. Dyn. 2007 vol. 236 (11) pp. 3077-87 
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Introduction 
Vascular endothelial growth factor C (Vegfc) is a secreted factor that is involved 
in blood and lymphatic vessel development in vertebrates8,14,16,59,64,84,132. In 
zebrafish, vegfc is expressed in the developing blood vessels14. Unlike Vegf, 
Vegfc is proteolytically cleaved in order to be active60. Vegfc induces the 
phosphorylation of its endothelial cell specific receptor, Flt4. During embryonic 
development in zebrafish, flt4 is initially expressed in the axial vasculature and 
developing segmental arteries (SeA) and later restricted to the posterior cardinal 
vein (PCV)28. Consistent with their expression, vegfc and flt4 are required for 
proper blood and lymphatic vessel patterning in vertebrates 14,15,33,62.  
The functional role of Vegfc in vascular development has mainly been attributed 
to lymphangiogenesis, even though its expression is evident during embryonic 
blood vessel development14,62. Overexpression of Vegfc in skin, muscle and 
mesenteric tissues of mice using adenoviral gene transfer noted strong induction 
lymphangiogenesis as well as effects on blood vessel morphology132. By 
contrast, a transgenic mouse allowing temporal control of endothelial produced 
Vegfc displayed potent angiogenic effects when expressed early in development 
84. In zebrafish, ectopic expression of vegfc mRNA causes mild aberrant 
sprouting of segmental arteries (SeA), indicating it has an effect on blood 
vessels15. Although ectopic mRNA expression is a rapid way the assess gene 
function in zebrafish, investigating the function of a gene with a highly restricted 
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expression pattern such as vegfc, requires the use of functional tools that allow 
spatial and temporal control of gene expression.  
Engineering a system that allows spatial and temporal control of vegfc during 
embryonic development in zebrafish requires 1) an efficient way to test different 
epitope tags to monitor vegfc expression. Vegfc is a secreted protein with a 
signal sequence. Therefore, testing various methods of tagging would be needed 
to assess proper functionality. In addition to a functional tagged Vegfc, it is 
necessary to 2) express vegfc in either a temporal or endothelial cell autonomous 
manner, which requires the use of distinct promoters. Lastly, this would also 
require a transgenic system that 3) allows low mosaic expression of a transgene, 
thus enabling immediate assessment of vegfc overexpression without the 
generation of transgenic lines, which may take up to six months.  
It is often the case that establishment of functional tools such as the one 
described above, results in laborious cloning efforts. Therefore, the availability of 
an efficient cloning system would simplify standard day-to-day cloning efforts, 
making the analysis of gene function in zebrafish less labor-intensive. Recently, a 
recombination-based cloning technique (Gateway Cloning) that allows efficient 
and rapid transfer of DNA fragments between plasmids, has been used to 
generate clone collections of both open reading frames (ORFs) and promoters 
that can be used together to rapidly generate constructs for transgenesis in C. 
elegans133-135. An important benefit of the Gateway system is its use to 
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simultaneously clone multiple contiguous DNA fragments within a single 
vector134. 
In this supplementary chapter, we establish a robust transgenic approach to 
show that Vegfc induces angiogenic effects through its receptor Flt4, when 
expressed in a temporal and endothelial cell-autonomous manner in zebrafish. 
To investigate the spatial and temporal effects of Vegfc on blood vessels, we 
adapt and engineer Gateway cassettes into vectors that are commonly used to 
assess gene function in zebrafish. This system enabled rapid generation and 
testing of vectors that allow controlled expression of a tagged ORF. We establish 
proof of concept for this system and build constructs that allow spatial and 
temporal control of Vegfc. We find that misexpression of Vegfc during blood 
vessel development induces ectopic angiogenesis in a flt4-dependent manner. 
Moreover, forced expression of Vegfc in endothelial cells induced similar 
angiogenic effects. These data suggest a pro-angiogenic role for Vegfc during 
developmental angiogenesis in zebrafish. 
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Materials and Methods 
 
Zebrafish Lines and Maintenance 
Zebrafish lines were maintained as described elsewhere136. Wild type EK (Ekkwill 
Farm derived), Golden (golb1) or Tg(fli1a:egfp)y1 embryos were used for 
injections.    
 
Plasmid Construction  
Generation of Entry Clones. The pDONR221, pDONRP2r-P3 and pDONRP4P1R 
were obtained as part of the Multisite gateway cloning kit (Invitrogen). pDONR 
plasmids were maintained in ccdB-tolerant bacteria (DB3.1) and grown in the 
presence of kanamycin and chloramphenicol. To generate an Egfp clone 
(pMEegfp3) to test C-terminal fusions, we amplified the Egfp CDS with the 
following primers Forward attB1 5’GGGGACAAGTTTGTACAAAAAAGCAG 
GCTGGGCCACCATGGTGAGCAAGGGCGAG3’ and Reverse attB2 
5’GGGGACCACTTTGTACAAGAAAGCTGGGTGTCTAGATCCGGTGGATCC3’. 
The forward primer was designed in frame with the recommended reading frame 
to generate C- or N-terminal fusions. In addition, the CDS was preceded by a 
Kosack consensus. The reverse primer was designed to omit the stop codon and 
to maintain the recommended frame for N- or C-terminal fusions by multisite 
Gateway cloning. The attB1-egfp-attB2 flanked PCR product was gel purified 
(Qiagen) and subsequently mixed with pDONR221 and subjected to a BP 
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reaction for 1 hr. at room temperature. The reaction mixture was subsequently 
diluted fivefold in dH20 (Nuclease free water) and electroporated into TOP10 
electrocompetent bacteria and subsequently grown in the presence of 
kanamycin. In order to generate the C-terminal epitope entry plasmids we 
amplified the mCherry coding sequence with the following primers containing a 
forward attB2 and reverse attB3 primers: attB2 forward 
5’GGGGACAGCTTTCTTGTACAAAGTGGACATGGTGAGCAAGGGCGAGG3’ 
and attB3 Reverse 
5’GGGGACAGCTTTCTTGTACAAAGTGGACATGGTGAGCAAGGGCGAGG3’. 
We designed an in-frame stop codon in the reverse oligo. The attB2-mcherry-
attB3 PCR product was gel purified and mixed with pDNORP2r-P3 and subjected 
to BP reaction as described above. The attB4-attB1 flanked zebrafish bactin2 
promoter entry clone (p5Ebactin2) was kindly provided by Chi-Bin Chein. A list of 
all 3’ entry clones generated for this study can be accessed at: 
http://lawsonlab.umassmed.edu/GWEntryplasmids.htm.  
Generation of Destination Vectors. To generate the multisite gateway pCS-based 
plasmid (pCSDest2): pCSDest was digested with PstI and XhoI to remove the 
attR2 site and replaced with an attR3 site from pDESTR4-R3 (Invitrogen). The 
multisite tol2 vector (pDestTol2pA) containing an attR4-attR3 cassette was 
constructed by Clemens Grabher and kindly provided by Chi-Bin Chien. A list of 
all Destination vectors generated for this study can be accessed at: 
http://lawsonlab.umassmed.edu/GWDestplasmids.htm 
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Generation of Expression Constructs. To generate the pCSegfpmcherry 
construct we mixed pMEegfp3, p3Emcherry and pCSDest2 at equal molar ratios 
and performed an LR reaction using LR clonase II plus (Invitrogen) and 
incubated the mixture at room temperature for 1 hr. To generate the 
pTol2bactin2:egfpmcherry; pDestTol2pA was mixed with pMEegfp3 and 
p3Emcherry at equal molar ratios and subjected to a multisite LR reaction using 
the LR clonase II plus (Invitrogen) recombinase. The reaction was incubated as 
described above. After incubation, the LR reactions were diluted fivefold in dH2O 
and electroporated into TOP10 electrocompetent cells. The cells were 
subsequently selected in the presence of amplicillin. Clones were screened by 
PCR and/or mini prep (Qiagen).  To construct pTol2HSP:vegfc-2Acherry we 
subjected pDestTol2pA, pMEvegfc-w/ostp, p5EHSP70prm, and p3E-2Amcherry 
to a multisite LR reaction as described above. To construct pTol2HSP:dsRED-
IRESnlsegfp we subjected pTol2DestpA:CG (Chi-Bin Chein), pMEdsRedEX, 
p5EHSP70prm (Chi-Bin Chein), and p3E-IRESnlsegfp (Chi-Bin Chein) to 
multisite LR reaction. To generate the pTol2flieb:vegfc-2Amcherry and 
pTol2flieb:egfp-2Amcherry we subjected pDestTol2pA, pMEvegfc-w/ostp (for 
vegfc expression) or pMEegfp3 (egfp control expression), and p3E-2Amcherry to 
a multisite LR reaction as described above.  
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Injections 
To generate mRNA for injection, pCS vectors were digested with NotI, extracted 
with phenol/chlorophorm and subsequently ethanol precipitated. Koichi 
Kawakami kindly provided the pCS2-TP plasmid encoding the Tol2 Transposase. 
The linearized plasmids were used in a standard in vitro transcription reaction 
using SP6 polymerase (Message Machine Ambion). We performed mRNA 
injections as described elsewhere25. For injections using Tol2 constructs, we 
injected one–cell stage embryos with 25pg of Tol2 transposase mRNA and 25pg 
of indicated Tol2-containing plasmid. For injections involving genetic knockdown, 
we used a previously published morpholino targeting the flt4 transcript. At after 
injection with the indicated Tol2 and transposase constructs, embryos were 
separately a injected with either 2ng of Flt4 SD3 MO or Ctrl MO at the 4-8 cell 
stage14.    
 
Imaging and Phenotypic analysis 
In order to monitor fluorescent protein expression and embryo morphology we 
made use of a Leica MZFLIII microscope equipped with epifluorescence. Digital 
images were captured using an AxioCam camera and Axiovision software. 
Confocal images were captured on a Leica SP2 confocal microscope. 
hsp70:vegfc-2Acherry and hsp70:dsRED-IRESnlsegfp injected Tg(fli1a:egfp)y1 
embryos were heat shocked at 18 somite stage (ss) in egg water (ref). at 40°C 
for 20 min. Embryos where allowed to develop normally at 28°C and 
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subsequently analyzed for Vegfc-2AMcherry or DsredEx expression and ectopic 
segmental artery branching at 28 hpf. flieb:vegfc-2Amcherry and flieb:egfp-
2Amcherry  injected Tg(fli1a:egfp)y1 embryos were analyzed at 30 hpf for 
segmental arteries expressing Vegfc-2AMcherry or Egfp-2AMcherry, 
respectively. 
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Results  
 
Multisite Gateway Cloning Technology 
Gateway cloning technology is a universal system based on site-specific 
recombination reactions that allow rapid cloning of a gene of interest into multiple 
expression clones. This technology has been further engineered to allow 
simultaneous directional cloning of a promoter, gene of interest and epitope tag 
in to one expression clone; a method referred to as multisite Gateway cloning. A 
specific overview of this technology can be found in Appendix II.    
 
Construction of a Gateway compatible cassette that allows expression of 
C-terminal tagged ORFs to analyze gene function in zebrafish. 
Visually monitoring Vegfc expression in a spatial or temporal manner requires 
labeling it with a fluorescent epitope tag. Vegfc is a secreted factor that contains 
a signal sequence that allows it to be secreted. As a result, placing an N-terminal 
tag may affect is localization due to interference with the signal sequence, as 
observed in studies of membrane proteins. In these cases, placing an epitope tag 
on the C-terminus may avoid localization defects 137. To construct a system that 
allowed for the rapid parallel construction and testing of C-terminus epitope 
tagged ORFs, we took advantage of multisite Gateway technology and 
engineered a Destination vector that allowed simultaneous directional cloning of 
an ORF fused to a 3’ epitope tag.  
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Generally, Destination vectors contain attR1 and attR2 sites, which recombine 
with attL1 and attL2 of a given Middle entry clone(usually containing an ORF of 
interest). In this case we wanted to engineer a Destination vector that allowed 
introduction a second DNA fragment (3’ epitope tag). As described in Appendix I, 
3’ entry clones (usually encoding an epitope tag) are flanked by attR2 and attL3 
sites, thus allowing recombination of the attL2 site contained in the Middle entry 
clone and attR2 site contained in the 3’entry clone (Figure 1A, notice blue box 
recombine with orange boxes, attL2/attR2). Simultaneous and directional cloning 
of these fragments into a Destination vector would require the existence attR1 
and attR3 sites in the Destination plasmid itself, allowing recombination of the 
remaining attL1 site of the Middle entry clone and attL3 site of the 3’entry clone 
(Figure 1A, notice, attL1/attR1 as well as attL3/attR3 recombination). The 
resulting clone is an expression vector containing a 3’ epitope tagged 
ORF(Figure 1A). To generate such a Destination vector we modified the pCS 
vector, a commonly used vector to generate mRNA for gain-of-function analysis 
in zebrafish, so that in contained an attR1-attR3 cassette (Figure 1A, pCSDest2, 
See Methods). 
As proof of principle we first used pCSDest2 to generate pCSegfpmcherry. To 
generate appropriate Entry clones for multisite Gateway recombination we 
constructed a 3’ Entry clone encoding mcherry (p3Emcherry, see methods) 
(Figure 1B) and middle entry clone encoding egfp, minus the stop codon 
(pMEegfp3, see methods) (Figure 1B). We subsequently subjected pCSDest2,  
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Figure 1. Appendix I Multisite Gateway approach to generate C-terminal fusion proteins in 
a pCS-based vector.  
A. Depiction of the two-way multisite Gateway LR reaction between pMEORF, p3E Tag and 
pCSDest2 to generate C-terminal fusion proteins. Recombination can only occur between 
corresponding attL(Blue) and attR (Orange) sites resulting in the proper orientation in the Dest 
vector (pCSDest2), which contains an attR1 and attR3 site. This generates the pCSORF-Tag. B. 
Depiction of the two-way multisite Gateway LR reaction between pENTRegfp3, p3Emcherry and 
pCSDest2 to generate pCSegfpmcherry. Note that att sites are not to scale. C-E. A 24 hpf 
embryo injected with 100 pg of egfp-mcherry mRNA synthesized from the plasmid generated in 
B; lateral view, dorsal is up, anterior to the left; all pictures are from the same embryo. C. 
Transmitted light illumination. D. Illumination to visualize green fluorescence. E: Illumination to 
visualize red fluorescence. 
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pMEegfp3 and p3Emcherry to a multisite LR reaction and generated the 
pCSegfpmcherry construct (Figure 1B). Notice that corresponding attL and attR 
sites recombine (Figure 1B, Blue and Orange boxes recombine). The resulting 
pCSegfpmcherry vector was linearized and used to synthesized mRNA encoding 
the egfpmcherry fusion. Wild type embryos were injected at the one-cell stage 
with mRNA encoding egfpmcherry and subsequently monitored for transgene 
expression. We evidenced expression of EGFP-mCherry fusion in injected 
embryos at 24 hpf (Figure 1C-E). Taken together, these data demonstrate that 
the Gateway multisite system can be adapted for use with vectors commonly 
used to study gene function in zebrafish. Importantly, they demonstrate that this 
system can be used to tag ORFs at the C-terminus with a variety of epitope tags 
and test their functionality in a rapid manner. 
 
Validation of Gateway compatible transgenic constructs for use in 
zebrafish. 
Although ectopic expression of mRNA is often the easiest way to assess gene 
function in zebrafish, it often leads to unwanted developmental defects or indirect 
effects that can complicate a genetic analysis. Given the highly specific 
expression domains of certain genes, it is often preferable to control forced gene 
expression at the spatial and/or temporal level, which requires the application of 
transgenic DNA constructs containing the appropriate promoter elements. 
However, injection of transgenic DNA constructs in zebrafish results in high 
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mosiacism precluding the immediate analysis of the transgene, thus requiring 
higher doses of injection to achieve acceptable mosaic expression. 
Unfortunately, the increase of injection dose often results in toxic effects that 
decrease embryo viability. Recently, the development of the Tol2 transgenic 
vectors has alleviated the aforementioned drawbacks. The Tol2 transposon 
belongs to the hAT family of transposons. This transposon was originally isolated 
from the Japanese Medaka fish (Oryzias latipes) and has proved to be an 
efficient way to facilitate transgene integration into the zebrafish genome 138. 
Integration of the Tol2 element is mediated by the Tol2 Transposase, which 
catalyzes the movement of the Tol2 transposon.       
To generate a system that allowed spatial and/or temporal control over 
expression of a tagged Vegfc; we first tested an engineered Gateway compatible 
Tol2 transgenic vector139 for its ability to robustly induce transient transgenesis in 
zebrafish embryos. This vector contains an attR4-attR3 cassette Gateway 
cassette that allows the incorporation a promoter fragment upstream of an ORF 
and its C-terminal tag (Figure 2A, referred to as pDestTol2pA)139. As proof of 
principle, we used pDestTol2pA to generate a construct that drove ubiquitous 
expression of the EgfpMcherry fusion protein(above). To do this we used a 
bactin2 promoter entry plasmid (p5Ebactin2) (Figure 2A); this promoter has been 
shown to robustly drive transgene expression following integration (personal 
communication). We performed a three-way multisite LR reaction using p5E-
bactin2, pMEegfp3, and p3Emcherry together with the pDestTol2pA plasmid 
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(Figure 2A, again notice Blue boxes recombine with Orange boxes). This created 
a plasmid in which the bactin2 promoter was placed upstream of an egfp-
mcherry fusion coding sequence (pTol2bactin2:egfp-mcherry) (Figure 2A). We 
subsequently co-injected this plasmid with transposase mRNA into one-cell stage 
wild type zebrafish embryos. At 26 hpf we noted that embryos injected with 
pTol2bactin2:egfp-mcherry displayed both green and red fluorescence in 
identical mosaic patterns (Figure 2B-D). These results indicate that it is possible 
to generate Tol2-based constructs in which the expression of C-terminally tagged 
fusion proteins are driven by a tissue-specific promoter in one single cloning 
step. 
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Figure 2. Appendix I Multisite Gateway cloning to generate a tissue-specific Tol2 construct 
for expression of C-terminal fusion proteins.  
A. Three-way multisite reaction into pDestTol2pA. The egfp and mcherry Entry clones are the 
same as those used in Figure 1. Note that att sites are not to scale. B–G. Embryos injected with 
25 pg transposase mRNA and 25 pg pTolbactin2:egfp-mcherry; lateral view, dorsal is up, anterior 
to the left. B. Transmitted light illumination. C. Illumination to visualize green fluorescence. D. 
Illumination to visualize red fluorescence. E–G: Confocal micrographs; embryo is different than 
the one pictured in B. E. Mosaic green fluorescence of Egfp-mCherry observed in epidermal cells 
(arrows) and muscle cells (arrowheads). F. Red fluorescence of Egfp-mCherry. G. Overlay of 
images in E,F. 
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Spatial and Temporal over-expression of Vegfc reveals a conserved pro-
angiogenic effect during developmental angiogenesis in zebrafish.  
Until recently the effect of Vegfc on blood vessels during embryonic development 
was unknown 15. To investigate whether there was a conserved role for Vegfc on 
blood vessel physiology in zebrafish, we induced expression of Vegfc in a 
temporal and endothelial cell-autonomous manner during embryonic 
development in zebrafish. To analyze the effects of Vegfc on blood vessels in 
temporal manner we used the Gateway multisite technology and Tol2 Gateway 
vectors to generate a heat-shock inducible Vegfc Tol2 transgenic vector 
(pTol2hsp70:vegfc-2Acherry) (Figure 3A). We used a fragment of the hsp70 
promoter that has previously been used for heat shock induction139, to drive 
expression of vegfc. To visualize vegfc expressing cells, vegfc was fused in 
frame to mcherry separated by a viral 2A peptide sequence, which allows the 
production of multiple proteins from a single transgene140; this transgene is 
capable of rescue a vegfc mutant phenotype(Chapter III). We injected 
pTol2hsp70:vegfc-2Acherry together with tol2 transposase in to Tg(fli1a:egfp)y1 
embryos. The Tg(fli1a:egfp)y1 is a transgenic zebrafish line allows visualization of 
endothelial cells which express Egfp. Injected embryos were subsequently heat-
shocked at 18 hpf. At this time point embryos are just beginning to undergo 
angiogenesis from the DA to form SeA 7,28. We noted that after heat shock, 
transiently injected hsp70:vegfc-2Acherry embryos express Mcherry in  a 
ubiquitous mosaic pattern at 28 hpf. Mcherry expression was evidence of 
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presumed sites of transgene expression (Figure 3C, notice yellow arrowhead). 
Analysis of the blood vessels in these embryos showed ectopic branching of the 
developing SeA within the horizontal myseptum at 28 hpf (Figure 3B-C and F), 
while SegA in non heat-shocked embryos developed normally (personal 
observation).  By contrast, heat shocked hsp70:dsRedEx-IRESnlsegfp embryos 
displayed normal segmental arteries (Figure 3D-F). In this case, the 3’ epitope 
included an Internal Ribosomal Entry Sequence (IRES) that allowed bicistronic 
mRNA production of dsRedEx and nls-egfp. Together these data suggest that 
early forced expression Vegfc during blood vessel development is able to induce 
angiogenic effects on endothelial cells.  
It is very well established the Vegfc functions by binding and inducing 
phosphorylation of its corresponding receptor, Flt4 58,60. To investigate whether 
the effects of Vegfc on blood vessels were through Flt4 during developmental 
angiogenesis in zebrafish, we genetically down regulated flt4, using an antisense 
morpholino (MO), in heat shocked hsp70:vegfc-2Amcherry injected embryos. We 
observed that heat shock induced expression of vegfc failed to induce ectopic 
angiogenic sprouting in flt4 deficient embryos when compared to heat shocked 
hsp70:vegfc-2Amcherry control morphant embryos (Figure 3G-K).   Taken 
together, these data suggest that the effect of Vegfc on blood vessels in vivo is 
mediated through its receptor Flt4. 
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Figure 3. Appendix I Temporally controlled pro-angiogenic effects of Vegfc on blood 
vessels during embryonic blood vessel development are dependent on flt4.  
A. Heat-shock inducible Vegfc Tol2 transgenic vector, pTol2hsp70:vegfc-2Acherry, generated by 
Multisite Gateway cloning B-E and G-J. Confocal micrographs of trunk blood vessels at 28 hpf. 
Anterior is to the left, dorsal is up. DA, Dorsal Aorta. PCV, Posterior Cardinal Vein.  (B-C) 
Tg(fli1a:egfp)y1 embryos injected with 25 pg transposase mRNA and 25 pg  pTol2hsp70:vegfc-
2Acherry and heat shocked  at 18 hpf. C. Yellow arrowhead indicates vegfc transgene 
expression. B-C. White arrows indicate ectopic branching of SegA. (D-E) Tg(fli1a:egfp)y1 embryos 
separately injected with 25 pg transposase mRNA and 25 pg pTol2hsp70:dsRedEx-IRESnlsegfp 
and heat shocked  at 18 hpf. White arrows indicate normal SeA. (G-H) Tg(fli1a:egfp)y1 embryos 
injected with 25 pg transposase mRNA and 25 pg  pTol2hsp70:vegfc-2Acherry and subsequently 
with Ctrl MO. Embryos were heat shocked  at 18 hpf and analyzed at 28 hpf. G-H. White Indicate 
ectopic branching of SeA. (I-J) Tg(fli1a:egfp)y1 embryos injected with 25 pg transposase mRNA 
and 25 pg  pTol2hsp70:vegfc-2Acherry and subsequently with flt4 MO. Embryos were heat 
shocked at 18 hpf and analyzed  at 28 hpf. White arrows indicate normal SeA. F and K. 
Quantification of ectopic SegA branching per six hemisegments for the indicated manipulation. 
Values shown are based on the average of three independent experiments.  
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Vegfc expression is restricted to endothelial cells lining the DA and SeA in during 
development in zebrafish (personal observation)14. Recent evidence in mouse 
shows that vegfc induces angiogenesis when expressed in the endothelium 
during embryonic development 84. To investigate whether Vegfc had a similar 
conserved role in zebrafish, we again used the Gateway system and Tol2 
Gateway vectors to generate an endothelial driven Vegfc construct. In this case 
we used an Ets-binding element from the fli1a gene (referred to hereafter as 
fli1ebs) to drive expression of Vegfc (pTol2fliebs:vegfc-2Amcherry). As above, 
vegfc was fused to 2Amcherry to visualize expression. We noted that 
Tg(fli1a:egfp)y1 embryos transiently expressing fli1ebs:vegfc-2Amcherry in 
developing segmental arteries induced ectopic branching of segmental arteries 
within the horizontal myoseptum, as compared to transient expression of egfp-
2Amcherry, which had no effect (Figure 4A-C). The ectopic branching of 
segmental arteries was similar to those observed during temporal 
missexpression of Vegfc (above). Taken together, these data suggest a pro-
angiogenic role for Vegfc during embryonic blood vessel development in 
zebrafish.  
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Figure 4. Appendix I Pro-angiogenic effects of cell autonomous expression of Vegfc 
during blood vessel formation in zebrafish.  
(A-B) Confocal micrographs of trunk blood vessels at 30 hpf. Anterior is to the left, dorsal is up. 
DA, Dorsal Aorta. PCV, Posterior Cardinal Vein. A. Tg(fli1a:egfp)y1 embryos injected with 25 pg 
transposase mRNA and 25 pg  pTol2fliebs:egfp-2Acherry. White arrows indicate co-localization of 
transgene expression in SegA. B. Tg(fli1a:egfp)y1 embryos injected with 25 pg transposase 
mRNA and 25 pg  pTol2fliebs:vegfc-2Acherry. White arrows indicate co-localization of the 
transgene in SegA that display ectopic branching. C. Quantification of ectopic branching of SegA 
in for fliebs:egfp-2Acherry (n=12) and fliebs:vegfc-2Acherry (n=18) injected embryos expressing 
the transgene in SeA.   
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Discussion  
In this study, we show that spatial and temporal overexpression of Vegfc during 
developmental angiogenesis induces pro-angiogenic effects in zebrafish. To 
engineer a system that allows spatial and temporal control of Vegfc, we first 
adapted and modified Gateway cloning cassettes into vectors commonly used to 
assess gene function in zebrafish and subsequently validated the ability to 
rapidly generate vectors that allow specific expression of a 3’ tagged ORF. We 
generate constructs that allow spatial and temporal control of Vegfc during blood 
vessel development and find that Vegfc has conserved pro-angiogenic effect on 
blood vessels when it is temporally missexpressed or expressed in an 
endothelial-cell autonomous manner. Moreover, we find that the pro-angiogenic 
effects of Vegfc are likely through Flt4.  
Our study shows that the Gateway cloning system is modular and can be used to 
establish a collection of appropriate vectors that are suitable for transient and 
transgenic functional studies in zebrafish. Projects similar to the one described 
here have generated extensive Gateway compatible gene collections for human, 
C. elegans, Schizosaccharomyces pombe and viral genes 141-144. We illustrate 
the combined use of multisite Gateway cloning and a collection of zebrafish 
compatible vectors to rapidly clone C-terminally tagged ORFs and promoter 
driven C-terminal tagged ORFs. One important advantage of this method of 
cloning is that it obviates the use of cloning strategies using restriction enzymes 
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and ligases. In addition, it creates a standardized cloning system where clones 
are sequence verified once, and can then be used in a modular fashion to 
generate multiple tagged versions of an ORF. As a consequence, this system 
results in more time and effort directed toward functional analysis of genes rather 
than toward plasmid construction. 
Once Entry clones were inserted into Tol2 Gateway compatible Destination 
vectors the Entry sequences were flanked on either side by attB sites, which 
could presumably affect protein function or localization. However, during the 
course of our study we did not observe any overt defects in protein function or 
localization. This seems to be the case for the majority ORF analyzed (personal 
observation) and is consistent with other reports, which did not observe ectopic 
expression 145,146. The Tol2 vectors contain cis elements that facilitate integration 
into the genome. Although the LR recombinases have been shown to be specific, 
it is possible that this recombinase could interfere with the Tol elements flanking 
the transgenic plasmid. However, we did not observe any evidence of this 
scenario in our multisite cloning reactions, implying that the LR clonase is highly 
specific and does not interfere with the Tol2 elements of the transgenic vector.  
Previous studies in zebrafish showed that exogenous vegfc mRNA induced mild 
angiogenic effects on blood vessels during embryonic development15. Given the 
temporal and restricted expression domain of vegfc we a decided to investigate 
the effect of Vegfc on blood vessels during developmental angiogenesis using 
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promoter elements to restrict transgene expression. Here we show that temporal 
exogenous expression of vegfc, using heat shock promoter, is strongly 
angiogenic during developmental angiogenesis. Temporal misexpression of 
Vegfc at 18-24 hpf coincides with sites of active angiogenesis as well as the 
concomitant expression of Vegfrs such as flt4 and zebrafish homologue of vegfr2 
(kdrl). Given that Vegfc has the ability to activate Flt4 and Kdrl60, these data imply 
that Vegfc is able to elicit an angiogenic response through Vegfrs.  
In particular, we found that flt4 but not kdrl (personal observation) both of which 
are expressed is segmental arteries during blood vessel development, is required 
in order for Vegfc to prompt a pro-angiogenic phenotype. These data suggest 
that Vegfc specifically acts through Flt4 to induce the observed ectopic vessel 
sprouting. Consistent with this idea, we find that forced expression of Vegfc in 
segmental arteries also induces ectopic branching of blood vessels, further 
implying a role for Vegfc through Flt4 during this process; given the co-
expression of both these factors in SeA, it is probably doing so in an autocrine 
mode of signaling. Together these data imply a conserved pro-angiogenic effect 
by Vegfc/Flt4 signaling on blood vessels in zebrafish. 
In conclusion, this work describes a cloning system that allows for rapid 
construction of transgenic vectors to analyze gene function in zebrafish. Using 
this cloning technique we generated a system that allows spatial and temporal 
expression of Vegfc in order to determine if it had angiogenic effect on blood 
vessels during embryonic development. We find that Vegfc likely can act in a cell 
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autonomous manner and drives angiogenic effects through Flt4. The findings 
should prompt new investigation into the functional and cell autonomous role of 
Vegfc during developmental angiogenesis.  
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APPENDIX II 
 
 
Overview of Multisite Gateway Technology 
 
Gateway cloning technology is based on site-specific recombination reactions 
that involve cis elements and the λ integrase family of recombinases147. 
Importantly, these recombinases are conservative and highly specific, catalyzing 
a reaction that yields no net gain or loss of nucleotides. The cis elements are 
homologous in nature and are designated att sites. The multisite Gateway 
system (Invitrogen) makes use of several engineered att sites that recombine in 
a specific and directional manner to clone up to five fragments of DNA. In this 
study, we will make use of the single-insert and three-insert multisite Gateway 
system.    
The “BP” recombination reaction describes the recombination between attB and 
attP sites on two different DNA fragments. (Figure 1A). Typically, this reaction is 
used to recombine a fragment generated by Polymerase Chain Reaction (PCR), 
which is flanked by attB sites, into a surrogate vector containing attP sites. This 
surrogate vector is usually referred to as a DONOR vector (Figure 1A, 
pDONR221). This reaction is catalyzed by bacteriophage λ intergrase (Int) and 
integration host factor (IHF).  Together, these factors are referred to as “BP 
clonase” (Invitrogen). BP clonase catalyzes recombination of two DNA fragments  
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Figure 1. Appendix II 
Gateway BP recombination reactions. A: Depiction of a BP reaction for a polymerase chain 
reaction amplified open reading frame. B: Depiction of a BP reaction for a polymerase chain 
reaction amplified promoter fragment, notice the attB4 and attB1 sites. Depiction of a BP reaction 
for a polymerase chain reaction amplified epitope tag. Notice the attB1 and attB3. Note that att 
sites are not to scale. 
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that yields two plasmids or DNA fragments that now correspond to attL and attR 
sites (Figure 1A). The attL site containing plasmid forms part of what is now 
called a “Middle Entry” plasmid (pME-ORF). Typically, these Middle Entry clones 
encode a reporter or the open reading frame (ORF) for a gene of interest. To 
promote high efficiency recovery of Entry plasmids, the Gateway system relies 
on a counter-selection method. In this case, DONOR vectors contain a ccdB 
cassette that is toxic to standard bacterial strains used for cloning (e.g., DH10B, 
DH5α); an adjacent chloramphenicol resistance gene allows maintenance of the 
cassette in ccdB-tolerant cells. Therefore, un-recombined DONOR vector, or 
attR-containing byproducts will not be propagated after a BP reaction resulting in 
high efficiency recovery of the desired Entry clone.  
As described earlier, it is often necessary to use a promoter fragment to drive 
specific expression of a reporter or gene of interest. To generate these clones, 
promoter fragments can be amplified with flanking attB4-attB1sites and 
subsequently inserted into a surrogate vector containing engineered attP4 and 
attP1R sites (pDONRP4-P1R) performing a BP reaction (Figure 1B). Similar to 
the BP reaction described above, the reaction yields fragments of DNA that 
correspond to attL4-attR1 and attR4-attL1 sites. The plasmid containing the 
attL4-attR1 site is referred to as a “5’ Entry plasmid” (p5E-Prom). The attR4-attL1 
fragment contains the ccdB/chloramphenicol cassette and is counter selected 
(Figure 1B).  Additionally, a BP reaction can be used to generate “3’ Entry 
plasmid” (p3E-Epitope) (Figure 1C). These clones often contain C-terminal 
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epitopes encoding fluorescent proteins such as Mcherry. In this case, BP clonase 
recombines pDONRP2R-P3, which is flanked by attP2R and attP3 sequences, 
and an amplified PCR product flanked by attB2 and attB3 sequences (Figure 
1C). This recombination event results in an attR2-attL3 flanked p3Entry plasmid 
and counter a selected ccdB/chloramphenicol fragment flanked by attL2-attR3 
sequences. Together, these three forms of Entry plasmids serve as building 
blocks that can be used to simultaneously generate multiple variants of a 
particular expression clone in a rapid manner.  
Once appropriate Entry plasmids are generated, they can be used in a multisite 
LR reaction with corresponding “Destination” vectors which contain homologous 
attR sites. Usually, Destination vectors contain elements for eukaryotic or 
prokaryotic expression (Figure 2A, ex. CMV, SP6).  Int, IHF, and excisionase 
(referred to as LR clonase) catalyzes the LR recombination. The LR reaction 
results in the recombination of corresponding attL and attR sites contained in the 
Entry and Destination plasmids (Figure 2A). The resulting plasmid is usually an 
Expression clone where the inserts are flanked by attB sites (Figure 2B, Blue 
boxes). In addition to this plasmid, a by-product plasmid that contains a 
ccdB/chloramphenicol cassette flanked by attP sites is also generated (Figure 
2B, Orange boxes). As with the BP reaction, both un-recombined Destination 
vector and the attP-containing by-product are selected against by the presence 
of the ccdB gene in an LR reaction. Additionally, Destination vectors contain 
ampicillin resistance, while DONOR or Entry plasmids contain kanamycin 
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resistance cassettes. Thus, introduction of an LR reaction into standard cloning 
bacteria and selection on ampicillin results in high efficiency recovery of the 
desired Expression clone. The resulting Expression clone that contains the attB-
flanked inserts can then be used for appropriate functional studies.
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Figure 2. Appendix II 
Gateway LR recombination reaction. A. Depiction of LR reaction between an ENTRY clone and a 
Destination vector. Note that att sites are not to scale. B. Depiction of Expression clone and attP 
site containing by-product.  
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APPENDIX III 
 
in vivo forced expression of vegfcum18 induces ectopic branching of SeA  
During the course of our biochemical characterization of Vegfcum18 in mammalian 
cells we noted that overexpression of VEGFC-ΔC (human equivalent of 
Vegfcum18) led to its eventual secretion at 72 hours post transfection (Chapter 4 
Figure 2C). To investigate whether overexpression of Vegfcum18 led its eventual 
secretion in vivo, we transiently overexpressed either vegfc or vegfcum18 in 
Tg(fli1a;egfp)y1 embryos using a heat shock inducible promoter. This promoter 
allows temporal control as well as high induction of transgene expression. To 
visualize ligand-expressing cells, we again fused 2Amcherry to both vegfc and 
vegfcum18. In contrast to heat shocked hsp70a:dsredEX-IRESnlsegfp controls, we  
observed ectopic branching of segmental arteries at 26 hpf in hsp70a:vegfc-
2Amcherry injected embryos heat-shocked at 18hpf (Figure 1A-D,G). Similarly, 
we noted that heat-shock overexpression of hsp70a:vegfcum18-2Amcherry elicited 
ectopic branching of segmental arteries similar to those induced by 
hsp70a:vegfc-2Amcherry (Figure 1E-F). Consistent with our previous 
biochemical observations these data suggest that higher levels of Vegfcum18 
expression result its eventual secretion.  
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Figure 1. Appendix III Elevated misexpression of vegfcum18 induces pro-angiogenic effects 
on blood vessels.  
(A-F). Confocal micrographs of trunk blood vessels at 28 hpf. Anterior is to the left, dorsal is up. 
DA, Dorsal Aorta. PCV, Posterior Cardinal Vein.  Red channel indicates sites transgene 
expression (A-B) Tg(fli1a:egfp)y1 embryos injected with 25 pg transposase mRNA and 25 pg 
pTol2hsp70:dsRedEx-IRESnlsegfp. Embryos were heat shocked at 18 hpf. (C-D) Tg(fli1a:egfp)y1 
embryos injected with 25 pg transposase mRNA and 25 pg pTol2hsp70:vegfc-2Acherry. Embryos 
were heat shocked at 18 hpf. (E-F) Tg(fli1a:egfp)y1 embryos injected with 25 pg transposase 
mRNA and 25 pg pTol2hsp70:vegfcum18-2Acherry. Embryos were heat shocked at 18 hpf. (G) 
Quantification of ectopic SegA branching per six hemisegments for the indicated manipulation. 
Values shown are based on the average of three independent experiments.  
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